



# **Board of Directors Public Meeting Agenda**

Meeting to be held at 10am on Thursday 06 May 2021 remotely via Teams in line with social distancing

| Item<br>No. | Title  | Purpose                | Type and Ref.          | Lead  |  |  |  |
|-------------|--|------------------------|------------------------|---|--|--|--|
|             | 1. Introduction and Administration   |                        |                        |   |  |  |  |
| 1.1         | Apologies  | Receive                | Verbal                 | Chair   |  |  |  |
| 1.2         | <ul> <li>Declarations of Interest</li> <li>Any new interests to declare</li> <li>Any interests to declare in relation to open items on the agenda</li> </ul> | Noting                 | Verbal                 | Chair   |  |  |  |
| 1.3         | Minutes of the meeting held in<br>Public on 11 March 2021  | Approve                | Pg. 4                  | Chair   |  |  |  |
| 1.4         | Matters Arising  | Receive                | Verbal                 | Chair   |  |  |  |
|             | air and Chief Executive Strategic U  | •                      |                        |   |  |  |  |
| 2.1         | Chair's Report   | Receive and Discuss    | Verbal                 | Chair   |  |  |  |
| 2.2         | Chief Executive's Report   | Receive and Discuss    | Verbal                 | Chief Executive                                       |  |  |  |
| 3. Qu       | ality  |                        |                        |   |  |  |  |
| 3.1         | Patient Story  | Receive and Discuss    | Presentation To Follow | Director of Patient<br>Care and Chief<br>Nurse        |  |  |  |
| 3.2         | Maternity Staffing Update  | Receive and Discuss    | Pg. 11                 | Director of<br>Operations                             |  |  |  |
| 3.3         | Incident, Improvement and Learning Report  | Receive and<br>Discuss | Pg. 15                 | Medical Director/<br>Director of<br>Corporate Affairs |  |  |  |
| 3.4         | Nursing Staff Update   | Receive and<br>Discuss | Pg. 25                 | Director of Patient<br>Care and Chief<br>Nurse        |  |  |  |
|             | orkforce   |                        |                        |   |  |  |  |
| 4.1         | Workforce Report Month 12  | Receive and Discuss    | Pg. 32                 | Director of<br>Workforce                              |  |  |  |
| 4.2         | 2020 Staff Survey Report   | Receive and Discuss    | Presentation To Follow | Director of<br>Workforce                              |  |  |  |
| 4.3         | Annual Report on Clinical Excellence Awards  | Receive and<br>Discuss | Pg. 38                 | Medical Director                                      |  |  |  |

| Item         | Title  | Purpose                | Type and Ref. | Lead                             |  |  |
|--------------|--|------------------------|---------------|----------------------------------|--|--|
| No.<br>5. Pe | 5. Performance and Finance                                       |                        |               |                                  |  |  |
| 5.1          | Performance Report Month 12                                      | Receive and Discuss    | Pg. 43        | Deputy Chief<br>Executive        |  |  |
| 5.2          | Elective Performance Update                                      | Receive and Discuss    | To Follow     | Deputy Chief<br>Executive        |  |  |
| 5.3          | Finance Report Month 12  | Receive and Discuss    | Pg. 44        | Director of Finance              |  |  |
|              | rategy and Investment  |                        |               |                                  |  |  |
| 6.1          | BLMK ICS Strategic Priorities                                    | For Ratification       | Pg. 54        | Chief Executive                  |  |  |
|              | surance and Statutory items                                      |                        |               |                                  |  |  |
| 7.1          | Significant Risk Register  | For Information        | Pg. 59        | Director of<br>Corporate Affairs |  |  |
| 7.2          | Board Assurance Framework  | Receive and<br>Discuss | Pg. 78        | Director of<br>Corporate Affairs |  |  |
| 7.3          | (Summary Reports) Audit<br>Committee –                           | For Information        | Pg. 138       | Chair of Committee               |  |  |
|              | 23 March 2021  |                        |               |                                  |  |  |
| 7.4          | (Summary Reports) Finance and Investment Committee –             | For Information        | Pg. 139       | Chair of Committee               |  |  |
|              | 29 March 2021  |                        |               |                                  |  |  |
| 7.5          | (Summary Report) Charitable Funds Committee –                    | For Information        | Pg. 140       | Chair of Committee               |  |  |
|              | 22 April 2021  |                        |               |                                  |  |  |
| 7.6          | (Summary Report) Quality and Clinical Risk Committee –           | For Information        | Pg. 141       | Chair of Committee               |  |  |
|              | 23 March 2021  |                        |               |                                  |  |  |
| 7.7          | (Summary Report) Workforce and Development Assurance Committee – | For Information        | Pg. 142       | Chair of Committee               |  |  |
|              | 21 April 2021  |                        |               |                                  |  |  |
| 7.8          | Use of Trust Seal  | Ratify                 | Pg. 144       | Director of<br>Corporate Affairs |  |  |
| 8. Ad        | 8. Administration and Closing                                    |                        |               |                                  |  |  |
| 8.1          | Questions from Members of the Public                             | Receive and Respond    | Verbal        | Chair                            |  |  |
| 8.2          | Motion to Close the Meeting                                      | Receive                | Verbal        | Chair                            |  |  |

| Item<br>No. | Title                                      | Purpose | Type and Ref.   | Lead |
|-------------|--|---------|---|------|
| 8.3         | Resolution to Exclude the Press and Public | Approve | Resolution to Exclude the Press and Public The Chair to request the Board pass the following resolution to exclude the press and public and move into private session to consider private business: "That representatives of the press and members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted |      |



## **BOARD OF DIRECTORS MEETING**

## Minutes of the Public Trust Board of Directors Meeting held on Thursday, 11 March 2021 at 10.00 hours via Teams

#### Present:

| Alison Davis           | Chair  | (AD)  |
|------------------------|--|-------|
| Professor Joe Harrison | Chief Executive                                      | (JH)  |
| Andrew Blakeman        | Senior Independent Director / Non-Executive Director | (AB)  |
| Heidi Travis           | Non-Executive Director (from 11.15am)                | (HT)  |
| Helen Smart            | Non-Executive Director                               | (HS)  |
| Nicky McLeod           | Non-Executive Director                               | (NMc) |
| Haider Husain          | Non-Executive Director                               | (HH)  |
| John Lisle             | Non-Executive Director                               | (JL)  |
| John Blakesley         | Deputy Chief Executive                               | (JB)  |
| Dr Ian Reckless        | Medical Director & Deputy Chief Executive            | (IR)  |
| Terry Whittle          | Director of Finance                                  | (TW)  |
| Danielle Petch         | Director of Workforce                                | (DP)  |
| Nicky Burns-Muir       | Director of Patient Care and Chief Nurse             | (NBM) |
| Emma Livesley          | Director of Operations                               | (EL)  |

#### In attendance:

| Dr Luke James     | Associate Non-Executive Director                             | (LJ)  |
|-------------------|--|-------|
| Kate Jarman       | Director of Corporate Affairs                                | (KJ)  |
| Sally Burnie      | Head of Cancer Services and Lead Cancer Nurse (For item 3.1) | (SB)  |
| Samantha Timmins  | Advanced Nurse Practitioner, Cancer (For item 3.1)           | (ST)  |
| Philip Ball       | Freedom to Speak Up Guardian (For item 3.6)                  | (PB)  |
| Alice Fiancet     | Communications Officer                                       | (AF)  |
| Kwame Mensa-Bonsu | Trust Secretary (Minutes)                                    | (KMB) |
|                   |  |       |

#### 1 Welcome

1.1.1 AD welcomed all present to the meeting.

#### 1.2 Apologies

1.2.1 There were no apologies.

#### 1.3 Declarations of interest

1.3.1 No new interests had been declared and no interests were declared in relation to the items on the agenda.

#### 1.4 Minutes of the meeting held on 14 January 2021

1.4.1 The minutes of the Public Board meeting held on 14 January 2021 were reviewed and **approved** by the Board.

#### 2.1 Chair's Update

2.1.1 AD expressed her appreciation for the warm welcome which had been extended to her from all colleagues since she joined the Trust in February 2021. AD noted she had been conducting meetings with several individuals, and had also chaired a Consultant Appointment Panel which had been very informative. AD stated that she had also attended a meeting organised by the Bedfordshire, Luton and Milton Keynes Integrated Care System (BLMK ICS), and had on 08 March 2021, participated in the International Women's Day.

The Board **noted** the update.

#### 2.2 Chief Executive's Update

- 2.2.1 JH welcomed the Chair to her first Public Board meeting, and wished her a successful tenure as Chair of the Trust Board. JH also welcomed TW to the Trust, and to his first Public Board meeting as the substantive Director of Finance. JH referenced a localised flooding incident in February 2021, and stated that a mains water pipe had burst during development work at the hospital. JH thanked Anglian Water and the Trust's Estate Team for helping restore the Trust's water supplies, and noted that patients had been unaffected by the incident. JH referenced an IT system outage in March 2021, and noted that this had also been resolved by the IT Team without patient care being impacted.
- 2.2.2 JH stated that the eCARE, the hospital's new electronic patient record system, was having a transformative effect on patient care, and noted that patients were receiving letters on their future clinical care on their electronic devices before they had even left the hospital's grounds. JH stated that over 70k patients had so far received clinical letters electronically instead of via the post, and this number would continue to grow.
- 2.2.3 JH informed the Board that the Trust had been very well represented at the International Women's Day event, and added that with a 50:50 gender parity on the Board, the Trust was punching well above its weight. The Chair noted that, though a lot of work still needed to be done around the advancement of women, the event had been very encouraging due to the progress which had been achieved in the Trust. JH noted the presence of KMB at his first public meeting, and welcomed him to his role as the Trust's Company Secretary.
- 2.2.4 JH advised that the Trust had commenced elective care activity, and were providing treatment for the most urgent patients with a plan to increase activity from April 2021. JH stated that, in relation to the COVID-19 pandemic, 47 COVID-19 patients were identified on admission, while the Trust had progressed significantly with the COVID-19 vaccination programme having vaccinated 20k people. JH advised that the cohort of people who were currently being provided with the COVID-19 vaccine were those with underlying health conditions from the 18 to 64 year age range. In response to HS's query around the future of the Trust's vaccination programme, JH stated that this would close at the end of March 2021 and the capacity transferred to the public vaccination programme in the centre of Milton Keynes. HS congratulated the Trust for being able to provide 20k people with the COVID vaccine.

The Board **noted** the update.

#### 3 Quality

#### 3.1 Patient Story

- 3.1.1 ST presented the story, which highlighted the significant improvement in the experience of patients since the Cancer Centre was opened in March 2020. ST stated that the results of a National Patient Survey, which had placed the Trust in the bottom 10 nationally for cancer care, had shown the organisation that it needed a modern centre to improve the experience of its cancer patients. ST advised that the Centre had enabled the Trust to improve patient experience through the provision of, among others:
  - A clean, bright and spacious environment
  - All Cancer services under one roof
  - Purpose-built rooms
  - Closer working with ward 25
  - On site pharmacy.
- 3.1.2 IR noted that next to the Cancer Centre was a car park which was the planned site for a radiotherapy building, and this needed to be developed as soon as possible. AD stated that she planned to visit the Cancer Centre to meet the staff, and thanked them for the actions they took in response to the COVID-19 pandemic while continuing with the provision of cancer care.

The Board **noted** the patient story.

#### 3.2 Serious Incident (SI) Report

- 3.2.1 IR presented a report which provided an overview of the types of SIs reported in January and February 2021, the trends and a brief summary of linked programmes of work in response to the incidents. IR stated that the reporting format was developed in response to a recommendation in the December 2020 Ockendon Report which asked NHS providers to be transparent in their reporting of SIs. IR advised that though the incidents have been designated as "Significant", some may be downgraded after investigations had been concluded.
- 3.2.2 IR noted that of the 19 SIs, 8 of them had occurred at various points on the Maternity pathway, which did not indicate that there should be concerns about any particular point on the pathway. IR stated that all 6 babies, involved in the Maternity pathway incidents, were safe and well at home with their mothers. In response to HS's query around the 4 pressure ulcer SIs, NBM stated that these had occurred in areas where there had been previous incidents and more corrective steps were being undertaken to ensure staff understood the need to provide better patient care. NBM added that the Tissue Viability Nurse had returned to their own practice, after redeployment during the peak of the pandemic, and was providing pressure ulcer prevention training and circulating lessons to the various teams.
- 3.2.3 In response to AB's query around the process for reporting incidents, IR stated that though the rate of reporting was middle of the pack in comparison to peer NHS providers, the practice was to encourage staff to report all incidents on Datix. IR added that the preference of the Trust was to have lots of incidents to be reported and for SIs to be low. IR advised that in terms of the management of SIs, incidents which caused harm were robustly reviewed at weekly multidisciplinary Serious Incident Review Group (SIRG) meetings. IR stated that staff presented draft root cause analyses (RCAs) reports into these incidents for members of the SIRG to review and determine whether they were SIs or not. IR added that SIRG also took steps to ensure that the action plans of the RCAs they approved were implemented and embedded in practice. SIRG also reviewed incidents with moderate harm, and duty of candour letters forwarded to the patients involved.
- 3.2.4 In response to JL's query around incidents related to the Ophthalmology pathway, IR advised that a full investigation was being undertaken and the results of that would be submitted to the Quality and Clinical Governance Committee. NBM stated that the Trust was a learning organisation, and this attitude was exhibited at SIRG meetings, where the reviews, discussions and debates were challenging, honest and robust. HS advised that she had in the recent past followed the governance process for SIRG, and had found it to be assuring because it was appropriately robust and constructive.

The Board **noted** the SI report.

#### 3.3 Nursing Staffing Report

- 3.3.1 NBM presented the report and highlighted the following:
  - The Trust had, out of a requirement to fill 61 whole time equivalent (WTE) Healthcare Support Worker (HCSW) posts, recruited 60 WTEs since January 2021;
  - The Trust was taking comprehensive steps to recruit staff to fill 70 WTE Band 5 vacancies;
  - The Trust had recruited 3 international nurses, with a decision to be made in May 2021 if more international recruits were needed.
  - The Trust was taking steps to invest in senior clinical leadership with a plan to ensure that each inpatient ward had a Band 6 Nursing Sister on every shift. The aims were to, among others, enhance patient experience, safety outcomes and to provide an in-house career development opportunity for Staff Nurses.
- 3.3.2 In response to NMc's query around the availability of mentors for the new recruits, NBM stated that applicants for the Band 6 leadership roles would most likely have undergone a development programme and so would need minimal transitional mentoring. NBM added that the Senior Sisters would from March 2021 return to being supernumerary, which would ensure that any new recruits received the level of mentorship required to adapt to the practices and standards of the hospital. It was noted that the Senior

Sisters had come out of being considered supernumerary as they were needed to support the wards during the peak of the COVID-19 pandemic.

The Board **noted** the Nurse Staffing report.

#### 3.4 Responses to the Ockenden Report: Assessment and Assurance Tool

3.4.1 NBM informed the Board that the Trust had submitted its self-assessment and was awaiting the assessment of it from the Regional Team. The Regional Team's assessment would inform the Trust of any follow-up actions which needed to be undertaken.

The Board **noted** the update.

#### 3.5 Safeguarding Children and Young People Update

- 3.5.1 NBM presented the Safeguarding update and stated that the safeguarding referrals had altered in pattern and complexity since the onset of the COVID-19 pandemic. The pandemic had also altered the access children and young people had to spaces outside of their homes, increasing vulnerability and impacting access to social support and connections. NBM stated that the Trust had worked with partners during the year to address and manage the Safeguarding risks presented by the COVID-19 pandemic. NBM noted that the Safeguarding Team had since December 2020 been asked to support the COVID-19 vaccination programme, which had significantly increased the pressure on them to maintain the service provision.
- 3.5.2 HS expressed concern that the Safeguarding Team was under pressure to maintain the service provision and enquired if steps were being taken to resolve this. NBM advised that she had had a conversation with the CCG's Chief Nurse about the challenge, and the interaction would continue till a solution was found. In response to HH's query around support tools for the Safeguarding Team, NBM advised that several policies had been completed recently to ensure that they had the necessary support. NBM added that the Safeguarding Team also utilised apps for the young people in their care, to help those young people keep themselves safe.

The Board **noted** the update.

#### 3.6 Freedom to Speak Up (FTSU) Guardian - 2020/21 Annual Report

- 3.6.1 PB presented the annual report and advised that the FTSU Guardian Team had grown in number over the year from 1 to 7, and added that they had also resolved 6 cases in that period. In response to HH's query around BAME representation on the FTSU Guardian Team, PB stated that there were 2 members from BAME backgrounds, but steps were being taken to recruit more.
- 3.6.2 DP congratulated PB for taking up the Guardianship role and working to continue raising its profile in the Trust. KJ noted that the growing staff networks and peer to peer support groups would help staff gain the confidence to speak up and that would only help to support the function of the FTSU Guardian. AD on behalf of the Board, thanked PB for the effort he had put into raising the profile of the FTSU Guardian role in the Trust.

The Board **noted** the annual report.

#### 4 Performance and Finance

#### 4.1 Performance Report Month 10

- 4.1.1 EL presented the report and advised that it had been prepared when COVID-19 infections were at its highest peak in January 2021. EL highlighted the following:
  - The percentage of ambulance handovers to the Emergency Department taking more than 30 minutes, which improved to 8.6% in January 2021, had continued to improve;
  - Elective activity had been restarted;

• A recovery plan had been developed to increase activity and remove the backlog of patients who had waited longer than 52 weeks without being treated.

The Board **noted** the Month 10 Performance Report.

#### 4.2 Finance Paper Month 10

- 4.2.1 TW thanked Board members for the welcome that had been afforded him and presented the Month 10 Finance Report. TW noted the noted the following:
  - The Trust reported positive variance of £196k against a planned deficit of £762k;
  - The negative YTD position of £5,994k included an in-month adjustment to the untaken annual leave accrual of £5,914k;

JH noted that, as a result of the NHS's response to the COVID-19 pandemic, all NHS providers had been financially impacted by their staff's inability take annual leave as required.

The Board **noted** the Month 10 Finance report.

#### 4.3 Workforce Report Month 10

- 4.3.1 DP presented the Workforce Month 10 report and highlighted the following:
  - The vacancy rate has reduced slightly to 12.2% in month but remained higher than expected;
  - Recruitment activity in the Trust was progressing as expected;
  - In terms of staff sickness, 31 members of staff were off sick with COVID-19 as of 11 March 2021;
  - Statutory and mandatory training compliance and appraisals compliance rates were at 95% and 92% respectively;
  - The Trust's vaccination programme had provided 20k staff and members of the public with the first doses of the COVID-19 vaccine. The programme had progressed to providing second doses of the COVID-19 vaccine to eligible people.

The Board **noted** the Month 10 Workforce report.

#### 4.4 Staff Health and Wellbeing Report

- 4.3.1 DP presented the report which provided a summary of the support available to staff throughout the COVID-19 pandemic. DP advised that the Trust had also launched a '12 Weeks of Wellness' programme and other initiatives to support the Trust's workforce as it recovered from the impact of the pandemic. The Trust was also taking steps to develop some initiatives to provide mental health and physical support for the members of staff suffering from the effects of "long" COVID.
- 4.3.2 JH commended DP and her directorate for epitomising the Trust's response to the COVID-19 pandemic. The HR Directorate had played an excellent part in helping the Trust to progress with the vaccination programme. In response to HT's query around the impact of "long" COVID, DP advised that the support provided included adjustments so recovering staff could return and contribute to the Trust.

The Board **noted** the report.

#### 5 Strategy and Investment

#### 5.1 Revised Estates Strategy: 2020 – 2025

5.1.1 JB presented the Trust Estates Strategy, which had been revised to reflect all the key changes and requirements since it was approved by the Board 2018. The key changes included the development of a BLMK ICS Estates Strategy, a Health Infrastructure Plan, and the requirement to develop an energy strategy which would help the Trust achieve its environmental and net zero carbon targets. The revised strategy was approved at the Private Board meeting in February 2021.

The Board formally **approved** the revised Trust Estates Strategy.

- 6 Assurance and Statutory Items
- 6.1 Significant Risk Register
- 6.1.1 KJ presented the Significant Risk Register and advised the Risk Team was taking steps to comprehensively review it.

The Board **noted** the Significant Risk Register.

- 6.2 Board Assurance Framework (BAF)
- 6.2.1 KJ presented the BAF and advised that KMB had taken over the monthly reviews of the document. JL suggested that the process for transferring risk entries to the BAF needed to be clarified. KJ advised that Board members would have an opportunity to review the BAF in May 2021.

The Board **noted** the BAF.

- 6.3 Summary Reports for the Finance and Investment Committee 11 January 2021, 01 February 2021 and 01 March 2021
- 6.3.1 The Board **noted** the reports.
- 6.4 Summary Report for the Charitable Funds Committee 18 February 2021
- 6.4.1 The Board **noted** the report.
- 6.5 Summary Report for the Quality and Clinical Risk Committee 22 February 2021
- 6.5.1 The Board **noted** the report.
- 6.6 Summary Report for the Workforce and Development Assurance Committee 20 January 2021
- 6.6.1 The Board **noted** the report.
- 6.7 Use of Trust Seal
- 6.7.1 The Board **noted** the report.
- 7 Administration and Closing
- 7.1 Questions from Members of the Public
- 7.1.1 David Tooley, a local reporter asked whether there is any cause for concern over the number of SIs that involved babies and the hospital's maternity services, what the underlying causes of the SIs were.

IR provided the response below:

In all six incidents reported by the maternity and neonatal departments across the last two months, the mothers and babies involved were well and at home. The incidents were unrelated, and there were no apparent links to any individual member of staff or team.

In three of the cases, the challenges of delivering care with reduced face-to-face contact on account of COVID-19 may have partially contributed to a failure to follow to the letter an element of our relevant protocol for dealing with complex cases.

The patients and families involved in these incidents were all aware that they have been reported as serious incidents, and have received copies of investigation reports, have had the opportunity to meet clinicians to discuss what happened, and have received an apology for what went wrong during their care and what we were doing to prevent it happening again.

### 8 Any Other Business

The meeting closed at 12.10 am.





#### Midwifery workforce and staffing paper

#### 1 Purpose

This paper outlines the current midwifery workforce establishment staffed to deliver maternity services at Milton Keynes University Hospitals NHS Trust (MKUH). The paper also identifies additional staffing requirements as detailed in the Ockendon Review of Maternity Services 2021.

The review of the maternity workforce formulates part of the reporting requirements of the maternity incentive scheme. The Trust is expected to submit this review to the BLMK Local Maternity and Neonatal System (LMNS) and NHSE/I in May 2021.

#### 2 Background

The maternity staffing model has been managed historically using a flexible approach. Midwives often rotate across maternity services to ensure the midwifery workforce has the required skillset to be agile. This agility allows midwives to be redeployed to work in all areas dependent on increased activity levels or acuity changes.

The nationally recognised safe staffing for maternity services workforce planning system is Birthrate Plus.

#### This tool includes:

- Total midwifery time required to care for women based on minimal standard of providing one-to-one midwifery care throughout established labour
- A classification for intrapartum care which uses clinical indicators to assess the level of need of both mother and baby.
- Collecting real time data on the length of time a women required care during labour and delivery and an addition of extra midwife time for those with a higher level of need/ intervention or emergency

MKUH completed Birth-Rate plus in April 2018 and this was based on 3760 births and set the blueprint for the maternity services staffing model, providing assurance that our maternity workforce establishment would enable us to deliver safe staffing.

Birth-Rate plus was scheduled to be repeated in 2020 and due to the pandemic this was delayed. We are currently awaiting a timeframe to complete Birthrate Plus which has been funded from BLMK LMNS.

During April 2020 to April 2021 MKUH had 3493 births with 4553 women booked. Whilst the number of births is less than 2018 the complexity of the women has significantly increased, and the implementation continuity of carer model has impacted on the staffing model.

In the light of these changes and in response to the Ockendon Review recommendations each of the maternity services have had their maternity establishment recently reviewed by the interim Head of Midwifery and the Chief Nurse.





#### 3 Current staffing and establishment

The maternity teams are led by a Head of Midwifery, a deputy Head of Midwifery and a team of three matrons who provide leadership for labour ward and ADAU, antenatal / postnatal care, and the community/ continuity of care teams.

#### 3.1 Ward 9

Ward 9 is a 28 bedded ward providing care for women in their antenatal phase and women and babies postnatally. The establishment on ward 9 is detailed below based on current templates including the acuity and dependency of the women and babies.

|                      | Weekly Average     |                |  |
|----------------------|--------------------|----------------|--|
| Ward 9 Staff Numbers | Registered Midwife | Non registered |  |
| Day                  | 5                  | 3              |  |
| Night                | 4                  | 3              |  |

The table below sets out the total number of staff required for Ward 9.

| Staff Band            | Staff required |  |
|-----------------------|----------------|--|
| Band 7(Supernumerary) | 2 WTE          |  |
| Band 5/6              | 23.68 WTE      |  |
| Band 2/3              | 15.71 WTE      |  |
| Total                 | 43.4 WTE       |  |

#### 3.2 Labour ward

Labour Ward has 11 single rooms with the women on labour ward requiring 1 to 1 care. The following establishment takes into account the continuity of care model, which currently stands at 35% of the maternity case load. The assumption is based on 2 midwives present from the continuity of carer teams each day and each shift having 2 labour ward Coordinators Band 7 (1 supernumerary in charge).

| Labour ward staff | Weekly Average     |                |  |
|-------------------|--------------------|----------------|--|
| Numbers           | Registered Midwife | Non registered |  |
| Day               | 5                  | 2              |  |
| Night             | 5                  | 1              |  |

The table below sets out the number of staff required on labour ward.

| Staff Band            | Staff required |
|-----------------------|----------------|
| Band 7(Supernumerary) | 5.08 WTE       |
| Band 7                | 5.08 WTE       |
| Band 5/6              | 23.68 WTE      |
| Band 2/3              | 7 .97 WTE      |





#### **3.3 ADAU**

The antenatal day assessment unit is open from 08.00am to 20.00 seven days a week.

| Staff Numbers | Weekly Average     |                |  |
|---------------|--------------------|----------------|--|
| Stail Numbers | Registered Midwife | Non registered |  |
| Long Day      | 2                  | 1              |  |

| Staff Grade | Staff required |
|-------------|----------------|
| Band 7      | 1 WTE          |
| Band 5/6    | 5.17 WTE       |
| Band 2/3    | 3.08 WTE       |

## **3.5 Total current maternity workforce requirements** (including additional workforce detailed in Ockendon Review)

The figures below are dynamic due the flexibility of the service in meeting the demands of the patient group. For this paper, we have removed from the funded establishments the Home Birth team and the Continuity of Care team. There would need to be further reviews of the inpatient services establishments each time we establish another Continuity of Care team.

| Staff Band | Staff required for Inpatient | Funded    | Difference |
|------------|------------------------------|-----------|------------|
| Band 7     | 14.61 WTE                    | 13.2 WTE  | -1.41 WTE  |
| Band 5/6   | 52.53 WTE                    | 43.96 WTE | - 8.57 WTE |
| Band 2/3/4 | 26. 76 WTE                   | 26.98 WTE | + 0.22 WTE |

#### 4. Specialist Midwives

There is an allowance in Birthrate plus for specialist midwives We have a 16.6 WTE number of specialist midwives who work across the maternity services totalling Band 7 10.6 WTE and 6 WTE (Band 6).

#### 6. Recommendation from Ockendon Report

There are additional recommendations detailed in the Ockenden report for each Trust to be compliant with the following workforce requirements:

- Each maternity unit to have a Consultant midwife (1 WTE)
- A lead foetal surveillance midwife (1 WTE)
- A lead foetal surveillance Consultant
- A Consultant twice daily ward round review of the whole maternity unit.





As a consequence of the Ockendon Review we anticipate we will require an additional 11 WTE Band 6 midwives (which includes 1 WTE ward leader for the antenatal and postnatal ward (ward 9) within the maternity inpatient services.

In order to meet the requirement to enhance the onsite presence of a consultant obstetrician across the week, and to provide leadership resource in specific areas (for example, foetal surveillance) it is estimated that between 10 and 15 additional consultant programmed activities may be required. This will require additional consultant appointment rather than existing consultants taking on more work: consultant job plans are already full and additional consultants would mitigate the risk of disrupting elective activity (as we recover from the COVID-19 backlog).

#### 7. Conclusion

This paper details the current midwifery workforce establishment levels and outlines the additional staffing requirements identified following the release of the Ockendon Review.

The establishment of 5 continuity of carer teams has driven a review of the maternity workforce establishment due to the changing model of delivery. Currently there is a development of an implementation plan for further continuity of carer teams which will include the impact on core labour ward midwives which will come to board for approval prior to progressing.

MKUH will be working with Bedfordshire, Luton and Milton Keynes LMNS to seek additional national monies to support us to meet these national workforce requirements.



| Meeting title | Trust Board (public)         | 6 May 2021                         |
|---------------|------------------------------|------------------------------------|
| Report title: | Incident and Learning Report | Agenda item: 3.3                   |
| Lead director | Dr Ian Reckless              | Medical Director                   |
|               | Kate Jarman                  | Director of Corporate Affairs      |
| Report author | Tina Worth                   | Head of Risk & Clinical Governance |
| Sponsor(s)    |                              |                                    |
| Fol status:   | Public document              |                                    |

| Report summary                 | This report provides a monthly overview of Risk Management processes/systems in relation to serious incidents in the Trust. |  |  |
|--------------------------------|---|--|--|
| Purpose<br>(tick one box only) | Information Approval To note Decision   |  |  |
| Recommendation                 | The Group is asked to note the contents of the report   |  |  |

| Moderning              | The Group is deficed to held the contents of the report                |
|------------------------|--|
|                        |  |
| Strategic              | Refer to main objective and link to others                             |
| objectives links       | Improve Patient Safety   |
|                        | 3. Improve Clinical Effectiveness                                      |
|                        | 4. Deliver Key Targets   |
|                        | 7. Become Well-Governed and Financially Viable                         |
| <b>Board Assurance</b> | Lack of learning from incidents is a key risk identified on the BAF    |
| Framework links        | ,  |
| CQC outcome/           | This report relates to:  |
| regulation links       | This report relates to CQC:  |
|                        | Regulation 12 – Safe care & treatment                                  |
|                        | Regulation 17 – Good governance  |
|                        | Regulation 20 – Duty of Candour  |
| Identified risks       | Lack of learning from incidents is a key risk identified on the BAF    |
| and risk               |  |
| management             |  |
| actions                |  |
| Resource               | Breaches in respect of SI submission incur a £1000 penalty fine        |
| implications           | Breaches in respect of the Duty of Candour have potential for penalty  |
| _                      | fine of £2,500 if taken forward from a legislative perspective & up to |
|                        | £10,000 from a Commissioning contract perspective.                     |
|                        |  |
| Legal                  | Contractual and regulatory reporting requirements.                     |
| implications           |  |
| including equality     |  |
| and diversity          |  |
| assessment             |  |

| Report history | Serious Incident Review Group                    |  |  |
|----------------|--|--|--|
| Next steps     | Monthly incident/SI overarching issues reporting |  |  |
| Appendices     | Trends in graphical format                       |  |  |



#### **Introduction and Purpose of the Report**

This report is designed to give a summary of Serious Incidents (SIs) to the Board every two months (to each public Board). This report is in addition to a detailed Serious Incident report received at the Quality and Clinical Risk Committee at each of its meetings.

The purpose of this report is to be transparent around the Serious Incidents reported and investigated by the Trust, whilst maintaining the confidentiality of patients and families involved; and to provide assurance to the Board that the Trust has an effective and appropriate framework for the reporting and investigating of incidents, and ensuring actions are undertaken to reduce the likelihood of their recurrence.

The report also summarises programmes to support the continual improvement of the quality of the investigation process and outcomes in relation to learning and clinical care or service improvement.

#### **Serious Incident Report March 2021**

There were five new SIs reported on STEIS in March 2021 (table below).

| STEIS     | Category  | Details  |
|-----------|---|--|
| number    |   |  |
| 2021/6774 | Medication incident                             | Chemotherapy prescribing error   |
| 2021/6906 | Unexpected readmission                          | Baby readmitted following weight loss  |
| 2021/6261 | New pressure ulcer                              | Deep tissue injury to heel (Ward 18)   |
| 2021/6232 | Diagnostic error                                | Complete miscarriage confirmed without ultrasound (USS) confirmation. Pregnancy later noted to be viable |
| 2021/6762 | Unexpected admission to the Neonatal Unit (NNU) | Baby born via emergency caesarean section (EMCS) and admitted to NNU                                     |

With regard to Duty of Candour obligations, it is worth noting that whilst there is clear evidence that the Trust continues to be open and transparent with families verbally discussing incidents, there were nine formal Duty of Candour breaches at quarter end as letters were not sent within the timeframe.

The Risk Management Team will add any exemptions - for example maternity bereavements which are managed through the Bereavement Midwife - however the others are the responsibility of the investigating lead. It has been noticed that an increasing number are noted as not applicable (which is an unacceptable exemption) or patient deceased, in which case the written apology would go to the next of kin. On occasions SIRG will agree to an exemption where there are seen to be no care/service delivery concerns, but these are minimal.

Additional support will be provided to ensure lead clinicians and managers are fully aware of the requirement to fulfil the Duty and the steps they must take to do this. Compliance is monitored against every reported moderate harm incident.

Trends and Areas Identified for further investigation to March 2021

SI progress report for Trust Board 6 May 2021



- There has been an increase in incidents of major obstetric haemorrhage (MOH)/
  post-partum haemorrhage (PPH), with some reported as SIs. A deep dive thematic
  review has been requested to help identify any thematic contributing factors or
  issues. Early overview expects this to include:
  - · Failure to escalate
  - Documentation of blood loss
  - Identification and planning ahead
  - Medicines management
- 2. A number of **medication incidents** relating the scanning of patients and medications and the role of the second checker with intravenous medications. A working group is undertaking an analytical review of incidents.

There is also a working group in the Women's and Children's Division to review medication-related incidents, looking particularly at compliance with the Trust's Medicines Management Policy.

- 3. Compliance with clinical guidelines and timeframes for obstetric scans in relation to capacity and demand. Data analysis of bookings versus routine/urgent scan requirements in addition to Trust standard operating procedures on going
- 4. A deep-dive report is being undertaken in relation to **patient falls** looking specifically at the time of day the incidents occurred.
- Collaborative working with the Mental Health Team in relation to increased number of patients presenting with mental health issues/conditions and the challenging behaviours they display

#### **Preventing Future Deaths Report**

The Trust receiving a Preventing Future Deaths Report on March 28 following a Coronial Inquest into the death of Mr Nicholas Rousseau. The PFD relates to adherence to NICE guidelines and blood lactate levels. The Trust is required to respond to HM Coroner by 24 May and has drafted a detailed response, which the Trust will also share with Mr Rousseau's family. As this is still being prepared and has not yet been disclosed to the family (or HM Coroner) further detailed information will not be shared here.

All staff across the Trust are strongly encouraged to adhere to relevant clinical guidelines so that the safety of the patient is always prioritised.

## Covid-19 Outbreak Incidents – Summary of Investigations into Nosocomial (Healthcare Associated) Covid-19 Infections

An outbreak of an infectious disease is defined as two new cases linked in time and place. In relation to COVID-19, this can involve patients and/or staff. A key challenge is that by the time a first (index) case is identified, exposure and infection of others may well have occurred already.

NHS England have introduced defined timeframes in terms of the length of time between admission to a healthcare environment and a first positive COVID test. If this time period is relatively short, the patient likely acquired COVID in the community (and was asymptomatic and incubating the virus at the point of admission). If this time is longer, the likelihood is that SI progress report for Trust Board 6 May 2021



the patient acquired COVID in hospital – whether from the environment, other patients or staff members.

The specific timeframes are as follows: *community acquired* (positive within 48 hours of admission); *indeterminate* healthcare associated (positive screen 3-7 days after admission with no prior hospital admission in the previous 14 days); *probable* healthcare associated (positive specimen 8-14 days after admission, or a specimen date 3-14 days after admission in previous 14 days); and, *definite* healthcare associated (positive specimen date 15 days or more following admission).

In common with most other NHS organisations, we have had several COVID outbreaks over the course of the pandemic. These have been managed according to a standardised process with the involvement of Public Health England and infection prevention and control experts from the NHS Region (independent of MKUH).

Since 01 September 2020, 1,385 specific individuals have been admitted to hospital ('inpatients') and have had a positive Covid-19 swab.

Of these patients, 92 (6.5%) were definite nosocomial and a further 143 (10.3%) were probable nosocomial. We believe that this figure is average for the East of England region.

We are acutely aware of the need to provide the families of patients who have died and who may have acquired Covid-19 in hospital with reports and explanations are working hard to do that as quickly and as thoroughly as possible.

## Appreciative Inquiry – Supporting Investigation and Learning from Incidents in Maternity – Programme Update

#### **Summary**

The Trust commissioned external support in November 2020 to undertake a 12-month Appreciative Inquiry training with the aim of developing 'a culture that fosters appreciation, curiosity, meaningful engagement, co-creation and innovation that will lead to enhanced relationship-centred practices'.

Appreciative Inquiry builds on what works well, and also asks people to build on their experiences to seek out positive change. It is a well-regarded method to deliver continuous improvement in patient safety and patient and staff experience.

So far (with some delays due to the Covid-19 pandemic) the programme has introduced AI to over 75 people in the organisation which includes presentations to:

- Senior executive team,
- Maternity staff, including maternity support workers, midwives and doctors
- Trust Executive Group
- Governance team
- Quality & transformation team

#### **Maternity Workshops and In-Practice Work**

The programme has seen AI specialists work closely with 16 members of the maternity team via face-to-face workshops and in-practice work to support development of leading

SI progress report for Trust Board 6 May 2021



appreciative inquiry (Nov/Dec 2020). This cohort has continued to contribute to a community of practice that aims to share, develop and learn about appreciative inquiry.

A follow up workshop with the November maternity team was held in April; with a further workshop involving 12 new members of the multidisciplinary team from maternity, including consultants, nursery nurses, pharmacists, midwives and practice development staff.

The maternity team has piloted new appreciative systems and processes to align with appreciative inquiry principles which include:

- Exploring and reporting on incidents,
- Meetings with complainants,
- Debriefing with staff after incidents,
- Student experience check in sessions,
- Story elicitation to learn about staff, student partner and patient experience,
- Noticing, reporting and discussing positive practices,
- Appreciative meetings
- Reflective sessions on stories gathered

Reflective discussions with staff based on stories drawn from staff and patient experiences using appreciative inquiry principles are now happening once a week on a Wednesday lunchtime for a period of approx. 30 mins. The team have named these 'Hotwash'.

They are the "after-action" conversations following an event. This is not a debrief session or a traditional case review. Instead, it is a different way of learning and co-creating change, where we use creative methods to explore what is working well, what matters and what we care about in relation to the event to explore what we can take forward to improve care and safety for everyone.

So far, we have had nine Hotwash sessions with midwives, maternity care assistants, student midwives, managers, obstetricians, and anaesthetists attending. The theme for the Hotwash sessions has been mainly influenced by any current 'hot' topics however we have also run some ad-hoc topics based on the need of the staff and what's going on in the unit at the time.

Staff have shared that they truly value the Hotwash sessions as an opportunity to sit and talk to one another, to share their feelings and ideas and be heard.

In addition to the Hotwash sessions we have offered four support sessions to the multi-professional team following recent traumatic events. These have included midwives, student midwives, theatre staff, anaesthetics, paediatricians, medical doctors, emergency department nurses and managers. The overarching response from staff is that this 'feels different' – they feel heard, valued, and reassured.

Specific outcomes so far from these sessions include:

- Staff feeling supported
- Valuing the time to talk and share
- More face to face rounding in rooms
- Checking plans of care with staff more by the band 7 leads
- Explain the expectations of ward 9 postnatal care to women and how it is different to labour ward because of the staff/patient ratio.
- How important it is to stay calm and give good care regardless of what else is going on



- Share women's stories alongside other information at meetings such as risk, CSU and SIRG. This would provide a different aspect to the incidents
- Support and training for staff working in theatre and recovery on how to support bereaved parents.
- Triaging phone calls now to be logged on eCare
- Anaesthetic team already in discussions about the appropriate form of anaesthesia in events where babies require full resuscitation
- Put non-urgent requests on the eCare white board to enable doctors to action them from anywhere in the Trust and not being bleeped multiple times for the same thing
- Training and support for junior or staff that need structured support with running a shift and team leader
- Diabetes training for midwives physiology and managing sliding scales

#### Emerging learning and outcomes:

As a result of these pilots and the appreciative inquiry development workshops staff and patients have reported the following:

- Feeling heard
- Feeling more positive and calm as a member of staff and as a woman receiving care
- Feeling included and valued
- Feeling able to take forward small cycles of change that involve those who have the experience
- Having more confidence to try new things out
- Have a greater understanding of what is happening in the unit and how they can make small changes and influence change (incident)

#### Staff perspectives

From a survey carried out six months post initial workshops participants on the programme gave the following feedback (% number of people answering positively):

- Trying to see possibilities rather than joining in negative talk (83%)
- Finding out people's strengths (71%)
- Using respectful language (58%)
- Taking the time to explore why certain things go well (70%)
- Feeling confident to challenge the vision of our unit/organisation (65%)
- Feeling comfortable to discuss differences of opinion in an open way (85%)
- Feeling confident to encourage patients and families to talk about things that are worrying them (42%)

Aspects where there was less of a difference over the last six months since the programme started included:

Recognizing and seeking support for the emotional demands of my work

In discussion with staff some felt that using appreciative inquiry was an emotionful and emotionally draining experience and that they wondered how they could get support for support emotionally. This – and those areas which remain lower scoring - will be further explored with members of the community of practice and the wider quality teams.

#### Developments/changes in practice

Specific outcomes and changes in practice that were developed following discovery work about peoples' experiences of giving or receiving care include:

SI progress report for Trust Board 6 May 2021



- Emergency response: fewer people rush into woman's room which has been recognised to cause concern. others wait outside until they have been called in
- Handover: used to be in a busy corridor now in a separate room on the ward enabling better focus
- Supporting and caring for staff and patients: exploring how people are feeling after a
  major incident on the unit as the first step before exploring what happened and what
  went wrong
- Student, staff and women's experience: exploring how students feel about their experience at regular intervals during their placement to make immediate, small changes
- Exploring how women feel about their experience on a regular basis and using this to develop practice
- Changes to the language used in the maternity unit for example 'breast feeding assessment' to 'breast feeding support discussion' (based on one woman's experience that this term made her feel anxious that she was about to attend a test and was concerned she might fail.

#### Resources

The Trust intranet improvement site/hub is developing a Quality Improvement Hub with Appreciative Inquiry resources. This Hub will contain over 25 resources that enhance dialogue with staff, patients and families to learn about what is working well and why, and what matters to people to co-create future quality improvement initiatives, however small.

#### **Next Steps**

The Appreciative Inquiry programme will continue in maternity and will roll out to patient experience (corporately), the Emergency Department and Theatres (complimenting a programme of Human Factors training currently being undertaken by the multi-disciplinary Theatres team).



#### **Appendix 1: Summary Information on Nosocomial Infection to Families**

The following information is sent to families where a relative along with a summary of their admission and concise investigation with input from Medical Examiners and Infection Prevention and Control specialists.

#### Arrangements for the Management of COVID-19 in Hospital

You are receiving this information sheet as your relative has died at Milton Keynes Hospital and COVID-19 may have been a contributory or causative factor. We wish to extend our sympathies to you at this difficult time. The purpose of the information is to provide you with some context and background for some of the questions that you may have following your relative's death in the hospital. We are also conscious that the restrictions with allowing hospital visiting during the COVID pandemic have been very challenging and difficult for families to understand and accept.

#### COVID-19

Since COVID-19 (a type of coronavirus) was first seen in the United Kingdom a year ago, we have been building our knowledge about it over time. We know that COVID-19 is highly infectious, that it is spread via a number of routes including through respiratory 'droplets' in the air, and that its presentation can vary from no symptoms whatsoever to a very dangerous and serious situation where the lungs become inflamed to such a degree that they fail. This latter condition occurs sometime after initial infection and is driven in part by the body's own immune system.

For those who do have symptoms, there may well have been a period of incubation (since the infection was first acquired) when there would have been no symptoms and the person may or may not have been infectious. The risk of droplet spread is higher when the patient has a large amount of virus in their system (high viral load) and when certain procedures (known as 'aerosol generating procedures, AGPs') are undertaken: these include the use of non-invasive ventilators to support people to breathe sometimes known as CPAP. COVID-19 can also spread through contaminated surfaces. The elderly are at particular risk of dying with severe COVID lung involvement as they tend to have less 'physiological reserve' and are less able to withstand a deterioration in lung function.

#### Infection Prevention and Control

The key elements of infection prevention and control in relation to COVID-19 are identical inside and outside the hospital: hands, face and space. Regular hand washing (certainly between all patient contacts) and mask wearing have been in place in the hospital since early in the pandemic. Whilst social distancing is inevitably challenging given the work we do and the nature of direct patient care, staff have been making efforts in their own areas to make appropriate adjustments (for example, smaller ward rounds and use of digital internet solutions for team meetings). Just as adherence to hands, face and space in the community requires continual focus and attention in order to avoid complacency, the same is true in the hospital environment.

Throughout the pandemic, we have been carefully considering where best to look after patients according to the likelihood of them having COVID (with or without symptoms): a green pathway has been in place for patients coming into hospital in a planned way for surgery or a procedure (having had a negative swab a couple of days prior to admission); a red pathway exists for patients who are known to have COVID or who have symptoms highly suggestive of active COVID infection (pending the result of swabs and other tests); and, an amber pathway which is in place for patients coming into hospital without signs or symptoms SI progress report for Trust Board 6 May 2021



of COVID, or a significant history of exposure (again, whilst awaiting the results of an admission swab).

The nature of the red pathway has changed over time according to the levels of COVID in our community and our hospital. In early January 2021, over half of the hospital's admitted inpatients had confirmed COVID-19 and there was only a very small number of ward areas without any patients with COVID. Several wards areas were reserved for COVID positive patients only. The situation was different in the autumn (when the volume of COVID in the community and in the hospital was much lower) and some COVID positive patients were cared for in single rooms on our regular wards. Patients with known COVID undergoing aerosol generating procedures (increasing the risk of droplet spread to others in the vicinity) were cared for in specific areas and zones of the hospital.

#### **Outbreaks**

An outbreak of an infectious disease is defined as two new cases linked in time and place. In relation to COVID-19, this can involve patients and/or staff. A key challenge is that by the time a first (index) case is identified, exposure and infection of others may well have occurred already.

NHS England have introduced defined timeframes in terms of the length of time between admission to a healthcare environment and a first positive COVID test. If this time period is relatively short, the patient likely acquired COVID in the community (and was asymptomatic and incubating the virus at the point of admission). If this time is longer, the likelihood is that the patient acquired COVID in hospital – whether from the environment, other patients or staff members.

The specific timeframes are as follows: *community acquired* (positive within 48 hours of admission); *indeterminate* healthcare associated (positive screen 3-7 days after admission with no prior hospital admission in the previous 14 days); *probable* healthcare associated (positive specimen 8-14 days after admission, or a specimen date 3-14 days after admission in previous 14 days); and, *definite* healthcare associated (positive specimen date 15 days or more following admission).

In common with most other NHS organisations, we have had several COVID outbreaks over the course of the pandemic. These have been managed according to a standardised process with the involvement of Public Health England and infection prevention and control experts from the NHS Region (independent of MKUH).

#### Movement of patients within hospital

In ordinary times, a patient might expect to move wards a couple of times during a hospital stay – for example from the Emergency Department to an Assessment Ward on to an appropriate specialty ward. There is a balance to be struck between providing patients continuity of care (from a single team of healthcare professionals), accessing sub-specialist expertise (for example being looked after by a team which specialises in the cardiac care, the frail elderly or stroke, as opposed to general medicine) and maintaining an environment where the flow of patients through (and discharge from) the hospital can be maintained. When a patient is in an individual ward area they might move bed space for various reasons – usually depending upon the specific needs of the patients in the area (for example, high clinical care needs, psychological distress or palliative care needs), infection control measures, the maintenance of single sex facilities or individual patient preference.

During the pandemic, the factors above have remained relevant. In addition, we have had to adjust the respective footprints of the red and amber pathways. For example, moving from SI progress report for Trust Board 6 May 2021



the management of a total of 4 or 5 COVID patients in single rooms across a small number of ward areas, to cohorting 15 or more COVID positive patients on a specific ward.

#### **Testing**

The definitive test for COVID-19 is a Polymerase Chain reaction (PCR) test which involves analysis of a swab from the nose and/or throat. No test is 100% effective in picking up the virus (for several reasons including swabbing technique), and the test can pick up viral remnants that are no longer clinically relevant (many weeks down the line from initial and active infection) and no longer an infection risk. A positive COVID test does not always imply infectivity. Early in the pandemic the PCR tests were all sent to large central laboratories (in the case of MKUH, at the John Radcliffe in Oxford) although in recent months we have acquired local testing machines meaning that approximately half of the MKUH tests are now done here at the hospital. The time taken for the results of the test to be available has varied across the pandemic and now stands at between 2 and 20 hours depending upon the urgency and the testing route. Since mid-December, most of our urgent swabs (for patients being admitted to the hospital in an unplanned way) have been undertaken locally with a shorter turn around time. Other tests called 'lateral flow tests' have been in use at the hospital since Christmas: these tests can be helpful in providing earlier warning of COVID infection but a negative test cannot provide significant assurance and all lateral flow tests need to be sent with a paired laboratory PCR swab.

A small number of patients have persistently negative COVID swabs but a clinical picture and X-ray (CT) changes which are highly suggestive of COVID infection. These patients are also treated as COVID positive.

#### **Spread of COVID within hospital**

We aim to minimise the risk of spread of COVID within hospital and recognise that the impact of spread within hospital can be devastating as many inpatients are predictably elderly or frail.

Against this background, it is important to recognise that the hospital will inevitably be the venue within Milton Keynes where the highest number of COVID positive people congregate (as they require care and treatment), and that the nature of healthcare is such that social distancing is a relative rather than absolute concept. Every effort should be made to socially distance but a patient may require the physical help of two or three people to undertake a specific task, or to be turned in bed. Preventing the spread of a virus such as COVID-19 in a busy hospital is extremely challenging, not least because people may be infectious in the absence of any symptoms, tests can be imperfect and can take many hours to provide a result.

We hope that this note is helpful in considering the more specific circumstances which relate to the care your relative received whilst in the hospital.





Meeting title **Board of Directors Date:** May 6<sup>th</sup> 2021 Report title: Agenda item: 3.4 **Nursing Staffing Report** Lead director Name: Nicky Burns-Muir Title: Director of Patient Care/Chief Nurse Name: Matthew Sandham Title: Associate Chief Nurse Report author Sponsor(s) **Emma Thorne** Workforce Matron Fol status: Report summary Information[ Decision **Purpose Approval** To note (tick one box only) Recommendation That the Board receive the Nursing Staffing Report.

| Stratogio              | Objective 1 Improve nations agents                                     |
|------------------------|--|
| Strategic              | Objective 1 - Improve patient safety.                                  |
| objectives links       | Objective 2 - Improve patient care.                                    |
| <b>Board Assurance</b> | Inadequate staffing are contributory issues for BAF risks 1.1 and 1.4. |
| Framework links        |  |
| CQC outcome/           | Outcome 13 staffing.   |
| regulation links       |  |
| Identified risks       |  |
| and risk               |  |
| management             |  |
| actions                |  |
| Resource               | Unfilled posts have to be covered by Bank or agency staff, with agency |
| implications           | staff having a resource implication.                                   |
| Legal                  | None as a result of this report.                                       |
| implications           |  |
| including equality     |  |
| and diversity          |  |
| assessment             |  |

| Report history | To every Public Board |
|----------------|-----------------------|
| Next steps     |                       |
| Appendices     | Appendices 1          |





## Board of Directors Report on Nursing and Midwifery staffing levels Amalgamated report for February and March 2021

#### 1. Purpose

To provide Board with: -

- An overview of Nursing and Midwifery staffing levels.
- An overview of the Nursing and Midwifery vacancies and recruitment activity.
- Update the Board on controls on nursing spend.

#### 2. Planned versus actual staffing and CHPPD (Care Hours per Patient Day)

We continue to report monthly staffing data to 'UNIFY' and to update the Trust Board on the monthly staffing position.

CHPPD is calculated by taking the actual hours worked divided by the number of patients on the Ward at midnight.

CHPPD = hours of care delivered by Nurses and HCSW
Numbers of patients on the Ward at midnight

| CHPPD    | Total Patient | Registered      | Care  | Overall |
|----------|---------------|-----------------|-------|---------|
|          | Numbers       | Midwives/Nurses | Staff |         |
| February | 10765         | 5.1             | 3.2   | 8.3     |
| March    | 11215         | 5.1             | 3.4   | 8.5     |

| Month    | RN/RM<br>Day %<br>Fill Rate | HCA/MCA<br>Day %<br>Fill Rate | RN/RM<br>Night % Fill<br>Rate | HCA/MCA<br>Night %<br>Fill Rate |
|----------|-----------------------------|-------------------------------|-------------------------------|---------------------------------|
| February | 72.5%                       | 71.9%                         | 90.7%                         | 98.6%                           |
| March    | 69.3%                       | 73.8%                         | 91.0%                         | 103.0%                          |

<sup>•</sup> February and March 2021 data are included in Appendix 1.

#### Areas with notable fill rates

During the months of February and March the Trust continued with their staffing surge plan, therefore the data recorded per ward does not entirely reflect the staff allocated on the day. The surge staff could not be allocated to a clinical area as this would require a reallocation of budget. The staffing surge plan came to an end at the end of March with all staff returning to their normal place of work.

## Are we safe?

#### 3. Recruitment Overview

The Trust has remained proactive with Nursing and Midwifery recruitment throughout the pandemic. The Senior Nursing Workforce team continue work collaboratively with HR on initiatives to optimise recruitment across the organisation.

#### Medicine

| Band     | WTE Vacancy | Percentage | Turn over  |
|----------|-------------|------------|------------|
|          |             |            | percentage |
| Band 2   | 5.4WTE      | 4%         | 6.9%       |
| Band 5&6 | 45 WTE      | 11%        | 6%         |

#### Surgery

| Band     | WTE Vacancy | Percentage | Turn Over  |
|----------|-------------|------------|------------|
|          |             |            | percentage |
| Band 2   | 6.37 WTE    | 4%         | 6%         |
| Band 5&6 | 18.24 WTE   | 9%         | 5%         |

#### Women's and Children

| Band     | WTE Vacancy | Percentage | Turn Over percentage |
|----------|-------------|------------|----------------------|
| Band 2   | 1.17WTE     | 4%         | 6 %                  |
| Band 5&6 | 23 WTE      | 10.7%      | 2%                   |

#### **Health Care Support Workers Recruitment (HCSW)**

As reported in previous reports, Ruth May, the Chief Nursing Officer, for England announced a zero tolerance to HCSW vacancies in NHS Trusts. Milton Keynes University Hospital was therefore set the objective to recruit into all 61wte HCSW vacancies by the end of March/April 2021.

The Trust was commissioned to work with NHSI on the 'Accelerated Healthcare Support Worker Recruitment Scheme'. The aim of the program was to reduce vacancies swiftly, enhance the onboarding process (including mentorship, training, and pastoral support to candidates), and deliver training to optimise safety and enable staff to be competent and safe in practice. A high proportion of the new HCSW's are new to healthcare and have a breadth of previous job roles and experience which will significantly contribute to the clinical teams delivery of care.

During the induction process employees were offered an opportunity to consider undertaking the nursing apprenticeship programme and nursing associate programme.

To date 54.87wte HCSW (a total of 62 individuals) have commenced employment with us. With a further 7.44wte due to commence in May 2021.

This recruitment campaign has been a huge success with individuals starting in the time frame specified and the HCA Trainer from the Practice Education team has facilitated a two-week bespoke induction programme to ensure that all new HCSW's are well educated and fully prepared to undertake their role. The delivery of the programme has received significant interest from the RCN Bulletin and Health Education England to produce articles to share more widely.

Work is now underway related to the retention of this cohort of staff who historically have a higher rate of turnover than registered nursing and midwifery staff.

#### **Registered Nurses Band 5**

From a recruitment perspective generic recruitment campaigns have proven successful during the pandemic. As vacancies reduce the Medical and Surgical Divisions plan to return to Divisional recruitment campaigns to tailor their recruitment campaigns going forward led by the Divisional Chief Nurses.

The Workforce Matron continues to work with the Learning Environment Leads to plan and facilitate recruitment education workshops for Student Nurses to ensure that MKUH is their first choice to work. There are 40 MKUH Student Nurses due to qualify in September 2021 and MKUH has committed through BLMK to automatically recruited and offered positions within our organisation, without a formal interview. This process will ensure a supply of nurses three times a year. Therefore, these nurses have undertaken their nurse training with us and have been signed off by the organisation as ready for the professional register and are familiar with our organisational values, standards and policies to facilitate a smooth transition.

#### **International Nurse Recruitment**

In the height of the COVID-19 pandemic the trust worked on the national agenda with Health Education England 'Global Learners Programme' to optimise staffing in critical care areas

As part of this campaign MKUH recruited two nurses from India (1 staff Nurse for Neonatal Unit and 1 staff Nurse for Intensive Care Unit). Our international Nurses arrived in the UK on 6th April and following their isolation period have commenced a comprehensive induction programme in their clinical areas. As an organisation we will support both nurses with their Objective Structured Clinical Examination (OSCE) preparation and assist them in securing their NMC registration.

There are currently no further plans for international recruitment this will be continued to be reviewed on a regular basis by the Senior Workforce and Corporate Nursing team.

#### Band 6

To optimise patient experience, patient safety and drive standards the Trust has invested in senior clinical leadership that would allow for a Band 6 Junior Sister/ Charge Nurse to be present on every shift.

Interviews were held in March and 24.82wte (28 candidates) were successful at interview (3 external candidates). This has been an exciting opportunity for Staff Nurses here at MKUH to progress their career and leadership journey and has created positivity within the nursing teams.

All appointed band 6's will undergo a comprehensive induction with a number of study days over several months irrespective of years of experience to set the expectation of the role and ensure the impact of investment is realised ie. Improving quality; facilitating discharges and patient flow.

## Are we effective?

#### 4. Agency graph



During the period of February and March we saw the agency cost rise and is comparable with same period in 2018 and 2019. This has been driven staff sickness or isolating due mainly COVID 19. The Agency utilisation has been restricted in the month of April and we should see a reduction in spend.

#### 5. SafeCare Update

SafeCare is now 'live' in all wards across the organisation. Wards have been entering the required census data three times a day and Trust wide compliance has reached 90% for data entry.

As an organisation we are now enter the 'validation and professional judgement phase' of SafeCare'. This phase will ensure that data being entered is accurate (in line with the Shelford Safer Nursing Care Tool) and will require senior review from the Matrons to validate the RAG status of all wards to optimise patient safety with safe staffing levels.

SafeCare is now incorporated into the Daily Safety Huddle and Matrons have commenced using SafeCare when reviewing staffing and assessing safety across the organisation.

The data from SafeCare will help inform the establishment reviews planned for May 2021.

### We celebrate

Following the conclusion of the Divisional Nursing Leadership consultation there has been a change in the senior structure of nursing with the surgery and medicine divisions with the following appointments:

Liz Winter - Divisional Chief Nurse for Medicine

Emma Codrington - Divisional Chief Nurse for Surgery

Kieran Dunne - Senior Matron for Surgery

Louise Senior – Senior Matron for Medicine

We also welcomed Kirsty Sharp in March who is the Mental Health Practice Educator to MKUH. This post will educate and support staff in managing patients with mental health issues and provide expertise to the organisation on education programmes and operational policies to optimise outcomes for patients with mental health concerns.

The patient and family experience team have appointed a Matron Sharon Robertson who will provide clinical expertise to the complaints and PALS team and engage clinical staff in projects to deliver the patient experience strategy.

## Nursing, Midwifery and Care Staff February 2021 (Appendix 1)

|                 | Day  |   | Night  |   | Care Hours Per Patient Day (CHPPD)   |                                   |               |         |  |  |  |  |
|-----------------|--|---|--|---|--|-----------------------------------|---------------|---------|--|--|--|--|
| Ward<br>Name    | Average fill rate - registered nurses/midwives (%) | Average<br>fill rate -<br>care<br>staff (%) | Average fill rate - registered nurses/midwives (%) | Average<br>fill rate -<br>care<br>staff (%) | cumulative<br>count over<br>the month<br>of patients<br>at 23:59<br>each day | Registered<br>midwives/<br>nurses | Care<br>Staff | Overall |  |  |  |  |
| AMU             | 82.4%  | 79.5%                                       | 98.1%  | 108.9%                                      | 558  | 5.8                               | 2.4           | 8.2     |  |  |  |  |
| MAU 2           | 54.7%  | 72.3%                                       | 69.5%  | 114.3%                                      | 575  | 4.1                               | 2.8           | 6.9     |  |  |  |  |
| Phoenix<br>Unit | 78.6%  | 71.3%                                       | 94.1%  | 114.9%                                      | 476 3.9  |                                   | 3.7           | 7.6     |  |  |  |  |
| Ward<br>15      | 70.3%  | 66.3%                                       | 90.3%  | 90.3%                                       | 355  | 9.5                               | 8.9           | 18.4    |  |  |  |  |
| Ward<br>16      | 62.7%  | 78.4%                                       | 90.2%  | 96.4%                                       | 444  | 4.9                               | 3.5           | 8.4     |  |  |  |  |
| Ward<br>17      | 71.6%  | 77.3%                                       | 96.6%  | 106.3%                                      | 619  | 4.3                               | 2.1           | 6.5     |  |  |  |  |
| Ward<br>18      | 70.9%  | 71.1%                                       | 85.7%  | 110.8%                                      | 585  | 3.4                               | 3.8           | 7.2     |  |  |  |  |
| Ward<br>19      | 72.5%  | 72.0%                                       | 100.0%   | 108.3%                                      | 708  | 3.1                               | 3.1           | 6.2     |  |  |  |  |
| Ward<br>20      | 82.3%  | 61.8%                                       | 99.4%  | 110.7%                                      | 582  | 4.5                               | 3.0           | 7.5     |  |  |  |  |
| Ward<br>21      | 72.9%  | 70.8%                                       | 88.1%  | 83.9%                                       | 341  | 6.8                               | 3.3           | 10.0    |  |  |  |  |
| Ward<br>22      | 69.7%  | 89.7%                                       | 97.6%  | 97.6%                                       | 468  | 4.5                               | 4.3           | 8.8     |  |  |  |  |
| Ward<br>23      | 80.9%  | 82.5%                                       | 101.8%   | 107.1%                                      | 1135 3.0   |                                   | 3.0           | 6.0     |  |  |  |  |
| Ward<br>24      | 30.7%  | 28.8%                                       | 26.2%  | 28.6%                                       | 145  | 4.3                               | 4.3           | 8.7     |  |  |  |  |
| Ward 3          | 43.1%  | 61.7%                                       | 50.8%  | 83.5%                                       | 468  | 4.0                               | 4.1           | 8.1     |  |  |  |  |
| Ward 5          | 81.6%  | 69.5%                                       | 149.1%   | 49.4%                                       | 282  | 14.3                              | 1.6           | 15.9    |  |  |  |  |
| Ward 7          | 69.5%  | 72.0%                                       | 88.1%  | 103.6%                                      | 433  | 4.6                               | 5.0           | 9.6     |  |  |  |  |
| Ward 8          | 73.7%  | 85.7%                                       | 98.8%  | 149.9%                                      | 615  | 3.5                               | 3.3           | 6.8     |  |  |  |  |
| ICU             | 110.4%   | 126.0%                                      | 119.8%   | -   | 195  | 30.6                              | 2.7           | 33.3    |  |  |  |  |
| Labour<br>Ward  |  |   |  |   |  |                                   |               |         |  |  |  |  |
| Ward 9          | 77.3%  | 82.0%                                       | 71.4%  | 93.0%                                       | 1029   | 2.1                               | 1.8           | 3.9     |  |  |  |  |
| Ward<br>10      |  |   |  |   |  |                                   |               |         |  |  |  |  |
| NNU             | 70.0%  | 54.3%                                       | 77.4%  | 100.0%                                      | 220  | 15.0                              | 2.4           | 17.4    |  |  |  |  |
| Ward<br>25      | 69.1%  | 71.2%                                       | 98.9%  | 96.5%                                       | 532  | 4.3                               | 2.8           | 7.1     |  |  |  |  |

### Nursing, Midwifery and Care Staff March 2021(Appendix 1)

|              | Day  |   | Night  |   | Care Hours Per Patient Day (CHPPD)   |                             |               |         |  |  |  |  |
|--------------|--|---|--|---|--|-----------------------------|---------------|---------|--|--|--|--|
| Ward<br>Name | Average fill rate - registered nurses/midwives (%) | Average<br>fill rate -<br>care<br>staff (%) | Average fill rate - registered nurses/midwives (%) | Average<br>fill rate -<br>care<br>staff (%) | Cumulative<br>count over<br>the month<br>of patients<br>at 23:59<br>each day | Registered midwives/ nurses | Care<br>Staff | Overall |  |  |  |  |
| AMU          | 82.4%  | 79.5%                                       | 98.1%  | 108.9%                                      | 558  | 5.8                         | 2.4           | 9.3     |  |  |  |  |
| ICU          | 54.7%  | 72.3%                                       | 69.5%  | 114.3%                                      | 575  | 4.1                         | 2.8           | 32.1    |  |  |  |  |
| Ward 2       | 78.6%  | 71.3%                                       | 94.1%  | 114.9%                                      | 476  | 3.9                         | 3.7           | 6.3     |  |  |  |  |
| NNU          | 70.3%  | 66.3%                                       | 90.3%  | 90.3%                                       | 355  | 9.5                         | 8.9           | 16.0    |  |  |  |  |
| Ward<br>14   | 62.7%  | 78.4%                                       | 90.2%  | 96.4%                                       | 444  | 4.9                         | 3.5           | 9.2     |  |  |  |  |
| Ward<br>10   | 71.6%  | 77.3%                                       | 96.6%  | 106.3%                                      | 619  | 4.3                         | 2.1           | -       |  |  |  |  |
| Ward<br>15   | 70.9%  | 71.1%                                       | 85.7%  | 110.8%                                      | 585  | 3.4                         | 3.8           | 13.4    |  |  |  |  |
| Ward<br>16   | 72.5%  | 72.0%                                       | 100.0%   | 108.3%                                      | 708  | 3.1                         | 3.1           | 8.0     |  |  |  |  |
| Ward<br>17   | 82.3%  | 61.8%                                       | 99.4%  | 110.7%                                      | 582  | 4.5                         | 3.0           | 6.5     |  |  |  |  |
| Ward<br>18   | 72.9%  | 70.8%                                       | 88.1%  | 83.9%                                       | 341  | 341 6.8                     |               | 8.0     |  |  |  |  |
| Ward<br>19   | 69.7%  | 89.7%                                       | 97.6%  | 97.6%                                       | 468  | 4.5                         | 4.3           | 8.4     |  |  |  |  |
| Ward<br>20   | 80.9%  | 82.5%                                       | 101.8%   | 107.1%                                      | 1135   | 3.0                         | 3.0           | 6.6     |  |  |  |  |
| Ward<br>24   | 30.7%  | 28.8%                                       | 26.2%  | 28.6%                                       | 145  | 4.3                         | 4.3           | 9.9     |  |  |  |  |
| Ward<br>21   | 43.1%  | 61.7%                                       | 50.8%  | 83.5%                                       | 468  | 4.0                         | 4.1           | 10.2    |  |  |  |  |
| Ward<br>22   | 81.6%  | 69.5%                                       | 149.1%   | 49.4%                                       | 282  | 14.3                        | 1.6           | 8.0     |  |  |  |  |
| Ward<br>23   | 69.5%  | 72.0%                                       | 88.1%  | 103.6%                                      | 433  | 4.6                         | 5.0           | 13.8    |  |  |  |  |
| Ward<br>24   | 73.7%  | 85.7%                                       | 98.8%  | 149.9%                                      | 615  | 3.5                         | 3.3           | 7.6     |  |  |  |  |
| Ward 3       | 110.4%   | 126.0%                                      | 119.8%   | -   | 195  | 30.6                        | 2.7           | 10.0    |  |  |  |  |
| Ward 5       |  |   |  |   |  |                             |               | 8.7     |  |  |  |  |
| Ward 7       | 77.3%  | 82.0%                                       | 71.4%  | 93.0%                                       | 1029   | 2.1                         | 1.8           | 8.0     |  |  |  |  |
| Ward 8       |  |   |  |   |  |                             |               | 4.2     |  |  |  |  |
| Ward 9       | 70.0%  | 54.3%                                       | 77.4%  | 100.0%                                      | 220  | 15.0                        | 2.4           | 8.0     |  |  |  |  |
| Ward<br>25   | 69.1%  | 71.2%                                       | 98.9%  | 96.5%                                       | 532  | 4.3                         | 2.8           |         |  |  |  |  |



| Meeting title                  | Trust Board          | Date: 6 May 2021                 |
|--------------------------------|----------------------|----------------------------------|
| Report title:                  | Workforce Report     | Agenda item: 4.1                 |
| Lead director                  | Name: Danielle Petch | Title: Director of Workforce     |
| Report author Name: Paul Sukhu |                      | <b>Title: Deputy Director of</b> |
|                                |                      | Workforce                        |
| Fol status:                    | Public               |                                  |
|                                |                      |                                  |

| Report summary      | This report provides a summary of workforce Key Performance Indicators for the full year ending 31 March 2021 (Month 12) and relevant Workforce and Organisational Development updates to Trust Board |                         |                   |                 |  |  |  |  |  |  |
|---------------------|---|-------------------------|-------------------|-----------------|--|--|--|--|--|--|
|                     | and Organisationa   | <u>ii Development u</u> | paates to Trust B | oard            |  |  |  |  |  |  |
| Purpose             | Information X   | Approval                | To note X         | <b>Decision</b> |  |  |  |  |  |  |
| (tick one box only) |   |                         |                   |                 |  |  |  |  |  |  |
| Recommendation      | Trust Board is asked to note and receive the Workforce Report for Mont 12.  |                         |                   |                 |  |  |  |  |  |  |

| Strategic              | Objective 8: Investing in our people |
|------------------------|--------------------------------------|
| objectives links       |                                      |
| <b>Board Assurance</b> | BAF risks 19-24                      |
| Framework links        |                                      |
| CQC outcome/           | Well Led                             |
| regulation links       | Outcome 13: Staffing                 |
| Identified risks       |                                      |
| and risk               |                                      |
| management             |                                      |
| actions                |                                      |
| Resource               |                                      |
| implications           |                                      |
| Legal                  |                                      |
| implications           |                                      |
| including equality     |                                      |
| and diversity          |                                      |
| assessment             |                                      |
| Report history         |                                      |
| Next steps             |                                      |
| Appendices             |                                      |



### 1. Purpose of the report

1.1. This report provides a summary of workforce Key Performance Indicators as at 31 March 2021 (Month 12), covering the preceding 13 months.

#### 2. Summary of Key Performance Indicators (KPIs) and Compliance

| Indicator                        | Measure  | Target | 03/2020 | 04/2020 | 05/2020 | 06/2020 | 07/2020 | 08/2020 | 09/2020 | 10/2020 | 11/2020 | 12/2020 | 01/2021 | 02/2021 | 03/2021 |
|----------------------------------|--|--------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Staff in post (as at report      | WTE  |        | 3177.3  | 3177.0  | 3238.8  | 3266.8  | 3276.7  | 3227.3  | 3243.8  | 3245.1  | 3256.5  | 3251.3  | 3250.0  | 3284.0  | 3311.6  |
| date)                            | Headcount  |        | 3666    | 3656    | 3723    | 3761    | 3766    | 3707    | 3727    | 3728    | 3738    | 3729    | 3730    | 3765    | 3795    |
| Establishment (as at report      | WTE  |        | 3456.3  | 3690.8  | 3698.6  | 3693.9  | 3694.0  | 3693.0  | 3690.2  | 3699.9  | 3702.2  | 3706.8  | 3702.6  | 3701.9  | 3701.9  |
| date - as per finance data)      | %, Vacancy Rate (for Cost Centres, excludes Reserves)  | 10%    | 8.1%    | 13.9%   | 12.4%   | 11.6%   | 11.3%   | 12.6%   | 12.1%   | 12.3%   | 12.0%   | 12.3%   | 12.2%   | 11.3%   | 10.5%   |
| Staff Costs (12 months)          | %, Temp Staff Cost                                     |        | 13.8%   | 13.8%   | 13.3%   | 12.9%   | 12.5%   | 12.2%   | 12.1%   | 11.9%   | 11.7%   | 11.7%   | 11.6%   | 11.6%   | 11.6%   |
| Stari Costs (12 months)          | %, Temp Staff Usage                                    |        | 14.2%   | 14.1%   | 13.6%   | 13.2%   | 12.8%   | 12.5%   | 12.2%   | 12.0%   | 11.9%   | 11.8%   | 11.8%   | 11.8%   | 11.8%   |
|                                  | %, 12 month Absence Rate                               | 4%     | 4.1%    | 4.4%    | 4.5%    | 4.5%    | 4.4%    | 4.5%    | 4.5%    | 4.6%    | 4.7%    | 4.8%    | 5.0%    | 5.1%    | 4.8%    |
| Absence (12 months)              | - %, 12 month Absence Rate - Long Term                 |        | 2.2%    | 2.3%    | 2.4%    | 2.4%    | 2.3%    | 2.4%    | 2.4%    | 2.6%    | 2.6%    | 2.7%    | 2.7%    | 2.8%    | 2.8%    |
|                                  | - %, 12 month Absence Rate - Short Term                |        | 1.9%    | 2.1%    | 2.1%    | 2.1%    | 2.1%    | 2.1%    | 2.1%    | 2.1%    | 2.1%    | 2.2%    | 2.4%    | 2.3%    | 2.1%    |
|                                  | %,In month Absence Rate - Total                        |        | 6.5%    | 7.6%    | 4.7%    | 3.4%    | 3.3%    | 3.6%    | 4.0%    | 4.1%    | 5.0%    | 6.1%    | 6.7%    | 4.7%    | 3.4%    |
|                                  | - %, In month Absence Rate - Long Term                 |        | 2.5%    | 3.3%    | 3.0%    | 2.1%    | 2.2%    | 2.5%    | 2.5%    | 2.7%    | 2.6%    | 3.6%    | 2.9%    | 2.9%    | 2.5%    |
|                                  | - %, In month Absence Rate - Short Term                |        | 4.0%    | 4.3%    | 1.7%    | 1.4%    | 1.1%    | 1.1%    | 1.5%    | 1.4%    | 2.4%    | 2.5%    | 3.8%    | 1.8%    | 0.9%    |
|                                  | - %, In month Absence Rate - COVID-19 Sickness Absence |        | 1.4%    | 3.8%    | 1.3%    | 0.5%    | 0.2%    | 0.2%    | 0.2%    | 0.2%    | 1.1%    | 2.1%    | 3.3%    | 1.3%    | 0.5%    |
|                                  | WTE, Starters  |        | 362.1   | 369.4   | 363.3   | 355.1   | 355.9   | 362.0   | 360.5   | 336.0   | 329.9   | 329.2   | 313.0   | 318.0   | 311.6   |
|                                  | Headcount, Starters                                    |        | 414     | 424     | 415     | 406     | 408     | 414     | 413     | 386     | 376     | 373     | 358     | 363     | 356     |
| Starters, Leavers and T/O rate   | WTE, Leavers   |        | 268.3   | 270.4   | 259.9   | 249.5   | 251.7   | 251.5   | 249.0   | 241.2   | 244.7   | 240.1   | 233.7   | 229.3   | 203.4   |
| (12 months)                      | Headcount, Leavers                                     |        | 315     | 318     | 306     | 295     | 298     | 298     | 295     | 286     | 291     | 286     | 278     | 273     | 241     |
| ,                                | %, Leaver Turnover Rate                                | 10%    | 9.4%    | 9.6%    | 9.2%    | 8.8%    | 8.8%    | 8.9%    | 8.8%    | 8.5%    | 8.5%    | 8.4%    | 8.2%    | 8.0%    | 7.1%    |
|                                  | %, Stability Index                                     |        | 85.7%   | 84.4%   | 85.6%   | 86.3%   | 86.4%   | 86.3%   | 86.8%   | 87.0%   | 86.9%   | 87.2%   | 87.1%   | 87.0%   | 87.8%   |
| Statutory/Mandatory<br>Training  | %, Compliance  | 90%    | 94%     | 94%     | 93%     | 94%     | 94%     | 95%     | 95%     | 94%     | 95%     | 95%     | 95%     | 96%     | 97%     |
| Appraisals                       | %, Compliance  | 90%    | 94%     | 90%     | 90%     | 92%     | 93%     | 92%     | 92%     | 93%     | 91%     | 90%     | 92%     | 93%     | 95%     |
| Medical and Dental<br>Appraisals | %, Compliance  | 90%    | 97%     | 97%     | 95%     | 92%     | 92%     | 93%     | 86%     | 88%     | 87%     | 90%     | 86%     | 79%     | 83%     |
| Time to Hire (days)              | General Recruitment                                    | 35     | 48      | 66      | 58      | 60      | 49      | 51      | 48      | 47      | 41      | 56      | 49      | 39      | 43      |
| Time to nice (days)              | Medical Recruitment (excl Deanery)                     | 35     | 30      | 36      | 59      | 54      | 40      | 81      | 97      | 71      | 32      | 49      | 34      | 53      | 52      |
| Employee relations               | Number of open disciplinary cases                      |        |         |         |         | 26      | 26      | 26      | 27      | 28      | 25      | 22      | 19      | 23      | 14      |



- 2.1. The Trust's **vacancy rate** has reduced to 10.5% further to sustained efforts and investment to drive the vacancy level down towards nationally led targets since the turn of the year.
- 2.2. Overall **staff absence** remains high at 4.8% which is the 12-month rolling position. As with short term absence, this measure has fallen alongside falling infection rates. Covid related absence has reduced from 1.3% to 0.5% and is expected to fall further in line with national figures. The pre-Covid absence tolerance is 4%. Once Covid absence has reduced to much smaller numbers the Trust absence target is expected to return to within agreed tolerance.
- 2.3. The stability index figure (defined as proportion of staff in post at end of period who were in post at beginning of period). The stability index figure has increased slightly in-month to 87.8%. Stability within the organisation is crucial during turbulent times and is helpful to understand the longer-term impact of our various influencing interventions and staff support programmes. The 13-month trend shows an average increase of almost 2%. Similarly, staff turnover has improved by almost 2% in this time now at 7.1% reflecting the Trust's efforts to support wellbeing through engagement, culture and reward initiatives.
- 2.4. The time to hire trend is improving following the impact of targeted interventions to reduce this to acceptable levels in recent months. Medical staffing time to hire has continued to experience delays in issuing visas. UK Border Agency (Visas and Immigration) centres are open but quarantine restrictions remain in place for incoming new entrants in line with national guidance from the Foreign and Commonwealth Office, contributing to the adverse impact on the reported level.
- 2.5. Employee Relations cases have remained fairly static when compared to previous reporting months. As reported previously, case volumes have stabilised as the number of cases resolved at informal level in line with the Trust's Fair and Just Culture principles remains high. A detailed Employee Relations case report is produced on a quarterly basis for Workforce Board and JCNC.
- 2.6. Statutory and mandatory training compliance is at 97% and appraisals compliance is at 95%, an increase of 5% since Month 9. The Trust has now completed its temporary extension to appraisal compliance dates during the winter months of the pandemic and the Learning and Development Team has recommenced its reminders and support processes in March to support our drive to 100%, further supported by the Trust's Pay Progression policy.

#### 3. Continuous Improvement, Transformation and Innovation

3.1. In support of organisational recovery and reductions in infection rates, the Covid-19 staff swabbing process and Covid Staff Health helplines have reduced their staffing levels and amended their processes with effect from 1 April 2021. The helplines remain in operation, providing a valuable service to colleagues but are now being carried out in conjunction with other tasks as demand has reduced significantly



in line with falling infection rates. The swabbing process has also been amended. If colleagues are experiencing symptoms of Covid-19, calls to the Covid Staff Health lines must be made and if a PCR test/swab is required this will now be booked through a local Government testing facility. Results must be notified to the Covid Staff Health helpline and/or CovidStaffHealth@mkuh.nhs.uk

- 3.2. **Shielding** of Clinically Extremely Vulnerable colleagues came to an end on 31 March 2021; managers of colleagues directly affected by shielding were written to with further guidance to facilitate a gradual and supportive re-entry to the workplace, recognising concerns that colleagues might have in returning to our premises.
- 3.3. Colleagues were written to in March to offer additional information in support of staff uptake of the Trust's Covid-19 vaccination and a guide was produced by the Workforce team to support these conversations. Managers were asked to offer personal conversations to any colleagues who have yet to have the vaccine so that their concerns could be addressed. Where we do not know the vaccination status of colleagues were asked to confirm if they have received it at MKUH/elsewhere, aren't able to receive it or choose not to. Whilst colleagues do not have to have the vaccine it is required that they confirm their status/choice as all colleagues have been offered the vaccination. Approximately 120 colleagues are yet to confirm their status and these are being followed up by the Divisional HR Business Partners.
- 3.4. The Trust's Covid-19 vaccination programme moved out of the MKUH Academic Centre on 30 March having administered close to 35,000 vaccinations in-line with the Government prioritisation criteria. The centre has moved location to the Mass Vaccination site at Saxon Court in MK. Unfortunately, the Pfizer vaccine is not currently being offered from that site. It was originally planned that all Pfizer second doses would be delivered from the MKUH Academic Centre by bringing forward the final few to before their 11<sup>th</sup> week date. However, vaccine delivery/supply constraints meant this was not possible and so the small number of outstanding Pfizer second doses were handed over to Bedfordshire Hospitals NHS Foundation Trust to deliver with effect from 6 April 2021 as part of their second dose programme.
- 3.5. Managers have been asked to revisit their Workplace Covid-19 risk assessments as the UK moves into its planned lockdown release roadmap, escalating any concerns as required.

#### 4. Culture and Staff Engagement

4.1. The National NHS Staff Survey 2020 embargo was lifted on 11 March 2021. In w/c 19 April, the Workforce and Development Assurance Committee received a presentation on the key themes, questions and areas of improvement compared to our own results in 2019 and our comparators in 2020. Further to that which was presented to Trust Board Seminar in March, detail was included in respect of the prevalence and aggravating factors of patient on staff violence and the context of increased levels of additional paid hours work. Two distinct working groups have been commissioned to understand these issues further and to make recommendations for their improvement.



- 4.2. Divisional Staff Survey data and heatmaps are expected by 7 May for the HRBPs to engage with colleagues to report local outcomes and understand how best to drive further improvement through the Staff Survey Goes Large listening events established in 2019. Following this a full improvement plan for each area, based on survey results, will be drafted.
- 4.3. The Trust's Living our Values programme has commenced, with external partners A Kind Life. The programme complements Appreciative Inquiry approaches to Quality Improvement and aligns to the timescales outlined in the Trust's NHS People Plan delivery plan. Alignment pre-workshops took place in w/c 12 April, with co-design workshops scheduled for 5 to 10 May. A comprehensive communications plan has been drafted to support launch, engagement and delivery. Staff and patient culture surveys have also been drafted to provide local level data in support of upcoming workshops with the Trust.

#### 5. Current Affairs & Hot Topics

5.1. The Agenda for Change Pay Progression came into effect from 1 April 2021; colleagues need to be 100% compliant with their Statutory and Mandatory Training and must have had an appraisal within the previous 12 months to qualify for their next pay increment. Appraisals must be recorded on Electronic Staff Record to enable this process to run smoothly and so as not to disadvantage colleagues unfairly. A series of training sessions have been run via MS Teams since January 2021 and these are now available to watch on Workspace.

#### 6. Recommendations

6.1. Trust Board is asked to note and receive the Workforce Report for Month 12, in particular the outstanding Trustwide collaboration involved in delivery of the Trust's vaccination programme.

| Meeting title | Trust Board                      | Date: 06 May 2021       |
|---------------|----------------------------------|-------------------------|
| Report title: | Clinical Excellence Awards (CEA) | Agenda item: 4.3        |
|               | 2020 Awards Process              |                         |
| Lead director | Name: Dr Ian Reckless            | Title: Medical Director |
| Report author | Name: Rosie Sampson              | Title: Business Manager |
| Sponsor(s)    | Name: Alison Davis               | Title: Chairwoman       |
| FOI status:   |                                  |                         |

| Report summary         |                   |  |       |                  |         |                    |  |  |  |  |  |  |
|------------------------|-------------------|--|-------|------------------|---------|--------------------|--|--|--|--|--|--|
| Purpose                | Information       | Approval   |       | To note          |         | <b>Decision</b>    |  |  |  |  |  |  |
| (tick one box only)    |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| Recommendation         | •                 | This report is supplied to Trust Board for information only to |       |                  |         |                    |  |  |  |  |  |  |
|                        |                   | •  |       |                  |         | ditions of medical |  |  |  |  |  |  |
|                        |                   | •  |       | for consulta     | ints (a | and discretionary  |  |  |  |  |  |  |
|                        | points for Associ | points for Associate Specialists)                              |       |                  |         |                    |  |  |  |  |  |  |
|                        |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| Strategic              | Improving clinic  | al effectiver  | ess   |                  |         |                    |  |  |  |  |  |  |
| objectives links       | Improving patie   | nt safety  |       |                  |         |                    |  |  |  |  |  |  |
|                        | Improving patie   | nt experiend   | се    |                  |         |                    |  |  |  |  |  |  |
|                        | Investing in our  | people   |       |                  |         |                    |  |  |  |  |  |  |
|                        | Being well gove   | Being well governed and financially viable                     |       |                  |         |                    |  |  |  |  |  |  |
| <b>Board Assurance</b> |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| Framework links        |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| CQC regulations        | Regulations 17    | : Good Gove  | ernar | ice              |         |                    |  |  |  |  |  |  |
| Identified risks       |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| and risk               |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| management             |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| actions                |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| Resource               | Implementation    |  | ,     |                  |         | and                |  |  |  |  |  |  |
| implications           | Conditions of C   | onsultants (   | NHS   | <b>Employers</b> | )       |                    |  |  |  |  |  |  |
|                        |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| Legal                  |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| implications           |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| including              |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| equality and diversity |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| assessment             |                   |  |       |                  |         |                    |  |  |  |  |  |  |
| assessiiitiil          |                   |  |       |                  |         |                    |  |  |  |  |  |  |

| Report history | A previous year's report was submitted to Board in January 2020 |
|----------------|---|
| Next steps     |   |
| Appendices     |   |



## 1. Purpose of the Report

This report is for information only, to inform the Board of the process surrounding the execution of the local clinical excellence awards in respect of consultant performance in 2019/20.

## 2. Background

Clinical Excellence Awards (CEAs) are made available to eligible consultants on a competitive basis each year by application. We are currently in the midst of a three year 'transitionary period' from old style CEAs to a revised version. The revised version of the scheme (to which we are transitioning) has not yet been agreed and articulated through national negotiation.

Old style CEAs were awarded on a consolidated (recurrent) basis, were pensionable and were paid via monthly payroll. In the transitionary period, CEAs are non-recurrent and non-pensionable one-off payments.

For 2017/18 and 2018/19, competitive application rounds were operated, with a Local Awards Committee (LAC) in place. The outputs of the 2018/19 LAC were reported to Board in January 2020.

For 2019/20, a national decision was made that local CEA rounds could not be operated in their usual format on account of the pressures of the COVID-19 pandemic. Instead, available funds were to be distributed *pro rata* to eligible consultants.

It has subsequently been announced that 2020/21 will now be treated as a further (fourth) year of the transitionary period. It is highly likely that a similar approach (available funds to be distributed *pro rata* to eligible consultants) will be used again.

Each year, the CEA process is run in accordance with Schedule 30, Terms and Conditions – Consultants (England) 2003 (NHS Employers, April 2018) and/or (in the case of this round) subsequent national instruction from NHS Employers.

#### 3. Context

# Milton Keynes University Hospital MHS

The Clinical Excellence Awards (CEA) scheme is intended to recognise and reward those consultants who contribute above and beyond in the delivery of safe and highquality care to patients and to the continuous improvement of NHS services (including those who do so through their contribution to academic medicine).

As part of the framework for these awards, an annual report is required to ensure the process is transparent, fair and based on clear evidence.

Ordinarily, the annual report would describe the composition of the panel, the number / characteristics of applicants, and the number / characteristics of successful and unsuccessful applications. A key purpose of the report is to provide assurance as to the fairness and transparency of the process - both in general and from the perspective of protected characteristics.

## 4. Body of the Report

## a) Members of the LAC

In the absence of a competitive process, a local awards committee was not convened in respect of 2019/20.

## b) Number of consultants eligible

A list of the Trust's Consultant staff was derived from payroll and cross-checked with Medical Staffing. Eligibility was defined on the following basis (all five must apply):

- 1. Consultant working at MKUH (and not in another organisation) as a substantive consultant at the beginning of the relevant year (on 01 April 2019).
- 2. Consultant still working at MKUH as a substantive consultant when round launched (10 February 2021).
- 3. Doctor in post as a substantive Consultant at MKUH or in another NHS Trust for at least twelve months prior to the start of the relevant year (a substantive NHS consultant – at MKUH or elsewhere – since 01 April 2018). In other words, the doctor cannot have been in the first year of his/her substantive consultant appointment at the start of the reference year.
- 4. Consultant not in receipt of a Level 9 old style local CEA or a national award.

**NHS Foundation Trust** 

5. Consultant not in receipt during 2019/20 of the equivalent cash value of a Level 9 old style local CEA (for example, an old-style Level 7 award plus a transitionary CEA payment of £12,000).

| Category   | Number |
|--|--------|
| Consultant List  | 226    |
| Consultants removed from list based on criterion 4                 |        |
| or 5 above   | - 9    |
| Consultants removed from list on basis of:                         |        |
| <ul> <li>duplicates within the list;</li> </ul>                    |        |
| <ul><li>criterion 1 or 2 above;</li></ul>                          |        |
| <ul> <li>a non-substantive (fixed term / locum)</li> </ul>         |        |
| appointment; or,   |        |
| <ul> <li>resignation / retirement effective prior to 10</li> </ul> |        |
| February 2021  | - 78   |
| Consultants eligible for <i>pro rata</i> award                     | 139    |

These 139 eligible Consultants were given an opportunity to opt out of the receipt of the pro rata award if they so wished.

139 consultants received an award of £1,626 (gross) through March payroll representing a total calculated CEA resource for the Trust of £226K in respect of 2019/20 – this amount is fixed (calculated based on the number of eligible consultants and nationally determined investment ratios).

In addition, it was agreed that in recognition of the extension of the transitionary CEA period (secondary to the impact of COVID 19) to a fourth year, those in receipt of an award in respect of 2017/18 would receive a fourth and final payment. This round had been undertaken at MKUH before delayed national negotiations on the transitionary period had reached a conclusion – it had been agreed that 2017/18 awards would be non-consolidated and non-pensionable but that they would be paid annually for each of the three transitionary years.

## c) The names of people recommended for an award in respect of 19/20

Given the extraordinary circumstances this year and the absence of an application and scoring process, it is not felt appropriate or necessary to name those given a



**NHS Foundation Trust** 

Clinical Excellence Award in this paper. 1 In ordinary years, the paper would draw attention to the protected characteristics of those who had / had not been successful in the awards process. This year, the eligibility criteria are clear (above).

## d) The number of appeals that have been:

No concerns have been raised about the application of the eligibility criteria for this CEA awards year.

## e) Compliance statement

The process adopted by the Milton Keynes University Hospital was completed fairly and in accordance with the guidance (standing or exceptional) issued by ACCEA.

#### **Recommendations/ Actions**

No action is required by the Board.

<sup>1</sup> Note: The Medical Director (lead director in relation to this paper) is one of the 139 consultants in receipt of an award as described in this paper. The Medical Director is also the recipient of two old style clinical excellence awards made by a prior employer and therefore recognised at MKUH.



|           |   |              |                 |                     |            |              |               |              |               |                        |              |             |          |               |              |          | . (0.    |               |          |          |               |          |
|-----------|---|--------------|-----------------|---------------------|------------|--------------|---------------|--------------|---------------|------------------------|--------------|-------------|----------|---------------|--------------|----------|----------|---------------|----------|----------|---------------|----------|
|           |   |              | OBJECTIVE 3     | - CLINICAL EFFECT   | IVENESS    |              |               |              |               |                        |              |             |          |               |              | 202      | 0/21     |               |          |          |               |          |
| ID        | Indicator   | DQ Assurance | Target<br>20-21 | Month/YTD<br>Target | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data | M1           | M2          | M3       | M4            | M5           | M6       | M7       | M8            | M9       | M10      | M11           | M12      |
| 3.1       | Overnight bed occupancy rate                              |              | 93%             | 93%                 | 78.4%      | 84.1%        | ✓             |              | <b>√</b>      |                        | 54.1%        | 59.8%       | 67.3%    | 75.0%         | 71.6%        | 79.3%    | 87.8%    | 84.2%         | 88.6%    | 88.5%    | 84.0%         | 84.1%    |
| 3.4       | 30 day readmissions                                       |              |                 |                     | 8.5%       | 7.7%         |               |              |               | $\sim$                 | 6.5%         | 10.0%       | 11.4%    | 9.8%          | 9.3%         | 8.7%     | 6.8%     | 7.7%          | 8.6%     | 8.7%     | 8.9%          | 7.7%     |
| 3.5       | Follow Up Ratio   |              | 1.50            | 1.50                | 1.68       | 1.46         | √             |              | <u> </u>      |                        | 2.49         | 2.16        | 1.82     | 1.86          | 1.74         | 1.66     | 1.62     | 1.48          | 1.65     | 1.55     | 1.49          | 1.46     |
| 3.6.1     | Number of Stranded Patients (LOS>=7 Days)                 |              | 198             | 198                 |            | 184          | ✓             |              |               |                        | 71           | 99          | 122      | 112           | 115          | 149      | 176      | 144           | 172      | 196      | 172           | 184      |
| 3.6.2     | Number of Super Stranded Patients (LOS>=21 Days)          |              | 53              | 53                  |            | 77           | ×             | V            |               |                        | 20           | 23          | 24       | 30            | 38           | 42       | 71       | 58            | 58       | 76       | 75            | 77       |
| 3.7       | Delayed Transfers of Care                                 |              | 25              | 25                  |            | 12           | - ✓           |              |               | $\sim$                 | 6            | 9           | 7        | 8             | 12           | 11       | 19       | 11            | 16       | 10       | 9             | 12       |
| 3.9       | Ambulance Handovers >30 mins (%)                          |              | 5%              | 5%                  | 4.7%       | 5.0%         | ▼             | •            | ✓             |                        | 1.8%         | 2.7%        | 1.7%     | 3.4%          | 2.6%         | 2.4%     | 4.9%     | 5.7%          | 11.6%    | 8.6%     | 4.5%          | 5.0%     |
|           |   |              | OBJECT          | IVE 4 - KEY TARGE   | TS         | _            |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
| ID        | Indicator   | DO Assurance | Target          | Month/YTD           | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data | M1           | M2          | M3       | M4            | M5           | M6       | M7       | M8            | M9       | M10      |               | M12      |
|           |   | - 4          | 20-21           | Target              |            |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
| 4.1       | ED 4 hour target (includes UCS)                           |              | 90.0%           | 90.0%               | 93.1%      | 90.3%        | Ψ.            |              | ✓             | $\sim$                 | 95.6%        | 99.1%       | 98.8%    | 97.6%         | 97.6%        | 96.0%    | 94.3%    | 92.2%         | 84.4%    | 83.4%    | 86.7%         | 90.3%    |
| 4.2       | RTT Incomplete Pathways <18 weeks                         |              | 79.0%           | 79.0%               |            | 57.8%        | ×             |              |               |                        | 64.1%        | 56.9%       | 46.7%    | 42.0%         | 49.0%        | 53.0%    | 55.8%    | 58.0%         | 56.1%    | 53.2%    | 54.7%         | 57.8%    |
| 4.4       | RTT Total Open Pathways                                   |              | 18,878          | 18,878              |            | 23,271       | ×             |              |               |                        | 21,810       | 23,244      | 22,679   | 24,109        | 24,930       | 23,610   | 24,867   | 24,752        | 24,577   | 25,013   | 24,185        | 23,271   |
| 4.5       | RTT Patients waiting over 52 weeks                        |              | 99%             | 99%                 |            | 1073         | ×             | X            |               | $\overline{}$          | 10<br>53.57% | 58          | 93       | 175<br>83.34% | 249          | 393      | 404      | 343<br>81.98% | 311      | 450      | 773<br>82.29% | 1,073    |
| 4.6       | Diagnostic Waits <6 weeks                                 |              |                 |                     |            | 83.2%        | ×             |              |               |                        | 53.57%       | 70.06%      | 80.60%   | 83.34%        | 80.65%       | 79.34%   | 79.15%   | 81.98%        | 81.49%   | 74.92%   | 82.29%        | 83.16%   |
| ID        | Indicator   | DQ Assurance | Target<br>20-21 | Month/YTD<br>Target | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data |              | Q1 - 2020-2 |          |               | Q2 - 2020-21 |          |          | Q3- 2020-21   |          |          | Q4 - 2020-21  |          |
| 4.7       | All 2 week wait all cancers (Quarterly)                   |              | 93.0%           | 93.0%               |            | 82.7%        | ×             |              |               |                        |              | 86.35%      |          |               | 81.81%       |          |          | 82.74%        |          |          |               |          |
| 4.8       | 31 days Diagnosis to Treatment (Quarterly)                |              | 96.2%           | 96.2%               |            | 95.1%        | ×             |              |               | ~~~                    |              | 94.74%      |          |               | 94.81%       |          |          | 95.10%        |          |          |               |          |
| 4.9       | 62 day standard (Quarterly)                               |              | 85.5%           | 85.5%               |            | 77.4%        | ×             |              |               | ~~~~                   |              | 74.37%      |          |               | 84.75%       |          |          | 77.38%        |          |          |               |          |
|           |   | · ·          |                 | ,                   |            |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           |   |              | OBJECTIV        | /E 5 - SUSTAINABI   | LITY       |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
| ID        | Indicator   | DQ Assurance | Target<br>20-21 | Month/YTD<br>Target | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data | M1           | M2          | M3       | M4            | M5           | M6       | M7       | M8            | M9       | M10      | M11           | M12      |
| 5.1       | GP Referrals Received                                     |              |                 |                     | 66,504     | 7,922        |               |              |               | <b>\</b>               | 1,777        | 3,596       | 4,846    | 5,765         | 5,053        | 6,450    | 6,782    | 6,664         | 5,883    | 5,469    | 6,297         | 7,922    |
| 5.2       | A&E Attendances   |              |                 |                     | 73,397     | 6,981        |               |              |               | $\overline{}$          | 3,615        | 5,645       | 6,005    | 6,601         | 6,826        | 6,958    | 6,897    | 6,391         | 6,515    | 5,683    | 5,280         | 6,981    |
| 5.3       | Elective Spells (PBR)                                     |              | Not /           | Available           | 16,255     | 2,208        | Not Available |              | Not Available | $\overline{}$          | 496          | 485         | 885      | 1,230         | 1,293        | 1,583    | 1,759    | 1,879         | 1,615    | 1,350    | 1,472         | 2,208    |
| 5.4       | Non-Elective Spells (PBR)                                 |              | NOU             | wallable            | 22,208     | 2,273        | NOT AVAIIABLE |              | NOL Available | $\langle$              | 1,603        | 1,750       | 1,729    | 1,960         | 1,951        | 2,003    | 1,997    | 1,931         | 1,842    | 1,500    | 1,669         | 2,273    |
| 5.5       | OP Attendances / Procs (Total)                            |              |                 |                     | 313,363    | 33,870       |               |              |               | <b>\</b>               | 12,686       | 15,174      | 22,935   | 26,687        | 23,877       | 29,282   | 30,193   | 31,641        | 28,496   | 27,617   | 30,905        | 33,870   |
| 5.6       | Outpatient DNA Rate                                       |              |                 |                     | 6.1%       | 5.3%         |               |              |               | ~~~                    | 5.2%         | 3.9%        | 5.0%     | 5.8%          | 7.3%         | 6.9%     | 6.6%     | 6.7%          | 7.2%     | 6.4%     | 5.3%          | 5.3%     |
|           |   |              | OBJECTIVE 7 -   | FINANCIAL PERFO     | RMANCE     |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
| ID        | Indicator   | DQ Assurance | Target<br>20-21 | Month/YTD<br>Target | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data | M1           | M2          | M3       | M4            | M5           | M6       | M7       |               | M9       | M10      |               | M12      |
| 7.1       | Income £'000  |              |                 |                     | 309,993    | 46,026       |               |              |               |                        | 23,333       | 23,077      | 23,581   | 24,159        | 23,388       | 23,071   | 24,418   | 24,542        | 24,858   | 24,750   | 24,790        | 46,026   |
| 7.2       | Pay £'000   |              |                 |                     | (208,970)  | (26,239)     |               |              |               |                        | (16,069)     | (15,949)    | (15,229) | (15,694)      | (15,431)     | (15,355) | (15,318) | (16,483)      | (22,269) | (17,484) | (17,451)      | (26,239) |
| 7.3       | Non-pay £'000   |              |                 |                     | (86,928)   | (10,444)     |               |              |               |                        | (6,104)      | (5,960)     | (7,186)  | (6,584)       | (6,612)      | (6,659)  | (7,982)  | (7,421)       | (8,432)  | (7,117)  | (6,427)       | (10,444) |
| 7.4       | Non-operating costs £'000                                 |              |                 | Available           | (13,829)   | (446)        |               |              |               |                        | (1,229)      | (1,235)     | (1,234)  | (1,950)       | (1,400)      | (1,124)  | (1,334)  | (1,286)       | (1,338)  | (749)    | (504)         | (446)    |
| 7.5       | I&E Total £'000   |              | NOL A           | Available           | 266        | 8,897        | Not Available |              | Not Available |                        | (69)         | (67)        | (68)     | (69)          | (55)         | (67)     | (216)    | (647)         | (7,181)  | (600)    | 408           | 8,897    |
| 7.6       | Cash Balance £'000  |              |                 |                     |            | 48,765       |               |              |               |                        | 34,189       | 43,330      | 44,850   | 46,777        | 48,263       | 49,456   | 45,507   | 50,228        | 51,933   | 53,312   | 57,262        | 48,765   |
| 7.7       | Savings Delivered £'000                                   |              |                 |                     | 2,266      | 178          |               |              |               | Indiana.               | 0            | 0           | 0        | 0             | 0            | 0        | 1,097    | 150           | 476      | 172      | 193           | 178      |
| 7.8       | Capital Expenditure £'000                                 |              |                 |                     | 45,216     | 17,271       |               |              |               |                        | 398          | 1,549       | 359      | 368           | 387          | 454      | 536      | 1,316         | 1,489    | 9,052    | 12,037        | 17,271   |
|           |   |              | ORIECTIVE 8 - V | WORKFORCE PERF      | ORMANCE    |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           |   |              | Target          | Month/YTD           |            |              |               |              |               |                        | M1           | M2          | M3       | M4            | M5           | M6       | M7       | M8            | M9       | M10      |               | M12      |
| ID        | Indicator   | DQ Assurance | 20-21           | Target              | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data |              |             |          |               |              |          |          |               |          |          |               |          |
| 8.1       | Staff Vacancies % of establishment                        |              | 10%             | 10%                 |            | 9.6%         | <b>✓</b>      |              |               |                        | 13.1%        | 11.5%       | 10.9%    | 10.4%         | 9.3%         | 10.6%    | 10.9%    | 10.9%         | 10.8%    | 10.8%    | 9.6%          | 9.6%     |
| 8.2       | Agency Expenditure %                                      |              | 4.1%            | 4.1%                | 2.6%       | 1.1%         | ✓             |              | <b>√</b>      | ~                      | 3.5%         | 3.0%        | 2.0%     | 1.8%          | 2.4%         | 2.4%     | 2.6%     | 3.6%          | 3.6%     | 2.8%     | 3.5%          | 1.1%     |
| 8.3       | Staff Sickness % - Days Lost (Rolling 12 months)          |              | 4%              | 4%                  |            | 5.1%         | ×             |              |               |                        | 4.1%         | 4.4%        | 4.5%     | 4.5%          | 4.4%         | 4.5%     | 4.5%     | 4.6%          | 4.7%     | 4.8%     | 5.0%          | 5.1%     |
| 8.6       | Substantive Staff Turnover                                |              | 10%             | 10%                 |            | 7.1%         | ✓             |              |               |                        | 9.5%         | 9.2%        | 8.8%     | 8.8%          | 8.9%         | 8.8%     | 8.5%     | 8.5%          | 8.4%     | 8.2%     | 8.0%          | 7.1%     |
|           | <u> </u>  | ·            | OBI             | ECTIVES - OTHER     |            |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           |   |              |                 |                     |            |              |               |              |               |                        | M1           | M2          | M3       | M4            | M5           | M6       | M7       | M8            | М9       | M10      | M11           | M12      |
| ID        | Indicator   | DQ Assurance | Target<br>20-21 | Month/YTD<br>Target | Actual YTD | Actual Month | Month Perf.   | Month Change | YTD Position  | Rolling 15 months data |              |             |          |               |              |          |          |               |          |          |               |          |
| 0.2       | Rebooked cancelled OPs - 28 day rule                      |              | 95%             | 95%                 | 48.4%      | NULL         | <b>─</b> ✓    |              | x             |                        | 88.9%        | 75.0%       | 100.0%   | NULL          | NULL         | NULL     | 100.0%   | 0.0%          | 0.0%     | 10.0%    | 100.0%        | NULL     |
| Kov: Mont | hly/Quarterly Change                                      |              | YTD Position    |                     |            |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           | Improvement in monthly / quarterly performance            |              | V FUSICION      | Achieving YTD Ta    | irget      |              |               | 7            |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           | Monthly performance remains constant                      |              |                 | Within Agreed To    |            | _            |               | ]            |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           | Deterioration in monthly / quarterly performance          |              | x               | Not achieving YT    |            |              |               | 1            |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |
|           | NHS Improvement target (as represented in the ID columns) | 1            |                 | Annual Target bro   |            |              |               |              |               |                        |              |             |          |               |              |          |          |               |          |          |               |          |

Acceptable levels of assurance but minor areas for improvement identified and potentially independently audited \*/No Independent Assurance

Satisfactory and independently audited (indicator represents an accurate reflection of performance)

NHS Improvement target (as represented in the ID columns)

Annual Target breached

Data Quality Assurance Definitions
Rating Data Quality Assurance

Red Unsatisfactory and potentially significant areas of improvement with/without independent audit

Independently Audited – refers to an independent audit undertaken by either the Internal Auditor, External Auditors or the Data Quality Audit team.



| Meeting title  | Public Board Meeting           | Date: May 2021      |
|----------------|--------------------------------|---------------------|
| Report title:  | Finance Paper Month 12 2020-21 | Agenda item: 5.3    |
|                |                                |                     |
| Lead director  | Terry Whittle                  | Director of Finance |
| Report authors | Chris Panes                    | Head of Management  |
|                |                                | Accounts            |
| Fol status:    | Private document               |                     |

| Report summary                   | An update on the financial position of the Trust at Month 12 (March 2021) |
|----------------------------------|---|
| Purpose (tick one box only)      | Information Approval To note X Decision                                   |
| Recommendation                   | Trust Board to note the contents of the paper.                            |
|                                  |   |
| Strategic                        | 5. Developing a Sustainable Future  |
| objectives links                 | 7. Become Well-Governed and Financially Viable                            |
| -                                | 8. Improve Workforce Effectiveness  |
| <b>Board Assurance</b>           |   |
| Framework links                  |   |
| CQC outcome/<br>regulation links | Outcome 26: Financial position  |

|                        | 8. Improve Workforce Effectiveness                                   |
|------------------------|--|
| <b>Board Assurance</b> |  |
| Framework links        |  |
| CQC outcome/           | Outcome 26: Financial position                                       |
| regulation links       |  |
| Identified risks       | See Risk Register section of report                                  |
| and risk               |  |
| management             |  |
| actions                |  |
| Resource               | See paper for details  |
| implications           |  |
| Legal                  | This paper has been assessed to ensure it meets the general equality |
| implications           | duty as laid down by the Equality Act 2010                           |
| including equality     |  |
| and diversity          |  |
| assessment             |  |

| Report history | None   |
|----------------|--------|
| Next steps     | None   |
| Appendices     | 1 to 3 |

## FINANCE REPORT FOR THE MONTH TO 31st MARCH 2021

#### **PUBLIC BOARD MEETING**

## **PURPOSE**

- 1. The purpose of the paper is to:
  - Present an update on the Trust's latest financial position covering income and expenditure;
     cash, capital and liquidity; NHSI financial risk rating; and cost savings; and
  - Provide assurance to the Trust Board that actions are in place to address any areas where the Trust's financial performance is adversely behind plan.
  - Provide assurance that the Trust is adequately responding to change in funding regime and additional financial impacts of the COVID-19 pandemic.

## **EXECUTIVE SUMMARY**

- 2. Due to COVID-19 (covid) the Trust's previously submitted budget has been suspended and the Trust is being funded by a national block payment. For M1-6, the block payment was made up of three components; a fixed amount based on run rate from last year, a top up amount to address a deficit from the block and a covid top up by return for additional covid related costs (allowing the Trust to report a breakeven position). For M7-12 the block payment has been revised with the top up amount being restricted to a fixed envelope and the implementation of an "elective incentive scheme" to encourage Trusts to meet its activity targets. For the second half of the year the Trust plannned to report a deficit of £3.6m.
- 3. Income and expenditure –Against the revised plan and funding arrangement the Trust has reported a positive variance of £8,418k against (£3,615k positive FY) a planned deficit of £444k (£3,615k FY) for March 2021. Within this position the Trust has claimed an additional £1.2m (£11m YTD) of income directly related to the COVID-19 outbreak (against which the Trust is able to evidence an additional £10m of direct costs relating to covid).
- 4. Cash and capital position the cash balance as at the end of March 2021 was £48.8m, which was £38.8m above the revised plan.
  - The Trust has spent £44.1m on capital up to month 12 after accounting for donations and derecognition of assets, against a budget allocation (CDEL) of £44.7m. The spend for 20/21 relates to £10.1m on various IT projects including replacement of the Pathology IT system (LIMS), £8.9m HIP2, £3.9m on Adapt and Adopt schemes supporting endoscopy and imaging, £3.6 additional backlog infrastructure including replacement of flat roofs and installation of solar panels, £2.3m Covid including Diagnostic equipment, £2.7m MRI equipment, £1.6m on ICS, £1.7m Pathway Unit, £1.6m UEC, £0.2m Radiotherapy and £7.6m patient safety and clinically urgent capital expenditure.
- 5. NHSI rating the Use of Resources rating (UOR) score is '3', which is in line with Plan, with '4' being the lowest scoring.
- 6. Cost savings –As of at M12 £2.2m of schemes had been identified and added to the trust tracker with a delivery of £2.3m for the year.

## **INCOME AND EXPENDITURE**

7. The Trust is required to report externally against a revised plan based on the national block funding arrangement. However, in order for the Trust to get a better understanding of the Trust's cost base and how this has been impacted by covid, the Trust is also monitoring performance against a planned position that would meet the original financial control total (excluding the regional 0.5% additional efficiency requirement). The tables below summarise performance against the revised plan and the Trust's original plan. For the purposes of the report, the narrative discusses performance against the Trust's original plan and the revised forecast plan.

#### **Revised Forecast Plan:**

|                                      |          | Month 12 |          | N         | /lonth 12 F\ | 1        |
|--------------------------------------|----------|----------|----------|-----------|--------------|----------|
| All Figures in £'000                 | Plan     | Actual   | Var      | Plan      | Actual       | Var      |
|                                      |          |          |          |           |              |          |
| Clinical Revenue                     | 18,547   | 24,475   | 5,928    | 220,494   | 227,282      | 6,788    |
| Other Revenue                        | 1,355    | 16,027   | 14,672   | 15,762    | 31,167       | 15,405   |
|                                      |          | 1        |          |           | 1            |          |
| Total Income                         | 19,902   | 40,502   | 20,600   | 236,256   | 258,449      | 22,193   |
|                                      |          |          |          |           |              |          |
| Pay                                  | (16,281) | (26,239) | (9,958)  | (192,395) | (208,971)    | (16,576) |
| Non Pay                              | (7,225)  | (10,439) | (3,214)  | (82,197)  | (86,921)     | (4,724)  |
| Total Operational Funered            | (22 500) | (20,070) | (12 172) | (274 502) | (205 902)    | (21 200) |
| Total Operational Expend             | (23,506) | (36,678) | (13,172) | (274,592) | (295,892)    | (21,300) |
| EBITDA                               | (3,604)  | 3,824    | 7,428    | (38,336)  | (37,444)     | 892      |
| EBITOR                               | (3,004)  | 3,024    | 7,420    | (30,330)  | (37,444)     | 032      |
| Financing & Non-Op. Costs            | (1,178)  | (489)    | 689      | (14,931)  | (13,092)     | 1,839    |
|                                      |          |          |          |           |              |          |
| Control Total Deficit (excl. top up) | (4,782)  | 3,334    | 8,116    | (53,267)  | (50,536)     | 2,731    |
| Adjustments excl. from control total | :        |          |          |           |              |          |
|                                      |          |          |          |           |              |          |
| FRF                                  | 0        | 0        | 0        | 0         | 0            | 0        |
| MRET                                 | 0        | 0        | 0        | 0         | 0            | 0        |
| National Block                       | 0        | 0        | 0        | 0         | 0            | 0        |
| National Top up                      | 3,413    | 3,413    | 0        | 39,523    | 39,523       | 0        |
| COVID Top up                         | 925      | 1,227    | 302      | 10,150    | 11,034       | 884      |
|                                      |          |          |          |           |              |          |
| Control Total Deficit (incl. top up) | (444)    | 7,974    | 8,418    | (3,594)   | 21           | 3,615    |
| B                                    |          | 4.010    | 4.010    |           | 4 4 4 =      | 4 404    |
| Donated income                       | 0        | 1,012    | 1,012    | 14        | 1,115        | 1,101    |
| Donated asset depreciation           | (68)     | 36       | 104      | (815)     | (732)        | 83       |
| Impairments & Rounding               | 0        | (11)     | (11)     | 0         | (11)         | (11)     |
| Reported deficit/surplus             | (512)    | 9,011    | 9,523    | (4,395)   | 393          | 4,788    |

# Performance against original internal plan:

|                                     |          | Month 12  |            | N         | Month 12 F | 1         |
|-------------------------------------|----------|-----------|------------|-----------|------------|-----------|
| All Figures in £'000                | Plan     | Actual    | Var        | Plan      | Actual     | Var       |
|                                     |          |           |            |           |            |           |
| Clinical Revenue                    | 21,125   | 19,027    | (2,098)    | 233,455   | 186,750    | (46,705)  |
| Other Revenue                       | 1,584    | 16,027    | 14,443     | 19,309    | 31,169     | 11,860    |
|                                     |          |           |            |           |            | (         |
| Total Income                        | 22,708   | 35,054    | 12,345     | 252,763   | 217,919    | (34,845)  |
| Devi                                | (15.003) | (20, 220) | /11 1FC\   | (100,000) | (200 071)  | (20.270)  |
| Pay Non Boy                         | (15,083) | (26,239)  | (11,156)   | (180,692) |            | (28,279)  |
| Non Pay                             | (6,840)  | (10,439)  | (3,599)    | (82,026)  | (86,921)   | (4,895)   |
| Total Operational Expend            | (21,923) | (36,678)  | (14,755)   | (262,718) | (295,892)  | (33,174)  |
|                                     | (==/===/ | (00,010)  | (= :/: ==/ | (===,===) | (===,===,  | (00)=1.1) |
| EBITDA                              | 785      | (1,624)   | (2,410)    | (9,955)   | (77,974)   | (68,019)  |
|                                     |          | , , ,     | , , ,      |           |            | , , ,     |
| Financing & Non-Op. Costs           | (1,192)  | (478)     | 714        | (14,299)  | (13,092)   | 1,206     |
|                                     |          |           |            |           |            |           |
| Control Total Deficit (excl. PSF)   | (407)    | (2,103)   | (1,696)    | (24,254)  | (91,066)   | (66,812)  |
| Adjustments excl. from control tota | l:       |           |            |           |            |           |
|                                     |          |           |            |           | T          |           |
| FRF                                 | 4,946    | 0         | (4,946)    | 19,784    | 0          | (19,784)  |
| MRET                                | 269      | 0         | (269)      | 3,228     | 0          | (3,228)   |
| National/Other Block                | 0        | 5,448     | 5,448      | 0         | 40,532     | 40,532    |
| National Top up                     | 0        | 3,413     | 3,413      | 0         | 39,523     | 39,523    |
| COVID Top up                        | 0        | 1,227     | 1,227      | 0         | 11,032     | 11,032    |
|                                     |          |           |            |           |            |           |
| Control Total Deficit (incl. PSF)   | 4,808    | 7,985     | 3,177      | (1,242)   | 21         | 1,263     |
|                                     |          | T         |            |           | T          | 1         |
| Donated income                      | 300      | 1,012     | 712        | 1,000     | 1,115      | 115       |
| Donated asset depreciation          | (68)     | 36        | 104        | (816)     | (732)      | 84        |
| Impairments & Rounding              | 0        | (11)      | (11)       | 0         | (11)       | (11)      |
|                                     |          |           |            |           |            |           |
| Reported deficit/surplus            | 5,040    | 9,022     | 3,982      | (1,058)   | 393        | 1,451     |

#### Monthly and year to date review

- 8. The **deficit excluding central funding (top up) and donated income** in month 12 is £2,103k which is £1,696k adverse to the Trust's original plan; this is due to a combination of:
  - The national block contract income being lower than clinical income assumed in the internal plan (and agreed as part of the heads of terms with Milton Keynes CCG);
  - Lower non-clinical income streams due to lower activity volumes (e.g. parking income);
  - The impact of covid on the Trust's cost base.

However, on a control total basis after the block payment and top up income the Trust has reported a £7,985k surplus position for the month and £21k surplus for the year which is £8,418k favourable to the revised plan position in month and favourable by £3,615k for the year.

Included within the YTD position is £2,000k additional funding from the CCG, £3,911k annual leave accrual funding and £9,978k of direct covid costs (excluding loss of non-clinical income which is outside the scope of provider claims) against which the Trust expects to receive an additional £11,393k top-up.

The impact of the elective incentive scheme has not been reported in month due to the number of COVID beds being above 15% of the total bed base.

9. On a payment by results basis, income (excluding block, top up and donations effect) against the original plan is £12,345k favourable in March and £34,845k adverse for the year with significant reductions in non-elective activity and low levels of activity following suspension of non-urgent elective activity earlier in the year and the occurrence of the second wave (clinical income is £2,098k adverse to plan in month and £46,705k full year).

However, the shortfall on clinical income is offset by the top-up payments which act as both a) a replacement of the financial recovery fund that would otherwise have been in place; and b) additional payments to cover shortfalls on clinical income as a result of the impact of covid.

Against the revised trust plan/forecast income is 20,600k favourable in month and £22,193k for the year.

- 10. **Operational costs** in March are adverse to the original plan by £14,755k in month and £28,279k for the year. Against the revised plan/forecast operational costs are adverse by £13,172k in month and £21,300k full year.
- 11. **Pay costs** are £11,156k adverse to budget in Month 12 and £28,279k for the full year against the original plan. Against the revised plan pay costs are £9,958k adverse in month and £16,576k adverse for the year. The full year position includes a increase of £5,914k against untaken the annual leave accrual, £7,214k of pension costs and a further provision against 2021-22 backfill of additional annual leave. High costs against substantive, bank and agency include direct covid related costs due to changes in rotas, additional hours and cover of sickness/self-isolation.
- 12. **Non-pay** costs were £3,599k adverse to the original plan in month and £4,895k adverse full year. Against the revised plan non pay reported a £3,214k adverse variance in month and £4,724k adverse for the year. The in month and full year position includes £3,646k of expenditure related to PPE stock offset with income.

13. **Non-operational costs** are £1,279k favourable in month and £807k favourable for the year, this is a result of increase in PDC costs offset by timing differences in depreciation.

## **COST SAVINGS**

- 14. Work on tracking and delivering schemes has resumed following a temporary suspension due to COVID. The Trust submitted its financial plan which included a target of £5m for CIP delivery by year end, however progress was restricted by the emergence of the second wave of COVID-19.
- 15. For the year £2.2m of schemes have been identified and added to the trust tracker with a delivery of £2.3m.

## **CASH AND CAPITAL**

- 16. The cash balance at the end of March 2021 was £48.8m, which was £38.8m above the revised plan.
- 17. On 2 April 2020, the Secretary of State for Health and Social Care, announced that over £13bn of debt will be written off as part of a major financial reset for NHS providers. As a result, the Trust's Department of Health and Social Care interim revenue support and capital loans (totalling £130.8m as at 31 March 2020) was repaid in September 2020 and replaced with Public Dividend Capital for which there is no repayment obligation.
- 18. The **statement of financial position** is set out in Appendix 3. The main movements and variance to plan can be summarised as follows:
  - Non-Current Assets are above plan by £17.8m; this is driven by additional capital projects.
  - Current assets are above plan by £29.1m, this is due to cash £38.8m and inventory £0.2m above plan offset by receivables £9.9m below plan.
  - Current liabilities are above plan by £35.1m. This is being driven by Trade and Other Creditors £17.2m (of which £7.0m relates to untaken annual leave and £10.0m relates to capital), deferred income £12.2m, Provisions £0.2m and borrowings £0.1m above plan.
  - Non-Current Liabilities are on plan.
- 19. The trust ended the financial year with a capital spend of £44.1m, after accounting for donations and derecognition of assets, against a budget allocation (CDEL) of £44.7m. This resulted in a variance of £0.6m which relates to CT equipment that the Trust was allocated PDC funding during late February but was unable to procure and get delivered before the end of the financial year.

## **RISK REGISTER**

- 20. The following items represent the main finance risks on the Board Assurance Framework and a brief update of their current position:
  - a) There is a risk that if the future NHS funding regime is not sufficient to cover the costs of the Trust, then the Trust will be unable to meet its financial performance obligations or achieve financial sustainability.

To mitigate the risk the Trust has had cost and volume contracts replaced with block contracts (set nationally) for clinical income combined with top-up payments available where COVID-19 leads to additional costs over and above block sum amounts (until September 2021). Budgets are to be reset for FY22 based on financial regime with financial controls and oversight to be reintroduced to manage financial performance. Cost efficiency programme to be also reset to target focus on areas of greatest opportunity to deliver.

b) There is a risk that the Trust is unable to achieve the required efficiency improvements through the transformation programme leading to an overspend.

The Trusts Transformation programme has governance to ensure that savings are robust and measured aprropriately. Oversight of the programme is delivered through the Transformation programme board and Trust Executive Group.

c) There is a risk that if the Trust is unable to successfully tender for external audit services in 2021 then financial audits and other required annual assurance exercises will not take place LEADING TO the Trust failing in its statutory obligations.

Trust's current external audit contract ends August 21. The trust is looking to place a direct award for 1 years contract with its current external audit firm.

d) There is a risk that if the expenditure position cannot be appropriately controlled given the Trust's historic deficits then the cash available to meet its financial obligations will be insufficient

It should be noted that the Trust currently has sufficient cash balances to manage its obligations. Monthly cash flow forecasting is undertaken to establish at which point the Trust balances become close to £1m (historically the value advised by NHSEI to be held)

#### RECOMMENDATIONS TO BOARD

21. The Trust Board is asked to note the financial position of the Trust as at 31<sup>st</sup> March and the proposed actions and risks therein.

## Milton Keynes Hospital NHS Foundation Trust Statement of Comprehensive Income For the period ending 31<sup>st</sup> March 2021

|   | March 2021 |           |                | Y         | Full year |           |            |
|---|------------|-----------|----------------|-----------|-----------|-----------|------------|
|   | Plan       | Actual    | Variance       | Plan      | Actual    | Variance  | Plan       |
|   | £'000      | £'000     | £'000          | £'000     | £'000     | £'000     | £'000      |
| INCOME  |            |           |                |           |           |           |            |
| Outpatients                                   | 4,833      | 4,012     | (822)          | 51,328    | 37,060    | (14,267)  | 51,328     |
| Elective admissions                           | 2,787      | 2,149     | (638)          | 29,148    | 17,302    | (11,846)  | 29,148     |
| Emergency admissions                          | 6,300      | 6,200     | (101)          | 73,776    | 61,356    | (12,420)  | 73,776     |
| Emergency adm's marginal rate (MRET)          | (277)      | (270)     | 6              | (3,238)   | (3,162)   | 76        | (3,238)    |
| Readmissions Penalty                          | 0          | 0         | 0              | 0         | 0         | 0         | 0          |
| A&E   | 1,357      | 1,169     | (187)          | 15,489    | 12,522    | (2,968)   | 15,489     |
| Other Admissions                              | 266        | 164       | (102)          | 3,114     | 2,107     | (1,007)   | 3,114      |
| Maternity                                     | 1,897      | 1,901     | 5              | 21,186    | 21,046    | (140)     | 21,186     |
| Critical Care & Neonatal                      | 561        | 498       | (64)           | 6,572     | 6,146     | (426)     | 6,572      |
| Excess bed days                               | 0          | 0         | 0              | 0         | 0         | 0         | 0          |
| Imaging                                       | 554        | 703       | 149            | 5,799     | 4,237     | (1,561)   | 5,799      |
| Direct access Pathology                       | 477        | 409       | (68)           | 4,987     | 3,726     | (1,261)   | 4,987      |
| Non Tariff Drugs (high cost/individual drugs) | 1,850      | 2,024     | 174            | 19,348    | 18,854    | (494)     | 19,348     |
| Other   | 518        | 1,441     | 923            | 5,946     | 6,927     | 13        | 5,946      |
| National Block Top Up                         | 0          | 4,076     | 4,076          | 0         | 39,160    | 39,160    | 0          |
| Clinical Income                               | 21,125     | 24,475    | 3,350          | 233,455   | 227,282   | (6,173)   | 233,455    |
|   |            |           |                |           |           |           |            |
| Non-Patient Income                            | 7,099      | 21,679    | 14,580         | 43,321    | 82,839    | 39,518    | 43,321     |
| TOTAL INCORAL                                 | 20.222     | 46 454    | 17 020         | 276 775   | 210 121   | 22.245    | 276 775    |
| TOTAL INCOME                                  | 28,223     | 46,154    | 17,930         | 276,775   | 310,121   | 33,345    | 276,775    |
| EXPENDITURE                                   |            |           |                |           |           |           |            |
| Total Pay                                     | (15,083)   | (26,239)  | (11,156)       | (180,692) | (208,971) | (28,279)  | (180,692)  |
|   | (4.000)    | (0.445)   | (2.425)        | (62.670)  | (50.057)  | (5.200)   | (52,570)   |
| Non Pay                                       | (4,990)    | (8,415)   | (3,425)        | (62,678)  | (68,067)  | (5,389)   | (62,678)   |
| Non Tariff Drugs (high cost/individual drugs) | (1,850)    | (2,024)   | (174)          | (19,348)  | (18,854)  | 494       | (19,348)   |
| Non Pay                                       | (6,840)    | (10,439)  | (3,599)        | (82,026)  | (86,921)  | (4,895)   | (82,026)   |
|   | (24.222)   | (0.0.000) | (4.4.===)      | (222 242) | (222 222) | (22.47.1) | (222 = 12) |
| TOTAL EXPENDITURE                             | (21,923)   | (36,678)  | (14,755)       | (262,718) | (295,892) | (33,174)  | (262,718)  |
| EBITDA*                                       | 6,300      | 9,476     | 3,175          | 14,057    | 14,228    | 171       | 14,057     |
|   |            |           |                |           |           |           |            |
| Depreciation and non-operating costs          | (1,000)    | (255)     | 745            | (11,995)  | (10,234)  | 1,760     | (11,995)   |
| OPERATING SURPLUS/(DEFICIT) BEFORE            |            |           |                |           |           |           |            |
| DIVIDENDS                                     | 5,300      | 9,220     | 3,920          | 2,062     | 3,993     | 1,932     | 2,063      |
|   |            |           |                |           |           |           |            |
| Public Dividends Payable                      | (260)      | (198)     | 62             | (3,120)   | (3,601)   | (481)     | (3,120)    |
| OPERATING DEFICIT AFTER DIVIDENDS             | 5,040      | 9,022     | 3,982          | (1,058)   | 393       | 1,452     | (1,058)    |
| Adjustments to reach control total            |            |           |                |           |           |           |            |
| Donated Income                                | (300)      | (737)     | (437)          | (1,000)   | (840)     | 160       | (1,000)    |
| Donated Assets Depreciation                   | (300)      | (36)      | (104)          | 816       | 732       | (84)      | (1,000)    |
| PPE stock (excl.CT)                           | 0          | (275)     | (275)          | 910       | (275)     | (275)     | 0          |
| Impairments                                   | 0          | (2/5)     | 11             | 0         | (2/5)     | 11        | 0          |
| PSF/FRF/MRET                                  | (5,217)    | 0         | 5,217          | (23,016)  | 0         | 23,016    | (23,026)   |
| I SI / I MI / IVINE I                         | (3,411)    | U         | J, <b>Z</b> 1/ | (23,010)  | U         | 23,010    | (23,020)   |
| CONTROL TOTAL DEFICIT                         | (409)      | 7,985     | 8,394          | (24,258)  | 22        | 24,280    | (24,268)   |

<sup>\*</sup> EBITDA = Earnings before Interest, Taxation, Depreciation and Amortisation

## Appendix 2

## Milton Keynes Hospital NHS Foundation Trust Statement of Cash Flow As at 31<sup>st</sup> March 2021

|   | Unaudited     |           | In Month |
|---|---------------|-----------|----------|
|   | Mth12 2020-21 | Mth 11    | Movement |
|   | £000          | £000      | £000     |
| Cash flows from operating activities                          |               |           |          |
| Operating (deficit) from continuing operations                | 4.274         | (4,972)   | 9.246    |
| Operating surplus/(deficit) of discontinued operations        | <i>'</i>      | ( /- /    | -, -     |
| Operating (deficit)   | 4,274         | (4,972)   | 9,246    |
| Non-cash income and expense:                                  | ĺ             |           | •        |
| Depreciation and amortisation                                 | 9,947         | 9,726     | 221      |
| Non-cash donations/grants credited to income                  | (600)         | 0         | (600)    |
| (Increase)/Decrease in Trade and Other Receivables            | 5,098         | 8,567     | (3,469)  |
| (Increase)/Decrease in Inventories                            | (285)         | (7)       | (278)    |
| Increase/(Decrease) in Trade and Other Payables               | 18,846        | 18,131    | 715      |
| Increase/(Decrease) in Other Liabilities                      | 11,970        | 20,336    | (8,366)  |
| Increase/(Decrease) in Provisions                             | 1,949         | (14)      | 1,963    |
| NHS Charitable Funds - net adjustments for working capital    |               |           |          |
| movements, non-cash transactions and non-operating cash flows | (113)         | (103)     | (10)     |
| Other movements in operating cash flows                       | (3)           | (3)       | 0        |
| NET CASH GENERATED FROM OPERATIONS                            | 51,083        | 51,661    | (578)    |
| Cash flows from investing activities                          |               |           |          |
| Interest received   | 4             | 4         | 0        |
| Purchase of intangible assets                                 | (7,753)       | (2,898)   | (4,855)  |
| Purchase of Property, Plant and Equipment, Intangibles        | (31,164)      | (9,028)   | (22,136) |
| Net cash generated (used in) investing activities             | (38,913)      | (11,922)  | (26,991) |
| Cash flows from financing activities                          |               |           |          |
| Public dividend capital received                              | 154,600       | 134,814   | 19,786   |
| Loans repaid to Department of Health                          | (130,852)     | (130,852) | 0        |
| Capital element of finance lease rental payments              | (221)         | (202)     | (19)     |
| Interest paid   | (273)         | (273)     | 0        |
| Interest element of finance lease                             | (280)         | (257)     | (23)     |
| PDC Dividend paid   | (3,378)       | (2,096)   | (1,282)  |
| Receipt of cash donations to purchase capital assets          | 713           | 103       | 610      |
| Net cash generated from/(used in) financing activities        | 20,309        | 1,237     | 19,072   |
| Increase/(decrease) in cash and cash equivalents              | 32,479        | 40,976    | (8,497)  |
| Opening Cash and Cash equivalents                             | 16,286        | 16,286    |          |
| Closing Cash and Cash equivalents                             | 48,765        | 57,262    | (8,497)  |

# Appendix 3

## Milton Keynes Hospital NHS Foundation Trust Statement of Financial Position as at 31<sup>st</sup> March 2021

|  | Audited | Mar-21   | Mar-21     | In Mth | YTD    | %        |
|--|---------|----------|------------|--------|--------|----------|
|  | Mar-20  | YTD Plan | YTD Actual | Mvmt   | Mvmt   | Variance |
| Assets Non-Current                         |         |          |            |        |        |          |
| Tangible Assets                            | 143.2   | 163.4    | 174.0      | 10.6   | 30.8   | 21.5%    |
| Intangible Assets                          | 16.1    | 14.6     | 22.0       | 7.4    | 5.9    | 36.6%    |
| Other Assets                               | 0.9     | 0.9      | 0.7        | (0.2)  | (0.2)  | (22.2%)  |
| Total Non Current Assets                   | 160.2   | 178.9    | 196.7      | 17.8   | 36.5   | 22.8%    |
| Assets Current                             |         |          |            |        |        |          |
| Inventory                                  | 3.4     | 3.4      | 3.6        | 0.2    | 0.2    | 5.9%     |
| NHS Receivables                            | 18.7    | 20.2     | 7.3        | (12.9) | (11.4) | (61.0%)  |
| Other Receivables                          | 6.9     | 10.7     | 13.7       | 3.0    | 6.8    | 98.6%    |
| Cash                                       | 16.3    | 10.0     | 48.8       | 38.8   | 32.5   | 199.4%   |
| Total Current Assets                       | 45.3    | 44.3     | 73.4       | 29.1   | 28.1   | 62.0%    |
| Liabilities Current                        |         |          |            |        |        |          |
| Interest -bearing borrowings               | (131.3) | (0.1)    | (0.2)      | (0.1)  | 131.1  | -99.8%   |
| Deferred Income                            | (2.3)   | (2.0)    | (14.2)     | (12.2) | (11.9) | 517.4%   |
| Provisions                                 | (1.5)   | (1.3)    | (3.3)      | (2.0)  | (1.8)  | 120.0%   |
| Trade & other Creditors (incl NHS)         | (38.9)  | (46.9)   | (64.1)     | (17.2) | (25.2) | 64.8%    |
| Total Current Liabilities                  | (174.0) | (50.3)   | (81.8)     | (31.5) | 92.2   | (53.0%)  |
| Net current assets                         | (128.7) | (6.0)    | (8.4)      | (2.4)  | 120.3  | (93.5%)  |
| Liabilities Non-Current                    |         |          |            |        |        |          |
| Long-term Interest bearing borrowings      | (5.8)   | (5.7)    | (5.6)      | 0.1    | 0.2    | (3.4%)   |
| Provisions for liabilities and charges     | (1.6)   | (1.6)    | (1.7)      | (0.1)  | (0.1)  | 6.2%     |
| Total non-current liabilities              | (7.4)   | (7.3)    | (7.3)      | 0.0    | 0.1    | (1.4%)   |
| Total Assets Employed                      | 24.1    | 165.6    | 181.0      | 15.0   | 156.9  | 651.7%   |
| Taxpayers Equity                           |         |          |            |        |        |          |
| Public Dividend Capital (PDC)              | 105.3   | 251.2    | 259.9      | 8.7    | 154.6  | 146.8%   |
| Revaluation Reserve                        | 48.4    | 48.4     | 50.1       | 1.7    | 1.7    | 3.5%     |
| Financial assets at FV through OCI reserve | 0.0     | 0.0      | 0.2        | 0.2    | 0.2    | #DIV/0!  |
| I&E Reserve                                | (129.6) | (134.0)  | (129.2)    | 4.8    | 0.4    | (0.3%)   |
| Total Taxpayers Equity                     | 24.1    | 165.6    | 181.0      | 15.4   | 156.9  | 651.0%   |

| Meeting title  | MKUH Board meeting        | Date: 6 May 2021                  |
|----------------|---------------------------|-----------------------------------|
| Report title:  | BLMK Strategic Priorities | Agenda item:                      |
| SRO:           | Name: Rima Makarem        | Title: Chair                      |
|                |                           | Bedfordshire, Luton and           |
|                |                           | Milton Keynes ICS                 |
| Report Author: | Name: Nicola Kay          | Title: BLMK Programme<br>Director |

| Document summary  Potential Risks and Issues | To provide an update on the development of the strategic priorities for the Bedfordshire, Luton and Milton Keynes (BLMK) Integrated Care System (ICS).  |  |  |
|--|---|--|--|
| Purpose (tick one box only)                  | Information Approval To note Decision   |  |  |
| Recommendation                               | The Board is recommended to note the contents of this report and provide steers on how the work can best consider the challenges and opportunities for the people of Milton Keynes which CNWL serves. |  |  |
| Document<br>history                          | The outcome of the workshops is being reported to each partner organisation Board or Health and Wellbeing Board.  |  |  |
| Appendices                                   | None  |  |  |

## **Purpose**

1. This paper provides an update on the development of the strategic priorities for the Bedfordshire, Luton and Milton Keynes (BLMK) Integrated Care System (ICS). The purpose of this work is to create a common strategic direction for the ICS in terms of what it will deliver for population health over the medium and long term.

## Background


2. In 2019, BLMK produced a Long Term Plan<sup>1</sup>, following extensive engagement with partner organisations, residents, community groups and stakeholders. It is now the appropriate time to build on the basis outlined in the long term plan, ensure that BLMK strategic priorities align with the strategic objectives of partner organisations, identify any changes due to the pandemic and focus on population health outcomes. In addition, the Covid pandemic has further exposed inequalities in our society which we need to address collectively for the wellbeing of individuals and our communities.

<sup>&</sup>lt;sup>1</sup> https://www.blmkpartnership.co.uk/wp-content/uploads/2020/10/10137-BLMK-LTP-SUMMARY-Living-longer-in-good-health-05.03.2020-1.pdf

- 3. The intention of this work is to take a single system approach, with flexibility at place and care alliance level to meet local population needs. We will need to put in place appropriate governance to enable successful delivery of these priorities.
- **4.** BLMK Chair and Executive Lead have met with all the CEOs and Leaders/Chair of the partner organisations to ascertain their views on the priorities for BLMK and the place they represent. The organisational priorities for each partner organisation and the impacts of Covid have been taken into account in the consideration of the BLMK priorities.
- 5. A set of draft priorities were discussed at a workshop of BLMK Partnership Board members on 3<sup>rd</sup> March 2021 and those attending were asked to identify the medium and long-term outcomes to address population health. In addition, the impacts of the Covid pandemic on local people, the workforce and the provision of services were also considered. For example the changes in demand for ambulance services and the impact of the pandemic on our workforce. The outputs from this workshop were considered at a second workshop on 24<sup>th</sup> March, to further develop the priorities and unpack the activity needed at each level of the system to deliver on these.

## **Emerging priorities**

**6.** These are the emerging priorities for the ICS:



- 7. We have also identified a set of cross-cutting enablers, which will support the successful delivery of the priorities above, and where some activity will need to take place at ICS level. These include data and digital, workforce, ways of working, estates, communications, finance and operational & clinical excellence.
- **8.** We want to ensure that we are threading a reduction in inequalities throughout all the priorities set out above, as well as looking at reducing systemic inequality as part of priority 5. This means that the way delivery is designed is not entrenching inequalities and more vulnerable groups are explicitly supported. The full emerging strategy priority framework is in Annex A.
- **9.** At the workshop on the 24<sup>th</sup> March, we discussed the priorities in more detail for each place. MKUH representatives, with partners in Milton Keynes, focussed on priority 1

around supporting children and their families to make a healthy start in life which will continue into adulthood.

- **10.** As part of this development work, we are taking into account wider changes that will affect our population and services in BLMK. For example:
  - Making the most of the Oxford-Cambridge Arc
  - Additional investment in rail infrastructure as part of East West Rail, connecting Oxford and Cambridge via Bedford and taking in Milton Keynes on a branch will also open up opportunities for growth
  - Following on from the above, we may be able to identify greater research and investment opportunities, potentially working more closely with the universities in BLMK
  - Embedding technological advances in our system, including broadband access for all, and new advances which will enable better delivery of health and care
  - Shifting generational expectations about receiving services that we need to be mindful of and aligned with

## 11. Principles for how we work together

Across our system, we want to develop effective ways of working which mirror the more formal governance approaches. In the conversations with system leaders, we heard a range of perspectives about what is important around how we work. From these conversations, we developed a proposed set of principles which were agreed at the Partnership Board on 7 April 2021.

- We learn from good practice both from within and outside our system and we embed it, adapting to local circumstances as needed but not reinventing
- We take a subsidiarity approach, with activity taking place at the lowest possible level, with activity taking place at a higher level only where that is more efficient and effective
- We are mutually accountable for delivering our priorities, with everyone taking responsibility for delivering their contribution as well as supporting others in delivery of theirs
- We keep the needs of the population at the centre of everything we do, taking a coproduction approach with system partners across all sectors, the VCSE and with people with lived experience
- We build from where we are now, taking into account different starting points and reflect and adapt as we go along, embedding the principles of a learning system
- We take into account others' perspectives and are open with each other about our challenges, supporting each other in resolving any difficulties to better deliver continuous improvement

The Board are requested to adopt these principles of working in partnership with statutory, voluntary and community organisations in BLMK.

## **Next steps**

**12.** The next stage will be to:

- (i) Support the places in BLMK to develop activities across all of the 5 priorities the main focus so far has been deep dives into priorities 1 and 4; so we need to develop the thinking in partnership on priorities 2, 3 and 5
- (ii) Work with places to deliver place-based plans against all of the priorities, accelerating and building on existing activity and supporting development of appropriate resource and governance structures to enable successful delivery
- (iii) Develop the plans at ICS level for the cross-cutting enablers and governance for this work, and ensuring that all this work comes together in a single plan for 'year 1' for delivery of the priorities across BLMK for 2021/22

## Recommendation

- 13. The Board is recommended to note the contents of this report and provide steers on how the work can best consider the challenges and opportunities for the people of Milton Keynes.
- 14. The Board is asked to adopt the principles of how we work together in partnership.



## **Annex A: Priorities Summary Framework**

|                 | Priority 1: Every child has a strong, healthy start in life: from maternal health, through the first thousand days to reaching adulthood   | Priority 2: People are supported to engage with and manage their health and wellbeing   | Priority 3: People age well, with proactive<br>interventions to stay healthy, independent<br>and active as long as possible   | Priority 4: We work together to build the economy and support sustainable growth  | Priority 5: In everything we do we aim to<br>embed the principles of population health<br>and reduce inequalities  |
|-----------------|--|---|---|---|--|
| Evidence        | Our earliest experiences in life, starting in the womb, through birth, early years and into childhood and adolescence are vital in laying the foundations for future good health and wellbeing. Children with adverse experiences growing up, such as living in a household with substance misuse or domestic violence, are less likely to be healthily and achieve in life Fragmentation in the children's system leads to poorer outcomes for our most vulnerable children   | Supporting people to stay well for longer and making the most of the expertise, capacity and potential of people, families and communities in delivering better health and wellbeing outcomes and experiences will reduce pressures on health and care services     Earlier identification of health conditions can help to improve outcomes and reduce premature mortality   | <ul> <li>Tackling issues such as social isolation, alongside reducing risk factors such as physical activity, poor hydration and nutrition and sensory impairment improves quality of life and reduces health service pressures and demands</li> <li>Supporting independence, using an asset based approach, is a priority in maximising quality of life</li> </ul>   | People's economic circumstances – the security and safety of their jobs and their level of income – are key to their health. Good employment is closely linked to good health and wellbeing and protects against social exclusion High quality economic infrastructure enhances quality of life The quality and availability of affordable homes is a key contributor to wellbeing of individuals and families  | Health inequalities are unfair and avoidable differences in health across the population, and between different groups within society. Inequalities arise because of the conditions in which we are born, grow, live, work and age     Evidence says that people living in our most deprived areas face the worse inequalities in relation to health access, experiences and outcomes.   |
| BLMK<br>context | <ul> <li>39% of 15-16 year olds achieve grades 9-5 in English and Maths, compared to an England average of 43%</li> <li>One third of children in year 6 are overweight or obese. One third of 5 year olds in Luton have tooth decay</li> <li>24% of children living in Central Bedfordshire, 31% of children in MK and Bedford Borough and 46% of children in Luton live in poverty</li> <li>Infant mortality is higher in Luton compared with similar areas</li> <li>Covid has caused a rise in mental health needs and eating disorders</li> </ul> | Compared to England, the smoking prevalence in Luton and in routine/manual occupations in Milton Keynes are significantly higher  Milton Keynes and Bedford Borough residents are less likely than average to visit the natural environment for health or exercise purposes  A baby girl born in Central Bedfordshire can expect to live for almost six years longer than a baby boy born in Luton; this gap mainly reflects higher deaths from circulatory diseases, cancer and respiratory diseases in deprived areas | <ul> <li>44% of social care service users in BLMK feel they have as much social contact as they would like</li> <li>Over 150,000 over-65s live in BLMK and this is expected to increase to 210,000 over the next 20 years. The number of over-90s is expected to more than double in that period</li> <li>Emergency hospital admissions due to falls for people 65 and over are 11% higher in Milton Keynes than the England average</li> </ul> | <ul> <li>There are 1.15 jobs per person of working age in Milton Keynes and 0.75 jobs per person elsewhere in BLMK; England has 0.87 jobs per person</li> <li>The employment rate gap in BLMK is 11 percentage points worse for people with a long term condition, 67 for people with a learning disability and 68 for people in contact with secondary mental health services</li> <li>Overall, close to 1/5 jobs pay less than the living wage</li> </ul> | <ul> <li>In the most healthy wards of BLMK, women enjoy 20 years longer in good health than in the least healthy small areas. For men the gap is 17 years</li> <li>Babies born in the most affluent parts of BLMK will live longer than those born in the most deprived areas. The biggest gap for men is in Bedford Borough (10 years) and the smallest is for women in Luton (6 years).</li> <li>Two thirds of children are living in poverty in Biscot and Dallow wards in Luton and Queens Park ward in Bedford</li> </ul> |
| Goals           | All children, regardless of where they live or their background, will be supported to have the best possible health and emotional wellbeing Improved outcomes for pregnant women and infants; eliminating inequalities for Black and Asian women and those in deprived areas Children can grow up in a safe and healthy home environment There is an increase in educational attainment and employment levels for young people leaving education   | Levels of wellbeing in the population increase, with people able to manage their own health and wellbeing An increase in the number of years of healthy life expectancy A reduction in the gap between highest and lowest decile healthy life expectancy A reduction in premature mortality in BLMK   | <ul> <li>Fewer older people feel lonely or socially isolated</li> <li>Older adults stay healthier, happier and independent for longer</li> <li>There is a reduction in the number of older people having falls</li> <li>People receive good quality end of life care and have good deaths</li> </ul>  | Increased economic growth rates Increased levels of employment and the proportion of people earning the living wage Closing the employment gap for people with long term conditions and learning disabilities and mental health issues Increasing the quality and availability of our housing stock across BLMK   | Achieve reductions in inequalities through the work of priorities 1-4 Reduce the gap between outcomes for our wider communities and Gypsy and traveller communities BAME communities For people with specific conditions including people with learning disabilities, autism or both   |



| Meeting title | Public Board             | May 2021                      |
|---------------|--------------------------|-------------------------------|
| Report title: | Significant Risk Summary | Agenda item: 7.1              |
|               | Report                   |                               |
| Lead director | Paul Ewers               | Risk & Systems Manager        |
| Report author | Kate Jarman              | Director of Corporate Affairs |
| Sponsor(s)    |                          |                               |
| Fol status:   | Disclosable              |                               |

| Report summary              | The report includes all significant risks across all Risk Registers, where the Current Risk Rating is graded as 15 or above, as at 27 <sup>th</sup> April 2021 |  |  |
|-----------------------------|--|--|--|
| Purpose (tick one box only) | Information x Approval To note Decision  |  |  |
| Recommendation              | The Public Board is asked to note and discuss the contents within the report, in to ensure risks are being robustly and actively managed across the Trust.     |  |  |

| Strategic        | Objective 1 Improve Patient Safety                 |
|------------------|--|
| objectives links | Objective 7 Become well led and financially viable |
| Board            | Compliance paper                                   |
| Assurance        |  |
| Framework        |  |
| links            |  |
| CQC              | Good governance                                    |
| fundamental      | Safe   |
| Standards        |  |
| Identified risks | Compliance risk – good governance                  |
| and risk         |  |
| management       |  |
| actions          |  |
| Resource         | None   |
| implications     |  |
| Legal            | None   |
| implications     |  |
| including        |  |
| equality and     |  |
| diversity        |  |
| assessment       |  |

| Report history | The significant 15+ risks are an ongoing agenda item            |
|----------------|---|
| Next steps     | Public Board to note and discuss the contents within the report |
| Appendices     | Significant 15+ Risks   |

## **Executive Summary:**


This report shows the profile of significant risks across the Trust by type and area.

Currently there are no risks that require escalation to the BAF from the Significant Risk Register. Risks are managed in accordance with the Trust's risk management strategy.

The Board is asked to note the content of this report

#### **Risk Profile**

There is a total of 32 significant risks identified on Risk Registers across the Trust:



- Of these risks 10 are overdue their review date and have been escalated for corporate review.
- There was one new significant risk added during April 2021:

ID3066 - The neurology department runs a botox injection clinic for patient staffed by a single consultant, increasing the risk of longer waiting times due to consultant capacity.

- There were two significant risks closed within the last month:
- There is one risk that are graded the same as the Target Risk rating
- One of the risks are categorised as being tolerated even though their Current Risk Rating
  is higher than the target (i.e. the level of risk identified as tolerable) this has been
  escalated for corporate review.

• There are no Actions identified for 12 of the risks. It should be noted that, for many of these risks, actions have been and are being undertaken, however the risks have not been updated on Datix. A process has commenced for all risks to have an additional formal annual review (see below). One of the aims of this new process is to ensure that all actions are added to the risk register for completeness and to support the ongoing management of the risk.

## **Corporate Risk Register**

A proposal is going to the next Trust Executive Group (TEG) to introduce a Corporate Risk Register. This to enhance the ability to manage risks that impact more than one area of the Trust. It will also enable the Divisions to escalate significant risks that they do not have the capacity/ability to manage. Risks will not automatically move between Divisional to Corporate Risk Registers purely based on Current Risk Rating (which is currently the case), but by discussion and agreement by the Risk Board and/or TEG. This risk register will be used to ensure robust operational management of risk.

It is recognised that TEG need to have oversight of all significant risks. Therefore the Significant Risk Register will be used as a mechanism for reporting all significant risks to TEG on a regular basis.

#### **Annual Review of Risks**

A new process has commenced where all risks will have an annual review and refresh. A new 'Annual Review Date' column has been included onto Datix and the Risk Register templates. This annual review and refresh work will ensure the quality and completeness of the data on the risk register will be improved. It will also ensure that risks that have been on the risk register for some time, are still relevant. The annual review will be in addition to the necessary regular risk reviews currently undertaken by the Divisions/Departments.

As part of this work, the Risk & Systems Manager is undertaking a review of all Division's/Corporate Department's risk registers and providing feedback to the relevant managers for inclusion in their annual risk register review.

# **Significant Risk Register Summary**

| Division  | Description  | Controls in place  | Current<br>Risk<br>Level |
|---|--|--|--------------------------|
| Operations  | The risk of capabilities in responding to a Novel Coronavirus (COVID-19) impacting on patient care within clinical and non-clinical services, with the inability to maintain safety for staff and patients due to national pressures on supplies and infrastructure. | COVID-19 operational and contingency plans in place reviewed through Silver and Gold command structure, with meeting recorded through action logs  PPE logged daily covering delivery and current stock  | HIGH                     |
| Women's &<br>Children's<br>Health -<br>Children's<br>Health | Overcrowding and insufficient space in the Neonatal Unit, exacerbated by need for social distancing due to COVID-19  | Reconfiguration of cots to create more space and extra cots and capacity, though this still does not meet PHE or national standards     Parents asked to leave NNU during interventional procedures, ward rounds etc. Restricted visiting during COVID     Added to capital plan     Feasibility study completed   | HIGH                     |
| Women's &<br>Children's<br>Health -<br>Women's<br>Health    | Inability of Trust to provide maternity care locally for some women (during times of peak demand on service, delays in clinical care) and potential increased readmission rate due to reduced length of stay   | Daily huddle & bed state reviews Escalation process Review of obstetric clinical pathways Three times a day Maternity specific safety huddle (March 2021) Regular reviews with Exec Team   | HIGH                     |
| Finance   | If the future NHS funding regime is not sufficient to cover the costs of the Trust, then the Trust will be unable to meet its financial performance obligations or achieve financial sustainability.   | Cost and volume contracts replaced with block contracts (set nationally) for clinical income; 2. Top-up payments available where COVID-19 leads to additional costs over and above block sum amounts (until September 2021);     Budgets to be reset for FY22 based on financial regime; financial controls and oversight to be reintroduced to manage financial performance. 4. Cost efficiency programme to be reset to target focus on areas of greatest opportunity to deliver | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Pharmacy        | The risk is there will be insufficient staff in pharmacy to meet demands of the organisation and ensure patient safety in the use of medicines.  | Actively recruiting, listening events with staff, identifying quick wins from staff to reduce turnover, implementing 1-1 system to support staff, reviewing work activities of 8a's and above  | HIGH                     |

| Division          | Description  | Controls in place  | Current<br>Risk<br>Level |
|-------------------|--|--|--------------------------|
| Corporate Affairs | There is a risk that not all known incidents, accidents and near misses are reported onto Trust Incident Reporting System (Datix) and that they will not be robustly investigated within the required timescales | <ol> <li>Incident Reporting Mandatory/Induction Training</li> <li>Incident Reporting Training Guide and adhoc training as required</li> <li>Datix Incident Investigation Training sessions</li> <li>Daily review of incidents by Risk Management Team to identify potential Serious Incidents and appropriate escalation</li> <li>Serious Incident Review Group (SIRG) ensure quality of Serious Incident Investigations</li> <li>SIRG ensure appropriate reporting of Serious Incidents to Commissioners</li> <li>Staff able to have automatic feedback following investigation approval</li> <li>Incident Reporting Awareness Campaign - September 2017</li> <li>Standard Operating Procedure re Risk &amp; Governance Team supporting the closure of incident investigations during unprecedented demand on service (e.g. Covid-19 Pandemic) approved - February 2021</li> <li>Patient Safety Framework introduced</li> </ol> | HIGH                     |
| Operations        | Risk that patient discharges will significantly be delayed, especially those requiring complex coordination of the discharge process   | Covering a small number of shifts with former Discharge Coordinator carrying out bank shifts, when available. Offered bank shift to train an Agency Nurse who has shown an interest in the role. Recruited in to one vacancy and interviewing in to Bucks Coordinator role on 2/8/19.  Reviewed role and delegated minor responsibilities to Rotational Operations Liaison Officers.  Support requested from key nursing areas who have the skills to support a number of aspects relating to the role & discharge process- awaiting confirmation  | HIGH                     |

| Division   | Description  | Controls in place  | Current<br>Risk<br>Level |
|--|--|--|--------------------------|
| Finance  | There is a risk that the Trust is unable to achieve the required efficiency improvements through the transformation programme leading to an overspend against plan   | Tracker in place to identify and track savings and ensure they are delivering against plan     Savings measured against Trust finance ledger to ensure they are robust and consistent with overall financial reporting     All savings RAG rated to ensure objectivity     Oversight of the transformation programme through the Transformation Programme Board and Trust Executive Group. | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | The risk is that the trust is failing in its statutory legal duty under the Health & Safety at Work etc. Act 1974, Management of Health & Safety at Work Regulations 1999, Workplace (Health, Safety & Welfare) Regulations 1992 and Display Screen Equipment Regulations 1992 to provide a safe and well maintained place of work including welfare facilities for staff                    | Due to the number of staff within the area, some staff have to work from home (rota basis)  Mobile air conditioning units distributed.  Plumbed in water cooler in situ  | HIGH                     |
| IΤ   | IF the internal Trust telephone systems are not upgraded, THEN they will fall into a state where they cannot be supported by the Trust's IT Department or any third-party suppliers, LEADING TO potential loss of telephone systems either in small areas or across the Trust. This would have a significant impact upon operational procedures, especially during critical or busy periods. | Support in place, upgrade ETA Pending Capital funding  | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Diagnostic &<br>Screening    | The 10yr old mammography machine in BS2 could fail due to its age. The increased amount of unplanned downtime this year is consistent with aging equipment.  With the introduction of new technologies the availability of replacement parts is a worry. A replacement part needed to be shipped from Chicago.   | Comprehensive service contract All faults reported immediately to external contractor / physicist for support. Robust QA systemin process to monitor system performance. This is reviewed weekly by medical physics.   | HIGH                     |

| Division  | Description  | Controls in place  | Current<br>Risk<br>Level |
|---|--|--|--------------------------|
| Surgical -<br>Musculoskeletal   | There is a risk to head injury patients not being appropriately cared for as they are not being treated in accordance with NICE guidance (CG176: Head injury: assessment and early management, updated September 2019)   | 1, 2 & 3. Preventive controls On going discussions with Senior Medical Team CSU Lead to escalate via trauma network Alert process is in place for escalation within T&O & externally. Resources available at tertiary site for advice/support  1, 2 c& 3. mitigating controls Policy for management of head injuries has been developed Awaiting appointment of head injury liaison Nurse  | HIGH                     |
| Corporate<br>Affairs  | Clinical Governance and Imaging staff are unable to meet statutory and mandatory Good Governance requirements and accreditations if IT systems do not support their remit.   | System in place but requires updating and Q pulse which manages Trust documentation is no longer able to archive since the shared drive was moved.  Updates made to Q-Pulse and SharePoint   | HIGH                     |
| Performance & Information   | The Trust Information data warehouse could fail or be subjected to a security attack.  | There are reactive controls in to support the data warehouse using the in-house teams, including daily check of the servers, deleting redundant information stored on the server is conserve space. Additionally, A business case to migrate the information platform to Microsoft Azure platform has been submitted to the Executive directors for consideration and awaiting a decision.   | HIGH                     |
| Estates   | IF the estates infrastructure contingency plans are not adequately tested THEN in the event of a infrastructure failure plans may not succeed LEADING TO contingency plans not being effective and to potential loss of services, poor patient experience, financial loss and loss of reputation | <ol> <li>Partially tested Contingency Plans.</li> <li>Review of Business Continuity Plan review process completed in conjunction with Gordon Austin assisting with reviewing process and plans.</li> <li>Continuity plans reviewed and shared with team.</li> <li>Noted that plans partially tested during the recent flooding incident.</li> <li>Emergency Planning Officer has been sent the plan for review and comment.</li> <li>Met EPO and reived document, awaiting publication.</li> </ol> | HIGH                     |
| IT  | The current bleep system (main system A and back-up system B) is obsolete and no maintenance support contract is available from the company. The risk is that the equipment may not be able to be repaired if failed.  | -DISCUSSED WITH LINE MANAGER AND ESCALATED -TEMPORARY RADIO COMMUNICATION SYSTEM 3. User group formed with IT & EBME to identify options   | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Diagnostic &<br>Screening | Delayed detection of breast<br>screening cancers due to COVID 19   | Restart proposal approved by the Trust, SQAS and PHE. Guidance issued as to the management of the women to ensure that no-one is missed has been issued by Hitachi/PHE and has been implemented by the programme.  | HIGH                     |

| Division   | Description   | Controls in place   | Current<br>Risk |
|--|---|---|-----------------|
| Core Clinical &<br>Support<br>Services -<br>Diagnostic &<br>Screening    | Lack of space for appropriate management of CT and MRI with additional issues of lack of scanners to manage the increasing demand.  | Extended working hours and days, some scans sent off site to manage demand. Reduced appointment times to optimise service.  1.12.20 no change to risk rating services remain challenged due to lack of basic capacity made worse by Covid social distancing and cleaning issues. IS provider approached to provide more MRI capacity  | HIGH            |
| IT   | IF the IT Department does not have a stock of replacement network switches, THEN if a switch fails a replacement will need to be sourced, procured, delivered, and installed, LEADING TO a delay in bringing up to 48 devices back online, potentially losing IT devices for a whole area/department for up to two weeks. | There is no stock left.   | HIGH            |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | Unable to meet the demand for existing patients leading to increased waiting times  Unable to develop existing outpatient services  Unable to optimise student placements   | Extended working hours     Introduction of shift pattern     Introduction of telephone triage clinics     Group treatment sessions  | HIGH            |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | There is a risk that the Women & Men's Health Physiotherapy Service is unable to meet its referral demand   | Non clinical time including training, development and audit are being minimised to increase the number of available patient appointments  Job plans are being completed by all staff to show impact on workload  Patients are being booked into group where possible instead of individual appointment slots  Recruited to all vacant posts  To explore options for supporting dictation of letters to free up clinical capacity. | HIGH            |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | There is a risk that Children's Physiotherapists are not able to run to their full capacity in order to treat all children on their caseload/waiting list   | Physiotherapy staff timetables designed to avoid clusters of staff all working in the CDC at the same time. Room booking system in place. All have been in place for years; the problem is worsening as the building is shared with other teams which are growing.  | HIGH            |

| Division   | Description  | Controls in place   | Current<br>Risk<br>Level |
|--|--|---|--------------------------|
| Directorate of<br>Patient Care   | The MUST conformance criteria were set out in the NHS accessible information specification for compliance by the 31st July 2016  | Some of the meeting individual needs resources identified i.e.BSL sign language interpreters, braille, easy read  | HIGH                     |
|  |  | Ongoing EPR agile preparation events E Care launch plan in progress   |                          |
| Core Clinical &<br>Support<br>Services -<br>Diagnostic &<br>Screening    | There is a risk that the available space within Cellular Pathology will not be enough to meet the demands of the service as workload continues to expand   | Storage of specimens minimised. No unnecessary specimens stored Storage period reduced from 6 weeks to 4 weeks with the approval of Pathologists and Clinical Lead  | HIGH                     |
| Medical<br>Director  | R&D department has yearly running staff contracts, not permanent contracts and we are not able to provide longer term contracts for the team   | Requested support from the network CRN     Discussed with other Trusts Partners     regarding their existing contracts  | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | Increasing numbers of patients being added to the physiotherapy outpatient waiting list, in addition to those on hold due to the COVID-19 pandemic, resulting in waiting times of well over 18 weeks for any type of intervention. A further increase in referrals may result from patients with post-COVID symptoms | - Virtual management of patients - Video and telephone clinics - Additional IT sourced to support virtual management - Reconfiguration of department to support virtual working and enable social distancing along with staff working from home - recovery plans are being written/in place to enable essential patients to be seen in the department of a face to face basis - Educational material including exercise programmes and access to YouTube clips are made available to patients | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | Poor outcomes for children and young people referred to the children's physiotherapy service   | Coding and prioritizing of referrals 1:1s and caseload supervision  | HIGH                     |
| Medicine -<br>Specialty<br>Medicine                                      | The neurology department runs a botox injection clinic for patient staffed by a single consultant; this consultant is now on long term sick leave. There are 50 patients awaiting review and treatment in clinic.  | There is no substantial control in place  | HIGH                     |

| Division   | Description  | Controls in place   | Current<br>Risk<br>Level |
|--|--|---|--------------------------|
| Corporate<br>Affairs   | There is a risk that changes required to practice are not implemented and we are not meeting best practice criteria  | Audit report templates available to identify audit action plans. However these are not always being utilised and actions are not Always evidenced and monitored Monitoring via Clinical Audit & Effectiveness Committee (CAEB) TOR CAEB revised to include quality improvement, GIRFT etc Escalation/exception reporting to Management Board Refresh of Sharepoint data base to assist with data capture, with Level 1 audit a priority Transformation Team audit   | HIGH                     |
| Estates  | There is a risk of roof failure in relation to flat roofs across the Trust   | <ol> <li>Inspections and repairs as needed.</li> <li>Updated annual 6 facet survey by Oakleaf</li> <li>Large patch repairs undertaken as emergency business cases</li> <li>1 x Post Grad roof fully replaced 19/20.</li> <li>Ward 10 - 50% of roof patch repairs completed 19/20</li> <li>Phase 1, Phase 2 and Community Hospital survey completed.(52 roof leaks noted in 12 months Jan 19 -Aug 20) 16 leaks in 1st week of October 2020</li> <li>Pharmacy small roof replaced September 20.</li> <li>Business Case approved for 4 to 5 year rolling programme.</li> <li>Work underway March 2021</li> </ol> | HIGH                     |
| Core Clinical &<br>Support<br>Services -<br>Clinical Support<br>Services | The risk is that the paediatric team can not provide a full dietetic service to children and young people in the Milton Keynes area  | Existing staff are working some additional hours but this remains insufficient to meet the needs of the service.  | HIGH                     |
| Estates  | The current risk is that there is not enough space in the Medical Equipment Library(MEL) to carry out the required cleaning process to comply with the appropriate guidelines set by CQC and MHRA. | Staff members are taking processed equipment straight to the shelving areas as soon as it is cleaned to avoid cross contamination. This ensure equipment is kept separate, but this is not a productive method of working.  | HIGH                     |

## **Recommendations:**

The Board are asked to review and discuss this paper.

## **Definitions:**

**Significant Risks:** Any risk where the Current Risk Register (the level of risk now) is graded 15 or above

Current Risk: This is the level of risk posed at the time of the risk's last review

**Target Risk:** Recognising that there is always an element of risk and that (depending on the risk) the lowest level of risk is not always the optimum (e.g. cost vs benefit), this is the level of risk that the Trust is willing to accept/tolerate.

**Assurance on controls:** This is where the risk owner identifies how the Trust monitors whether the controls in place are effective and that the risk is being managed. For example, monitoring the increase/decrease of reported incidents etc.

## Significant Risk Register

| ID Re     |              | Executive<br>Responsible                     | Risk<br>Owner               | Division  | Specialty      | Description  | Cause   | Impact  |            | Inherent Controls in place<br>Risk Level   | Assurance on Controls   | C L Current<br>Risk<br>Rating | Current G<br>Risk Level   | Saps in Controls C   | L Target T<br>Risk R<br>Rating L | -                             |   | Date Risk Last<br>Reviewed |           | Trend<br>Rationale    | Review Due? |
|-----------|--------------|--|-----------------------------|---|----------------|--|---|---|------------|--|---|-------------------------------|---------------------------|--|----------------------------------|-------------------------------|---|----------------------------|-----------|-----------------------|-------------|
| 2920      | 05/05/2021   | Director of<br>Clinical<br>Services          | Biggs,<br>Adam              | Operation<br>s  |                | The risk of capabilities in responding to a Novel Coronavirus (COVID-19) impacting on patient care within clinical and non-clinical services, with the inability to maintain safety for staff and patients due to national pressures on supplies and infrastructure. | Surge of COVID-19 patients impacting on Trust ability to maintain patient care and clinical services.  Loss of staff to support clinical and non-clinical services due to high levels of absence.  Loss of national stockpile in PPE or medical devices (ventilators) resulting in the Trust not receiving deliveries to preserve the safety of patients and staff. | clinical services<br>Financial impacts<br>Risk to patient care<br>Risk to staff wellbeing   | 5 5 25     | COVID-19 operational and contingency plans in place reviewed through Silver and Gold command structure, with meeting recorded through action logs  PPE logged daily covering delivery and current stock  |   | 5 4 20                        | na<br>ar<br>re<br>is      | rust has no control over ational stockpile of PPE nd medical devices equired for response. This monitored and reported aily.                                       | 3 15 F                           | TREAT -<br>tolerab<br>approp  | le level -<br>riate cost-<br>e control  | 21/10/2020                 | No Change | National<br>oversight | 09/11/2020  |
| 2570 9-2  | 30/03/2021   | Director of<br>Clinical<br>Services          | Gawlowsk<br>, pr<br>Zuzanna | ii Women's<br>&<br>Children's<br>Health -<br>Children's<br>Health | Neonatal       | Overcrowding and insufficient space in the Neonatal Unit, exacerbated by need for social distancing due to COVID-19  | comply with BAPM guidance or the latest   | cot numbers and corresponding cot spacing we will be unable to meet patient needs or network requirements. We will now also be unable to meet PHE recommendations for                           | 5 5 25     | HIGH  1. Reconfiguration of cots to create more space and extra cots and capacity, though this still does not meet PHE or national standards  2. Parents asked to leave NNU during interventional procedures, ward rounds etc. Restricted visiting during COVID  3. Added to capital plan  4. Feasibility study completed  | NNU Feasibility study in progress awaiting decision of the Board as to whether to proceed with major reconfiguaration and increased cots to meet TVN demand.     Planning for a specific W&C build is being discussed | 5 4 20                        | N<br>de<br>es<br>su<br>pa | Outline business case for INU rebuild has been leveloped by Trust and states department and ubmitted to CCG/STP artners for consideration. waiting final decisions | 3 9                              | approp                        | le level - Business Case for Refurnishing Milk riate cost- Etitchen and Sluice e control  | 30/03/2021                 | No Change | No change             | 30/06/2021  |
|           | A 30/03/2021 | Director of<br>Patient Care /<br>Chief Nurse | Styles,<br>Janice           | &<br>Children's<br>Health -<br>Women's<br>Health                  | &<br>Maternity | Inability of Trust to provide maternity care locally for some women (during times of peak demand on service, delays in clinical care) and potential increased readmission rate due to reduced length of stay   | obstetric beds  | (inductions, pain relief etc) at times of heavy demand while beds sourced & potential need to divert to neighbouring maternity units when unable to accommodate women. Poor patient experience. | 5 5 25     | HIGH  Daily huddle & bed state reviews Escalation process Review of obstetric clinical pathways Three times a day Maternity specific safety huddle (March 2021) Regular reviews with Exec Team   | LOS data<br>Incident reporting<br>rate on<br>readmissions -<br>deep dive analysis<br>currently ongoing  | 5 4 20                        | ai<br>pr<br>Bi<br>in      | requirement for EPAU to be 3<br>way from ante and<br>ostnatal ward areas.<br>red space needs to be<br>ncreased   |                                  | approp<br>effectiv<br>require | le level - away from ante and postnatal ward<br>riate cost-<br>e control<br>d   |                            | No Change |                       |             |
| 940   7-3 |              | Director of<br>Finance                       | Aldridge,<br>Sophia         | Finance   |                | If the future NHS funding regime is not sufficient to cover the costs of the Trust, then the Trust will be unable to meet its financial performance obligations or achieve financial sustainability.   | beyond September 2021<br>due to disruption caused   |   | 4   5   20 | 1. Cost and volume contracts replaced with block contracts (set nationally) for clinical income;2. Top-up payments available where COVID-19 leads to additional costs over and above block sum amounts (until September 2021); 3. Budgets to be reset for FY22 based on financial regime; financial controls and oversight to be reintroduced to manage financial performance.4. Cost efficiency programme to be reset to target focus on areas of greatest opportunity to deliver | Monthly financial performance monitoring information by the F&I Committee and the Trust Board  Cost efficiency reporting  BLMK ICS finance performance reporting  |                               | oi<br>ye                  | inancial regime for FY22  nly valid for first half of the ear. Trust has minimal bility to influence   | 2  10   N                        | tolerab<br>approp             | above   Maintain dialogue with CCG re Contract   le level - Raise risk of dispute over interpretation riate cost- of Contract with Monitor   d   Contract | 19/04/2021                 | Increased | Increased             | 19/05/2021  |

## Significant Risk Register

| ID   | Aı     |           | Executive<br>Responsible            | Risk<br>Owner         | Division             | Specialty | Description  | Cause   | Impact  | Risk          | Inherent Controls in place<br>Risk Level   |  | Assurance on Controls   | Risk          | Current<br>Risk Leve |  | Risk         |  | t Action Plan Summary | Date Risk Last<br>Reviewed | Trend     | Trend<br>Rationale                                | Review Due? |
|------|--------|-----------|-------------------------------------|-----------------------|----------------------|-----------|--|---|---|---------------|--|--|---|---------------|----------------------|--|--------------|--|-----------------------|----------------------------|-----------|---|-------------|
| 2796 | -      | ate       | Director of<br>Clinical<br>Services | Chadwick,<br>Ms Helen |                      |           | The risk is there will be insuffient staff in pharmacy to meet demands of the organisation and ensure patient safety in the use of medicines.  | High turnover of staff<br>due to work pressure<br>and not having the<br>opportunity to work at<br>the top of their licence.<br>Also difficulty in<br>recruiting particuarly to<br>8a posts.   | increased length of<br>stay due to TTO delay     increase in prescribing<br>errors not corrected     increase in dispensing<br>errors     increase in missed<br>doses     5. failure to meet legal<br>requirements for safe and<br>secure use of medicines  Breach of CQC<br>regulations  | Rating 4 5 20 | quick wins from staff to<br>1 system to support st   | ening events with staff, identifyir<br>o reduce turnover, implementing<br>aff, reviewing work activities of<br>tify what could stop for a period   | g 1-low, turn over remains high.  | Rating 4 5 20 | нібн                 | Use of senior staff to support not viable long term.   | Rating 2 3 6 | OW TREAT - a tolerable appropria effective required  | evel -<br>te cost-    | 26/02/2021                 | No Change | turnover<br>remains<br>Reduced<br>pressure<br>c19 | 26/03/2021  |
| 1472 | 1-4 24 | 4/03/2021 | Director of<br>Corporate<br>Affairs | Ewers, Mr<br>Paul     | Corporate<br>Affairs |           | There is a risk that not all known incidents, accidents and near misses are reported onto Trust Incident Reporting System (Datix) and that they will not be robustly investigated within the required timescales | reporting culture; Lack of<br>understanding of the  | incidents, accidents and e near-misses; Inability to stop potentially preventable incidents occurring; Potential failure to comply with Duty of Candour legislation requiring the Trust to report all known incidents where the severity was moderate or higher; Potential under reporting to the National Reporting & Learning | 4 5 20        | 3. Incident Reporting T as required 4. Datix Incident Invest 5. Daily review of incid identify potential Seric escalation 6. Serious Incident Rev Serious Incident Invest 7. SIRG ensure approp to Commissioners 8. Staff able to have au investigation approval 9. Incident Reporting A 2017 10. Standard Operating Team supporting the c | Mandatory/Induction Training raining Guide and adhoc training Guide and adhoc training igation Training sessions ents by Risk Management Team us Incidents and appropriate lew Group (SIRG) ensure quality igations iate reporting of Serious Incident tomatic feedback following wareness Campaign - September, Procedure re Risk & Governance osure of incident investigations demand on service (e.g. Covid-1 February 2021 | monitoring trends 2. Weekly overdue incident reporting 3. Routine and exception reports of to Risk & Compliance Board 4. Weekly Compliance Report to Executive Team 5. Incident reporting rate and ever overdue incidents monitored |               | нібн                 | 1. Lack of a high incident reporting culture 2. Lack of robust investigations for non-Serious Incidents 3. Lack of feedback to reporters/staff following incident investigations 4. Staff lack access to a computer to report incidents 5. Staff lack time during shift to report incidents 6. More intuitive incident reporting system - procurement scoping exercise on going for Datix Cloud/new system | 4 3 12       |  |                       |                            | No Change | No change<br>since last<br>review                 | 30/04/2021  |
| 2791 |        |           | Director of<br>Clinical<br>Services | Orr, Mrs<br>Julie     | Operations           |           | Risk that patient discharges will significantly be delayed, especially those requiring complex coordination of the discharge process   | The Discharge Coordinators (Registered Nurses B6 level) are currently severely short staffed due to vacancies and sudden long term sickness, with an additional Discharge Coordinator due to have major surgery leading to additional long term sickness. The Discharge Team currently consists of 5 wte B6 Registered Nurses. At present there are 3wte in post howeve 2wte are on long term sick leave. | discharges, leading to a potential for an increase in hospital acquired infections, deconditioning Potential to affect the stranded and super stranded patient numbers and a failure achieve National target set for 2019-20, with associated impact on ED performance  | 4   5   20    | Coordinator carrying o Offered bank shift to to shown an interest in th vacancy and interview 2/8/19.  Reviewed role and dele Rotational Operations Support requested fro  | n key nursing areas who have th<br>ber of aspects relating to the role   | incidents figures<br>Superstranded<br>patirnt data  | 4 4 16        | HIGH                 | Additional funding to over recruit 1 WTE to for a 6 month period to cover the long term sickness   | 3   3   9    | AOD TREAT - a tolerable appropria effective required | evel -<br>te cost-    | 28/08/2019                 | No Change | New Risk  | 30/11/2019  |

## Significant Risk Register

| ID   |          | Executive<br>fiew Responsible       | Risk<br>Owner       | Division   | Specialty                   | Description   | Cause  | Impact  | Risk          | Inherent Controls in place<br>Risk Level  |  | Assurance on Controls   | Risk          | Current<br>Risk Level |  | C L Target 1<br>Risk F | isk Cate               |   | Date Risk Last<br>Reviewed | Trend     | Trend I<br>Rationale               | Review Due? |
|------|----------|-------------------------------------|---------------------|--|-----------------------------|---|--|---|---------------|---|--|---|---------------|-----------------------|--|------------------------|------------------------|---|----------------------------|-----------|------------------------------------|-------------|
| 1519 | 7-2 Date | Director of<br>Finance              | Aldridge,<br>Sophia | Finance  | Financial<br>Managem<br>ent | There is a risk that the Trust is unable to achieve the required efficiency improvements through the transformation programme leading to an overspend against plan  | is not adequately<br>resourced and prioritised<br>and/or schemes are   | The Trust may not deliver its financial targets leading to TO potential cash shortfall and non-delivery of its key targets                                      | Rating 4 4 20 | ensure they are delivering. Savings measured againg ensure they are robust a financial reporting.  3. All savings RAG rated.  4. Oversight of the trans | ainst Trust finance ledger to<br>and consistent with overall | 1. Divisional CIP review meetings in place attended by the DoF, divisional managers and finance business partners.  2. Cross-cutting transformation schemes being worked up.  3. Savings plan for 21/22 financial year not yet fully identified." | Rating 4 4 16 | нібн                  | Saving schemes to be identified to deliver maximum savings in 2021/22  | Ratine I               | tolei<br>appr<br>effe  | AT - above rable level - ropriate cost- ctive control uired | 19/04/2021                 | Increased | Schemes still need to be worked up | 19/05/2021  |
| 2055 |          | Director of<br>Corporate<br>Affairs | Stamp, M<br>Jamie   | Core<br>Clinical &<br>Support<br>Services -<br>Clinical<br>Support<br>Services | Dietetics                   | The risk is that the trust is failing in its statutory legal duty under the Health & Safety at Work etc. Act 1974, Management of Health & Safety at Work Regulations 1999, Workplace (Health, Safety & Welfare) Regulations 1992 and Display Screen Equipment Regulations 1992 to provide a safe and well maintained place of work including welfare facilities for staff | staff by law would be 11<br>staff, this is exceeeded<br>on a regular basis as staff<br>s are unable to write their<br>notes on the wards due | wellbeing concerns in<br>relation to staff welfare<br>with potential for<br>sickness absence and<br>potential litigation claims<br>2. Multiple breaches of      | 4 4 16        | HIGH  Due to the number of st have to work from hom Mobile air conditioning Plumbed in water cooled   | units distributed.   |   | 4 4 16        | HIGH                  | The portacabins continues to provide insufficient space for the staff using this base, this has been further compromised by the social distancing requirements for COVID-19. | 2 3 6 L                | lowe<br>prac           |   | 06/04/2021                 | No Change | No change (                        | 01/07/2021  |
| 2735 |          | Deputy CEO                          | York,<br>Craig      | ΙΤ   | n                           | telephone systems are not upgraded, THEN they will fall into a state where they cannot be supported by the Trust's IT Department or any third-party suppliers, LEADING TO potential loss of telephone systems either in small areas or across the Trust. This would have a significant impact upon operational procedures, especially during critical or busy periods.    | Failure of the telephone system, communications being lost across critical areas.  | older, the likelihood of  | 4 4 16        | HIGH Support in place, upgrad   | le ETA Pending Capital funding                               |   | 4 4 16        | нібн                  | An upgrade is required, that currently is not funded; network business case required.  | 4 1 4                  | toler<br>appr<br>effer | AT - above rable level - ropriate cost- ctive control uired | 13/01/2021                 | Increased | Technical :                        | 13/04/2021  |
| 2892 |          | CEO                                 | Noble,<br>Deborah   | Core<br>Clinical &<br>Support<br>Services -<br>Diagnosti<br>&<br>Screening     | Services                    | The 10yr old mammography machine in BS2 could fail due to its age. The increased amount of unplanned downtime this year is consistent with aging equipment.  With the introduction of new technologies the availability of replacement parts is a worry. A replacement part needed to be shipped from Chicago.  |  | Failure of the machine would lead to a loss of service capacity for the 2ww clinics and NHSBSP programme which give have a detrimental effect on Trust metrics. | 4 4 16        | physicist for support.<br>Robust QA systemin pro  | ediately to external contractor /                            | QA monitored weekly by physicists.  | 4 4 16        | нібн                  | Availability of replacement arts.  | 3 1 3                  | tolei<br>appr<br>effe  | AT - above rable level - ropriate cost- ctive control uired | 22/01/2021                 | Increased | Aging :<br>equipment               | 26/03/2021  |

| ID Ref Triumvirate Annual Review | Executive<br>v Responsible          | Risk<br>Owner       | Division        | Specialty | Description   | Cause                 | Impact  | C L Inherent<br>Risk<br>Rating | t Inherent<br>Risk Level | Controls in place  | Assurance on Controls  | C L Current<br>Risk<br>Rating | Current<br>Risk Leve |  |              | Risk |   | Action Plan Summary   | Date Risk Last<br>Reviewed | Trend     | Trend<br>Rationale | Review Due? |
|----------------------------------|-------------------------------------|---------------------|-----------------|-----------|---|-----------------------|---|--------------------------------|--------------------------|--|--|-------------------------------|----------------------|--|--------------|------|---|---|----------------------------|-----------|--------------------|-------------|
| 767 3-2 30/03/2021               | Medical<br>Director                 | James, Mr<br>Andrew |                 |           | patients not being appropriately cared for as they are not being treated in accordance with NICE guidance (CG176: Head injury: assessment and early management, updated September 2019) | should be managed and | patient safety - T&O surgeons and nursing teams may be unaware of how to care for patients with moderate to severe head injuries especially patient who are anticoagulated Clinicians may have to wait for an opinion from the Tertiary Centre Staff training, competency and experience - Serious incidents. | 4 3 12                         | MOD                      | 1, 2 & 3. Preventive controls On going discussions with Senior Medical Team CSU Lead to escalate via trauma network Alert process is in place for escalation within T&O & externally. Resources available at tertiary site for advice/support  1, 2 c & 3. mitigating controls Policy for management of head injuries has been developed Awaiting appointment of head injury liaison Nurse | 25/03/2021 Team continue to express concerns around the allocation of head injury patients to T&O.  - Monitoring of Datix reported incidents by CGL for Surgery and CSU Lead - Team discussion of incidents/mortaliti es at CIG and M&M meetings.  | 4 4 16                        | нібн                 | - 29/03/2021 T&O continues to received referral for complex head injury patients 23/09/2020 T&O continues to receive referrals for complex head injury patients under their speciality 28/01/2020 despite agreed pathway for admitting head injury patients under T&O team - non complex/ significant co-morbidities/ or anticoagulated the team are still having to care for these patient Trust is not in line with other trauma units - Regional trauma centre advises head injury should not be managed by trauma and orthopaedics and after 24 hours the patient should be referred to neurosurgery Potential delay in opinion from Tertiary Centre | Rating 4 2 8 | MOD  |   | Monitoring of incidents where tertiary advice/support was not available to Monitor incidents where delay in tertiary opinion has occurred | 31/03/2021                 | No Change | Ongoing            | 30/04/2021  |
| 2640 24/03/2021                  | Director of<br>Corporate<br>Affairs | Worth,<br>Mrs Tina  | Affairs Affairs |           |   | requirements and are  | Unable to meet statutory and mandatory Good Governance requirements and accreditations if IT systems do not support their remit.  | 5 5 25                         | нібн                     | System in place but requires updating and Q pulse which manages Trust documentation is no longer able to archive since the shared drive was moved.  Updates made to Q-Pulse and SharePoint   | The controls are ineffective to manage documentation on such a scale to support accreditation.  No response from Datix regarding system capabilities. IT support staff no longer able to support - new member of staff commences July 2018 for project to be handed over.  Scoping exercise with other IT systems to Datix that may include a document management service.  QPulse move to Microsoft Teams pending - further | 5 3 15                        | HIGH                 | Systems require updating Purchase of additional modules on Datix (business case fo Datix cloud/other system progressing)   | 2 1 2        |      | TREAT - above<br>tolerable level -<br>appropriate cost<br>effective control<br>required | t- system   | 26/02/2021                 | No Change | New risk           | 30/04/2021  |

| ID   | Ref Triumvirate<br>Annual Revie | Executive<br>w Responsible          | Risk<br>Owner       | Division  | Specialty             | Description  | Cause   | Impact   | Risk          | Inherent<br>Risk Level | ·   | Assurance on Controls  | Risk          | Risk Leve |   |              | Risk | Treatment<br>Category  |  | Date Risk Last<br>Reviewed |           | Trend<br>Rationale | Review Due? |
|------|---------------------------------|-------------------------------------|---------------------|---|-----------------------|--|---|--|---------------|------------------------|---|--|---------------|-----------|---|--------------|------|--|--|----------------------------|-----------|--------------------|-------------|
| 2894 | Date                            | Deputy CEO                          | ath,                | Performa<br>nce &<br>Informati<br>on  | Informatio            | The Trust Information data warehouse could fail or be subjected to a security attack.  | Server 2008 R2 servers (MKG-Arden-05 & MKG-BI-01) on site. Microsoft have ended extended support for SQL Server 2008 R2 on 09 July 2019**, which means the above server do not receive any security and technical updates from Microsoft, making it vulnerable to security attacks and technical failures. Furthermore, due to the outdated technology there have been intermittent outages of the server | to fulfil any internal and national reporting requirements including RTT and financial reporting, submission of CDS, ECDS (to SUS), etc. This will have operational and financial impact leading to compromised patient safety and patient experience.   | Rating 4 5 20 | HIGH                   | There are reactive controls in to support the data warehouse using the in-house teams, including daily check of the servers, deleting redundant information stored on the server is conserve space. Additionally, A business case to migrate the information platform to Microsoft Azure platform has been submitted to the Executive directors for consideration and awaiting a decision.  |  | Ratine 3 5 15 | HIGH      | None  | Rating 2 3 6 | LOW  | TREAT - above<br>tolerable level -<br>appropriate cost-<br>effective control<br>required |  | 11/09/2020                 | No Change | No Change          | 04/03/2021  |
| 824  |                                 | Deputy CEO                          | Eagles,<br>Phil     | Estates   | Estates               | IF the estates infrastructure contingency plans are not adequately tested THEN in the event of a infrastructure failure plans may not succeed LEADING TO contingency plans not being effective and to potential loss of services, poor patient experience, financial loss and loss of reputation | untested contingency<br>plans, in the event of a<br>infrastructure failure<br>plans may not succeed   | an increased safety and service disruption risk to patients and staff.   | 5 4 20        | HIGH                   | Partially tested Contingency Plans.     Review of Business Continuity Plan review process completed in conjunction with Gordon Austin assisting with reviewing process and plans.     Continuity plans reviewed and shared with team.     Noted that plans partially tested during the recent flooding incident.     Emergency Planning Officer has been sent the plan for review and comment.     Met EPO and reived document, awaiting publication. |  | 5 3 15        | нібн      | Waiting publication of agreed document.   | 5 1 5        |      | TREAT - above<br>tolerable level -<br>appropriate cost-<br>effective control<br>required | Testing regimes to be further developed with Gordon Austin | 09/03/2021                 | No Change | see<br>comments    | 30/06/2021  |
| 2740 |                                 | Deputy CEO                          | York,<br>Craig      | IT  | n                     | The current bleep system (main system A and back-up system B) is obsolete and no maintenance support contract is available from the company. The risk is that the equipment may not be able to be repaired if failed.  | the equipment failure   | failure of the current<br>bleep system will have<br>impact on patient care<br>due to clinicians not being<br>contacted via the bleep<br>system   | 5 4 20        | HIGH                   | -DISCUSSED WITH LINE MANAGER AND ESCALATED -TEMPORARY RADIO COMMUNICATION SYSTEM 3. User group formed with IT & EBME to identify options  |  | 5 3 15        | HIGH      | Identify costs of possible solutions and draft business case. Estates to own crash bleep solution; IT will own the clinical messaging and task-orientated communication functions. Digital Information Manager for Strategic estates will be driving the project to replace the emergency/urgent bleep replacement. | 5 1 5        |      | TREAT - above<br>tolerable level -<br>appropriate cost-<br>effective control<br>required |  | 29/09/2020                 | No Change | new risk           | 13/04/2021  |
| 2968 |                                 | Director of<br>Corporate<br>Affairs | Noble,<br>Deborah   | Core<br>Clinical &<br>Support<br>Services -<br>Diagnostic<br>&<br>Screening | Screening<br>Services | Delayed detection of breast<br>screening cancers due to<br>COVID 19  | The cessation of the programme has meant that women have been delayed an invite for screening. The programme has restarted but with reduced capacity to enable social distancing in both the mobile and static sites.   | Women of screening age may receive a positive diagnosis that has been delayed due to the cessation of the programme. Treatment regimes will be delayed as a result.  | 5 4 20        | HIGH                   | Restart proposal approved by the Trust, SQAS and PHE. Guidance issued as to the management of the women to ensure that no-one is missed has been issued by Hitachi/PHE and has been implemented by the programme.   | KPI's monitored<br>buy NHSBSP<br>Regular<br>communication<br>with QA team and<br>commissioners.  | 5 3 15        | HIGH      | No Gaps   | 2 2 4        |      | TREAT - above<br>tolerable level -<br>appropriate cost-<br>effective control<br>required |  | 24/04/2020                 | Decreased | No change          | 25/06/2021  |
| 2928 |                                 | Director of<br>Corporate<br>Affairs | Evans, Ms<br>Joanne | Core<br>Clinical &<br>Support<br>Services -<br>Diagnostic<br>&<br>Screening | Imaging               | Lack of space for appropriate management of CT and MRI with additional issues of lack of scanners to manage the increasing demand.   | The issue is increasing demand at upto 14% annually with a requirement to reduce turnaround times.  | Financial due to missed targets Reputation due to long waiting times Reputation and financial due to increased infection rates Staff leaving due to poor working conditions. This is delaying patient management and causing issues with meeting the diagnostic waiting times. Inability to manage patients privacy and dignity also increased risk of infection due to overcrowding of faciliities. | 4 5 20        | нібн                   | Extended working hours and days, some scans sent off site to manage demand.  Reduced appointment times to optimise service.  1.12.20 no change to risk rating services remain challenged due to lack of basic capacity made worse by Covid social distancing and cleaning issues.  IS provider approached to provide more MRI capacity  | patients are managed through the service safely although space is compromised and capacity limited Adoption of the MRI service from the IS and the installation of a second MRI scanner will help (expected late 2020) | 3 5 15        | HIGH      | no current gaps, just<br>shortage of capacity. Should<br>be addressed by the<br>development of the scanner<br>centre  | 2 2 4        |      | TOLERATE - at<br>lowest<br>practicable/cost-<br>effective level                          |  | 01/12/2020                 | No Change | No Change          | 30/06/2021  |

| ID   | Ref Triumvirate Annual Review | Executive<br>Responsible                     | Risk<br>Owner               | Division   | Specialty | Description   | Cause   | Impact   | C L Inherent<br>Risk<br>Rating | Inherent<br>Risk Level | Controls in place  | Assurance on Controls   | C L Current<br>Risk<br>Rating | Current<br>Risk Leve |  | L Target<br>Risk<br>Rating | Risk | Treatment<br>Category   | Action Plan Summary  | Date Risk Last<br>Reviewed | Trend     | Trend<br>Rationale                | Review Due? |
|------|-------------------------------|--|-----------------------------|--|-----------|---|---|--|--------------------------------|------------------------|--|---|-------------------------------|----------------------|--|----------------------------|------|---|--|----------------------------|-----------|-----------------------------------|-------------|
| 2546 | Jace                          | Deputy CEO                                   | Chandler,<br>Ollie          | IT   | n         | If the IT Department does not have a stock of replacement network switches, THEN if a switch fails a replacement will need to be sourced, procured, delivered, and installed, LEADING TO a delay in bringing up to 48 devices back online, potentially losing IT devices for a whole area/department for up to two weeks. |   |  | 4 4 16                         | HIGH                   | There is no stock left.  | to have stock will mean that there are no outages within key functional areas. This is an entirely appropriate measure to assure the current control. | 3 5 15                        | нібн                 | No stock available,<br>discussions regarding<br>replacement network are in<br>flight.  | 3 6                        | LOW  | TREAT - above<br>tolerable level -<br>appropriate cost<br>effective control<br>required | Write business case for additional switches  | 13/01/2021                 | Increased | Increase -<br>no stock            | 13/04/2021  |
| 1970 |                               | Director of<br>Clinical<br>Services          | Hyem-<br>Smith, Ms<br>Celia | Core<br>Clinical &<br>Support<br>Services<br>Clinical<br>Support<br>Services | apy       | r Unable to meet the demand<br>for existing patients leading<br>to increased waiting times<br>Unable to develop exisiting<br>outpatient services<br>Unable to optimse student<br>placements   | The cause is the lack of clinical space available for patient treatment   | The impact is failure to meet contracts, lost revenue, poor patient experience and poor staff morale   | 3 5 15                         | HIGH                   | Extended working hours     Introduction of shift pattern     Introduction of telephone triage clinics     Group treatment sessions   |   | 3 5 15                        | нідн                 | Amalgamation and integration of department space and teams to utilise current space more efficiently.  Potential to increase clinical space but this would require significant investment.   | 5 15                       | HIGH | TREAT - above<br>tolerable level -<br>appropriate cost<br>effective control<br>required | Review of space in Therapies   | 17/02/2021                 | No Change | No change                         | 31/05/2021  |
| 2983 |                               | Director of<br>Clinical<br>Services          | Hyem-<br>Smith, Ms<br>Celia | Core<br>Clinical &<br>Support<br>Services<br>Clinical<br>Support<br>Services | apy       | r There is a risk that the<br>Women & Men's Health<br>Physiotherapy Service is<br>unable to meet its referral<br>demand   | Insufficient<br>staffingleading to<br>increased waiting times<br>Referral number into<br>service via multiple<br>routes   | Potential for poor clinical outcome, poor patient experience, complaints and staff stress Potential delay to patient treatment Potential for patients with new diagnosis of cancer and pregnant women are not seen in a timely fashion further   | 3 5 15                         | HIGH                   | Non clinical time including training, development and audit are being minimised to increase the number of available patient appointments  Job plans are being completed by all staff to show impact on workload  Patients are ebing booked into group where possible instead of individual appointment slots  Recruited to all vacant posts  To explore options for supporting dictationn of letters to free up clinical capacity. | meet the needds<br>of their clinical<br>repsentation.<br>Team is fully<br>established and<br>Band 4 assistant is                                      | 3 5 15                        | нібн                 | Staff capacity to meet current referral demand   | 4 8                        | MOD  | TREAT - above<br>tolerable level -<br>appropriate cost<br>effective control<br>required | Establish increasing referral rate trends, map against capacity and establish increase income vs uplift in staff to meet demand Budget reallocation and VCP for Band 6 post Therapy Strategy is being finalised to support investment for business case, to present strategy at management once shared with senior members of the Trust To discuss interim plans to manage staffing and impact on Women's division | 19/06/2020                 | Increased | No changes<br>to staffing         | 31/05/2021  |
| 1695 |                               | Director of<br>Clinical<br>Services          | Chappell,<br>Faye           | Core<br>Clinical &<br>Support<br>Services<br>Clinical<br>Support<br>Services | apy       | r There is a risk that Children's<br>Physiotherapists are not able<br>to run to their full capacity in<br>order to treat all children on<br>their caseload/waiting list   | the Child Development   | Poor use of NHS funds as therapists are not treating patients     Inabiliity to treat all children on caseload leading to increased waiting list     Soss of income as the Trust are only paid when physios are with a patient and reduced treatment for children with physical needs     Poor patient experience and potential impact on clinical | 3 5 15                         | HIGH                   | Physiotherapy staff timetables designed to avoid cluster of staff all working in the CDC at the same time. Room booking system in place. All have been in place for years the problem is worsening as the building is shared with other teams which are growing.   |   | 3 5 15                        | НІСН                 | Insufficient space for treating therapists   | 3 6                        | LOW  |   | Action required Contact and attend meetings with CNWL-Eind out who owns the buildingReview the feasibility of moving to SSHC Review of space in Therapies additional OP space required - looking to use current SLT office (when they move offices) Negotiating additional space at Stony Stratford Health Centre, awaiting update from NHS Property Services  | 15/04/2021                 | Increased | Access to<br>rooms has<br>reduced | 17/05/2021  |
| 1874 |                               | Director of<br>Patient Care /<br>Chief Nurse | Tait, Mrs<br>Michaela       |  | at PPI    | The MUST conformance criteria were set out in the NHS accessible information specification for compliance by the 31st July 2016   | The Trust currently cannot meet all of requirements set out in this specification which is driven by the NHS England, the Equality Act 2010 and Care Act 2014 to ensure patients with a disability are not discriminated against. | particular information   | 3 5 15                         | HIGH                   | Some of the meeting individual needs resources identified i.e.BSL sign language interpreters, braille, easy read  Ongoing EPR agile preparation events E Care launch plan in progress  | Patient Experience of team are working with external providers and will be picked up as part of the Quality Account                                   | 3 5 15                        | нібн                 | Go live date agreement for EPR - Cerner have confirmed that the system will allow the required alert flags etc.  Equality and Diversity Trust legal requirements to be identified, documented in policy and staff advised.  This impacts on all policies and guidelines.  Interpreting and translation policy - contract now agreed  Gap analysis of patient information (sits with Patient Experience) - what is available? | 2 6                        | LOW  | TOLERATE - at<br>lowest<br>practicable/cost<br>effective level                          | Steering Group to monitor progress Review of proces for patient information publication & availability   |                            | No Change | First review                      | 28/08/2019  |

| ID Ref | Triumvirate Executive Annual Review Responsible | Risk<br>Owner               | Division   | Specialty        | Description  | Cause   | Impact   |               | Inherent<br>Risk Level | Controls in place   | Assurance on Controls   | C L Curre<br>Risk |      | Gaps in Controls  | C L Target Targ |   | Action Plan Summary   | Date Risk Last<br>Reviewed | Trend     | Trend<br>Rationale    | Review Due? |
|--------|---|-----------------------------|--|------------------|--|---|--|---------------|------------------------|---|---|-------------------|------|---|-----------------|---|---|----------------------------|-----------|-----------------------|-------------|
| 2297   | Director of Clinical Services                   | Thwaites,<br>Elizabeth      | Core<br>Clinical &<br>Support<br>Services -<br>Diagnosti<br>&<br>Screening     |                  | available space within Cellular<br>Patholgy will not be enough   | specimen storage,<br>workspace additional   | The department will be unable provide the storage space required to accommodate the increasing workload leading to 1. An inability to retain specimens for the period of time required to meet RCPath guidance 2. An increased risk of formalin spillage / increased levels of formalin vapour 3. Increasing risk to staff and to specimens because of cramped workspace e.g. Specimen reception area encroaches on cut-up area 4. Inability to safely operate and / or validate equipment | Rating 3 5 15 | HIGH                   | Storage of specimens minimised. No uneccessary specimens stored Storage period reduced from 6 weeks to 4 weeks with the approval of Pathologists and Clinical Lead  | Controls are currently not effective due to increased workload and pressure of social distancing. | Ratin 3 5 15      | HIGH | Additional storage space now identified - move to business case Staff continue to work within confined space and these working conditions were a contributing factor to SI Web65568 2019/3478 | Rating Leve     | TREAT - above tolerable level - appropriate cos                                       | Identify additional storage space Review space and workflow and identif t- activities that can be relocated I Develop business case for space expansion into courtyard area | 13/04/2021                 | No Change | Plans under<br>review | 17/05/2021  |
| 2438   | Medical<br>Director                             | Colda,<br>Antoanela         | Medical<br>Director  | &                | R&D department has yearly<br>running staff contracts, not<br>permanent contracts and we<br>are not able to provide longer<br>term contracts for the team   |   | number/quality   | 3 5 15        | HIGH                   | Requested support from the network CRN     Discussed with other Trusts Partners regarding their existing contracts  | Able to     maintain existing     staff     Increase staff level                                  | 3 5 15            | нідн | Longer term contracts   | 2 3 6 LOW       | TREAT - above<br>tolerable level -<br>appropriate cos<br>effective contro<br>required |   | 03/10/2018                 | No Change | no change             | 31/12/2020  |
| 2936   | Director of<br>Clinical<br>Services             | Hyem-<br>Smith, Ms<br>Celia | Core<br>Clinical &<br>Support<br>Services -<br>Clinical<br>Support<br>Services | Physiothe<br>apy | r Increasing numbers of patients being added to the physiotherapy outpatient waiting list, in addition to those on hold due to the COVID-19 pandemic, resulting in waiting times of well over 18 weeks for any type of intervention. A further increase in referrals may result from patients with post COVID symptoms | could be managed<br>effectively by groups, thi<br>is no longer possible due<br>to social distancing and                               |  | 3 5 15        | нібн                   | - Virtual management of patients - Video and telephone clinics - Additional IT sourced to support virtual management - Reconfiguration of department to support virtual working and enable social distancing along with staff working from home - recovery plans are being written/in place to enable essential patients to be seen in the department of a face to face basis - Educational material including exercise programmes and access to youtube clips are made available to patients |   | 3 5 15            | HIGH | To identify process for<br>validate routine patient lists<br>to ensure that clinical<br>priorities are seen the<br>correct order  | 2 3 6 LOW       | TREAT - above tolerable level - appropriate cos effective contro required             |   | 17/02/2021                 | No Change | new risk              | 31/05/2021  |
| 3055   | Director of<br>Clinical<br>Services             | Chappell,<br>Faye           | Core<br>Clinical &<br>Support<br>Services -<br>Clinical<br>Support<br>Services |                  | r Poor outcomes for children<br>and young people referred to<br>the children's physiotherapy<br>service  | Staffing level and staffing structure that do not meet the needs of the service. This is compounded by insufficient space to deliver. | Belayed treatment, insufficient treatment, less effective treatment resulting in poorer outcomes and experiences for children and young people referred to the service. Increased complaints and incidents. Difficulties with staff recruitment and retention due to low morale and low work satisfaction.   | 3 5 15        | нібн                   | Coding and prioritizing of referrals  1:1s and caseload supervision   |   | 3 5 15            | нібн | Insufficient staffing to<br>manage workload   | 2 2 4 LOW       | TREAT - above tolerable level - appropriate cos effective contro required             |   | 15/04/2021                 | No Change | n/a                   | 17/05/2021  |
| 3066   | 20/04/2021 Director of Clinical Services        |                             | e Medicine<br>Specialty<br>Medicine  |                  | The neurology department<br>runs a botox injection clinic<br>for patient staffed by a single<br>consultant; this consultant is<br>now on long term sick leave.<br>There are 50 patients<br>awaiting review and<br>treatment in clinic.   | deliver a botox service<br>due to lack of availability  | 50 patients awaiting clinic appointments   | 3 5 15        | HIGH                   | There is no substantial control in place  |   | 3 5 15            | HIGH | There is no clinical staff to<br>treat patient in this category   | 2 2 4 LOW       | TOLERATE - at lowest practicable/cos effective level                                  | -   | 31/03/2021                 | No Change | New Risk              | 31/05/2021  |

|   | ) Ref | Annual Review   |                                     | Risk<br>Owner      | Division   | Specialty           | Description  | Cause   | Impact  | Risk          | Inherent<br>Risk Level | Controls in place   | Assurance on C   | Risk        | Current<br>Risk Level |   | Risk F   | irget Treatme   |   | Date Risk Last<br>Reviewed | Trend     | Trend Review Due?<br>Rationale    |
|---|-------|-----------------|-------------------------------------|--------------------|--|---------------------|--|---|---|---------------|------------------------|---|--|-------------|-----------------------|---|----------|---|---|----------------------------|-----------|-----------------------------------|
|   | 740   | Date 24/03/2021 | Director of<br>Corporate<br>Affairs | Worth,<br>Mrs Tina | Corporate<br>Affairs   |                     | There is a risk that changes required to practice are not implemented and we are not meeting best practice criteria  | actions from audit are not evidenced,   | Potential impact on the top 3 Trust objectives (patient Safety, Clinical Effectiveness, Patient Experience) Potential poor quality of service and associated impact on resources CQC concerns re audit activitu. & learning from national audits  | Rating 3 5 15 | HIGH                   | Audit report templates available to identify audit action plans. However these are not always being utilised and actions are not Always evidenced and monitored Monitoring via Clinical Audit & Effectivess Committee (CAEB)  TOR CAEB revised to include quality improvement, GIRF1 etc  Escalation/exception reporting to Management Board Refresh of Sharepoint data base to assist with data capture, with Level 1 audit a priority  Transformation Team audit  | Limited assurances from RSM audit review Sharepoint has ability for audit action plans to be attached with evidence of completion but audit cycle not completed to this level Jan - Feb 2020 repeat RSMUK reveiw due Limited assurances from RCB?CAEB - pals to move to integrated governance & divisional meetings approach | Ratine 5 15 | нісн                  | Capturing audit evidence at specialty CIG meetings including actions to improve practice or examples of good practice. Divisional audit reports at CAEB detailing compliance on Level a audits Sharepoint evidence to support action plan from audits - review & overhaul of system scheduled for November at Risk Management Team Divisional accountability at Performance Management Board Implementation of new integrated governance agenda National audits on hold & local audits & audit meetings limited due to Covid pandemic | Rating L | OW TREAT -<br>tolerable<br>appropr                          | level - be monitored by Audit Committee ate cost- Meeting with CGLs to review Sharepoint control format for capturing audit | :                          | Increased | KPMG Audit 30/04/2021<br>/ CQC    |
| : | 964   |                 | Deputy CEO                          | Eagles,<br>Phil    | Estates  | Estates             | There is a risk of roof failure in relation to flat roofs across the Trust   | If the flat roofs identified in the Langley Roof report and 6 facet survey as requiring replacement or upgrading, are not replaced.                           | damage to equipment, disruption to service,   | 3 5 15        | нібн                   | 1. Inspections and repairs as needed. 2. Updated annual 6 facet survey by Oakleaf 3. Large patch repairs undertaken as emergency busines cases 4. 1 x Post Grad roof fully replaced 19/20. 5. Ward 10 - 50% of roof patch repairs completed 19/20. 6. Phase 1, Phase 2 and Community Hospital survey completed. (52 roof leaks noted in 12 months Jan 19 -Aug 20) 16 leaks in 1st week of October 2020 7. Pharmacy small roof replaced September 20. 8. Business Case approved for 4 to 5 year rolling programme. 9. Work underway March 2021 |  | 5 15        | нібн                  | NIL 3   | 1 3 N    | OW TREAT -<br>tolerabl<br>appropr<br>effective<br>required  | level - identified in the 6 facet survey ate cost-control   |                            | No Change | ONGOING 30/06/2021 RISK and works |
|   | 341   |                 | Director of<br>Clinical<br>Services | Stamp, Mr<br>Jamie | Core<br>Clinical &<br>Support<br>Services -<br>Clinical<br>Support<br>Services | Dietetics           | The risk is that the paediatric team can not provide a full dietetic service to children and young people in the Milton Keynes area  | through our outpatient<br>structure which is not<br>adequate to meet their<br>demands and needs. As a<br>results of this staff are be<br>stretched to cover a | patient safety will be at risk 2. Vulnerable children becoming nutritionally compromised. 3. Unable to assess and advise new patients and review existing patients in a timely manner. 4. Impacting on patients nutritional status and longer term dietary management on what is a very vulnerable group of patients. | 3 5 15        | HIGH                   | Existing staff are working some additional hours but this remains insufficient to meet the needs of the service.  | 3  | 5 15        | нібн                  | There is insufficient to paediatric dietetics to manage the demand for outpatients, inpatients specifically the paediatric dietetic service is unable to deliver the national standards for Home Enterally Fed and Diabetic patients on the caseload.   | 3 3      |   | level - dietetic service for patients on HEF ate cost- being raised with CCG control Current staffing provision is not      |                            | No Change | No change 01/07/2021              |
| - | 958   |                 | Deputy CEO                          | Ahmed,<br>Ayca     | Estates  | Capital<br>Planning | The current risk is that there is not enough space in the Medical Equipment Library(MEL) to carry out the required cleaning process to comply with the appropriate guidelines set by CQC and MHRA. | Space pressure<br>increasing due to growth<br>of the MEL and additional<br>tasks  | processing space due to   | 3 5 15        | нібн                   | Staff members are taking processed equipment straight to the shelving areas as soon as it is cleaned to avoid cross contamination. This ensure equipment is kept separate, but this is not a productive method of working   | 3  | 5 15        | нібн                  | Nil 3   | 1 3      | OW TREAT -<br>tolerable<br>appropring effective<br>required | level -<br>ate cost-<br>control   | 09/03/2021                 | No Change | New Risk 30/06/2021               |

| Meeting Title  | Trust Board  | Date: May 2021   |
|----------------|--|--|
| Report Title:  | Board Assurance<br>Framework   | Agenda item:   |
| Lead Director  | Name: Kate Jarman  | Title: Director of Corporate Affairs   |
| Fol Status:    | Public   |  |
| Report Summary | <ul> <li>Trust's objectives.</li> <li>1. The risk scores for the downwards:</li> <li>a. Risk Entry 10 – From 15</li> <li>b. Risk Entry 13 – From 15</li> <li>c. Risk Entry 19 – From 12</li> <li>d. Risk Entry 23 – From 12</li> <li>e. Risk Entry 24 – From 20</li> </ul> | to 10 (page 33);<br>to 8 (page 46);<br>to 8 (page 57);<br>to 15 (page 59).<br>owing risk entry has been revised upwards:<br>to 20 (page 39); |

| Purpose  | Information X Approval To note Decision                                   |
|--|---|
| (tick one box only)  |   |
| Recommendation   | The Group is asked to review the content of the Board Assurance Framework |
| Strategic objectives links                                     | All   |
| Board Assurance<br>Framework links                             | All   |
| CQC outcome/<br>regulation links                               | Governance/ Well Led (Regulation 17)                                      |
| Identified risks and risk management actions                   |   |
| Resource implications  |   |
| Legal implications including equality and diversity assessment |   |
| Report history   | New   |
| Next steps   |   |
| Appendices   |   |

#### The Board Assurance Framework – Summary of Activity April 2021

#### **COVID-19 Risks**

COVID-19 continues to present a dynamic risk environment. While the COVID-19 infections continue to decline and the vaccination programme continue to make significant progress, there remains a significant and escalating risk in relation to the restoration of services due to the protracted and prolonged impact of the pandemic. This is the most significant operational and safety risk on the Board Assurance

#### Strategic Risks to be Reviewed to the BAF at the June 2021 Trust Board Seminar

- 1. HIP2 programme and estate development given the scale and timeframe of this programme it is recommended that the Board consider the risks against the Trust's strategic aim of making best use of the estate
- 2. Use of health information the Trust has recently launched access to health data with Apple, enabling patients using MyCare to access
- 3. Use of health information –It is recommended that the Board consider whether it should consider further opportunistic risk around the use of health information for clinical research purposes against the Trust's strategic aims of developing teaching and research and being innovative and sustainable.

#### The Board Assurance Framework

The Board Assurance Framework (BAF) details the principal risks against the Trust's strategic objectives.

- The BAF forms part of the Trust's risk management framework, which includes the corporate risk register (CRR), divisional and directorate risk registers (down to ward/ department service level).
- Risks are scored using the 5x5 risk matrix, and each risk is assigned a risk appetite and strategy. Definitions can be found summarised below and are detailed in full in the Trust's risk strategy.
- Board sub-Committees are required to rate the level of assurance against each risk reviewed under their terms of reference. There is an assurance rating key included to guide Committees in this work.

#### **Strategic Objectives**

- 1. Improving patient safety
- 2. Improving patient experience
- 3. Improving clinical effectiveness
- 4. Delivering key performance targets
- 5. Developing MK at place
- 6. Developing teaching and research
- 7. Being well governed and financially viable
- 8. Investing in our people
- 9. Developing our estate
- 10. Being innovative and sustainable

**Risk treatment strategy**: Terminate, treat, tolerate, transfer **Risk appetite**: Avoid, minimal, cautious, open, seek, mature

#### **Assurance ratings:**

| Green | Positive assurance: The Committee is satisfied that there is reliable evidence of the appropriateness of the current risk    |
|-------|--|
|       | treatment strategy in addressing the threat/ opportunity. There are no gaps in assurance or controls and the current         |
|       | exposure risk rating is at the target level; or gaps in control and assurance are being addressed.                           |
| Amber | Inconclusive assurance: The Committee is not satisfied that there is sufficient evidence to be able to make a judgement      |
|       | as to the appropriateness of the current risk treatment strategy.  |
| Red   | Negative assurance: There is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the |
|       | nature and/or scale of the threat or opportunity.  |

#### 5X5 Risk Matrix:

|            |  |                   |                    | Co               | nsequence           |                  |                 |
|------------|--|-------------------|--------------------|------------------|---------------------|------------------|-----------------|
|            |  |                   | How seve           | re could the out | comes be if the ris | k event occurred | ?               |
|            |  |                   | 1<br>Insignificant | 2<br>Minor       | 3<br>Significant    | 4<br>Major       | 5<br>Severe     |
|            | urring?                                      | Almost<br>Certain | 5<br>Medium        | 10<br>High       | Very high           | 20<br>Extreme    | 25<br>Extreme   |
| -          | risk occu                                    | 4<br>Likely       | 4<br>Medium        | 8<br>Medium      | 12<br>High          | Very high        | 20<br>Extreme   |
| Likelihood | What's the chance the of the risk occurring? | 3<br>Moderate     | 3<br>Low           | 6<br>Medium      | 9<br>Medium         | 12<br>High       | 15<br>Very high |
| 5          | ne chance                                    | Unlikely          | Very low           | 4<br>Low         | 6<br>Medium         | 8<br>Medium      | 10<br>High      |
|            | What's ti                                    | 1<br>Rare         | 1<br>Very low      | 2<br>Very low    | 3<br>Low            | 4<br>Medium      | 5<br>Medium     |

RISK 1: Ability to maintain patient safety during periods of overwhelming demand

| Strategic<br>Risk  | Ability to main demand | ntain patient safe | ty during p | eriods of | overwhelmin                   | 9            | Strategic Objective   | Improving Patient<br>Safety |
|--------------------|------------------------|--------------------|-------------|-----------|-------------------------------|--------------|-----------------------|-----------------------------|
| Lead<br>Committee  | Quality                | Risk Rating        | Current     | Target    | Risk Type                     | Patient harm | Track                 | ker                         |
| Executive Lead     | Director of Operations | Consequence        | 4           | 4         | Risk<br>Appetite              | Avoid        | 25                    |                             |
| Date of Assessment |                        | Likelihood         | 3           | 2         | Risk<br>Treatment<br>Strategy | Treat        | 20                    |                             |
| Date of Review     | 30/03/21               | Risk Rating        | 12          | 8         |                               |              | 15 —                  |                             |
|                    |                        |                    |             |           |                               |              | 5                     |                             |
|                    |                        |                    |             |           |                               |              | 0 Jun Jul Aug Sep Oct | Nov Dec Jan Feb Mar         |
|                    |                        |                    |             |           |                               |              | Score •               | Target                      |

| Cause             | Controls             | Gaps in        | Action         | Sources of      | Gaps in           | Action     | Assurance |
|-------------------|----------------------|----------------|----------------|-----------------|-------------------|------------|-----------|
|                   |                      | Controls       |                | Assurance       | Assurance         |            | Rating    |
| Significantly     | Clinically and       | Vacancies in   | Ongoing        | Daily huddle /  | Short term        | Escalation |           |
| higher than usual | operationally agreed | nurse staffing | recruitment    | silver command  | sickness or       | By CSM     |           |
| numbers of        | escalation plan      |                | drive          | meetings        | unexpected        | and Silver |           |
| patients through  | ·                    | Higher than    |                |                 | staffing levels / | OCM on     |           |
| the ED            | Adherence to         | normal staff   | Redeployment   | System-wide     | surges            | shift      |           |
|                   | national OPEL        | absences and   | of staff from  | (MK/BLMK/ICS)   |                   |            |           |
| Significantly     | escalation           | sickness       | other areas at | Partnership     |                   |            |           |
| higher acuity of  |                      |                | times of need. | Board, Alliance |                   |            |           |

| maticuta the manuals |                     |              | 0 14/2 21/1.        |  |  |
|----------------------|---------------------|--------------|---------------------|--|--|
| patients through     | management          |              | & Weekly            |  |  |
| the ED               | system              |              | Health Cell         |  |  |
|                      | Clinically risk     |              |                     |  |  |
| Major incident/      | assessed escalation | Additional   | Regional and        |  |  |
| pandemic -           | areas available.    | senior nurs  | ing National - NHSI |  |  |
| constraints on       |                     | presence o   |                     |  |  |
| space and            | Surge plans,        | 24/7 rota to |                     |  |  |
| adherence to IPC     | COVID-specific      | manage sta   | · •                 |  |  |
| measures             | SOPs and protocols  | deploymen    | 1                   |  |  |
| measures             | have been           | patient safe | •                   |  |  |
|                      |                     | •            | <b>-</b>            |  |  |
|                      | developed           | through the  | ,                   |  |  |
|                      |                     | pandemic.    |                     |  |  |
|                      |                     |              |                     |  |  |
|                      |                     | Services     |                     |  |  |
|                      |                     | reorganise   | d to                |  |  |
|                      |                     | manage       |                     |  |  |
|                      |                     | pandemic     |                     |  |  |

**RISK 2:** If an effective reporting, investigation and learning loop is not established and maintained, the Trust will fail to embed learning and preventative measures following serious incidents/ Never Events.

| Strategic<br>Risk | establishe | tive reporting, inved and maintained entative measures | d, the Trus | t will fail t | o embed lear | ning    | Strategic Objective Improving Patient Safety            |  |  |  |  |
|-------------------|------------|--|-------------|---------------|--------------|---------|---|--|--|--|--|
| Lead              | Quality    | Risk Rating  | Current     | Target        | Risk Type    | Patient | T I   |  |  |  |  |
| Committee         |            |  |             |               |              | harm    | Tracker   |  |  |  |  |
| Executive         | Medical    | Consequence  | 4           | 4             | Risk         | Avoid   | 25 ————————————————————————————————————                 |  |  |  |  |
| Lead              | Director   |  |             |               | Appetite     |         |   |  |  |  |  |
| Date of           |            | Likelihood   | 3           | 2             | Risk         | Treat   | 20  |  |  |  |  |
| Assessment        |            |  |             |               | Treatment    |         |   |  |  |  |  |
|                   |            |  |             |               | Strategy     |         | 15  |  |  |  |  |
| Date of           | 19/04/21   | Risk Rating  | 12          | 8             |              |         |   |  |  |  |  |
| Review            |            |  |             |               |              |         | 10  |  |  |  |  |
|                   |            |  |             |               |              |         | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr  Score — Target |  |  |  |  |
|                   |            |  |             |               |              |         |   |  |  |  |  |
|                   |            |  |             |               |              |         |   |  |  |  |  |

| Cause  | Controls                                | Gaps in<br>Controls                                  | Action                       | Sources of Assurance | Gaps in<br>Assurance         | Action     | Assurance<br>Rating |
|--|---|--|------------------------------|----------------------|------------------------------|------------|---------------------|
| Not appropriately reporting, investigating or learning from incidents. | Improvement in incident reporting rates | Establishing<br>Learning and<br>Improvement<br>Board | October<br>2020 -<br>ongoing | NRLS data<br>SIRG    | Intuitive Reporting<br>Rates | Appraisals |                     |

|                    | SIRG reviews all                     | Establishing                    |         | CCG Quality |  |  |
|--------------------|--------------------------------------|---------------------------------|---------|-------------|--|--|
| A lack of          | evidence and action                  | Divisional Quality              | October | Team        |  |  |
| systematic sharing | plans associated with                | Governance                      | 2020 -  |             |  |  |
| of learning from   | Sis                                  | Boards                          | ongoing |             |  |  |
| incidents.         | Actions are tracked                  | OI/ Al atratagias               |         |             |  |  |
| A lack of evidence | Actions are tracked                  | QI/ AI strategies and processes |         |             |  |  |
| that learning has  | Trust-wide                           | well embedded                   | October |             |  |  |
| been shared        | communications in                    |                                 | 2020 –  |             |  |  |
|                    | place                                |                                 | ongoing |             |  |  |
|                    | Debaiefie e e e e tema in            |                                 |         |             |  |  |
|                    | Debriefing systems in place          |                                 |         |             |  |  |
|                    | piace                                |                                 |         |             |  |  |
|                    | Training available                   |                                 |         |             |  |  |
|                    |                                      |                                 |         |             |  |  |
|                    | Appreciative Inquiry                 |                                 |         |             |  |  |
|                    | training programme started (December |                                 |         |             |  |  |
|                    | 2020)                                |                                 |         |             |  |  |
|                    | 2020)                                |                                 |         |             |  |  |
|                    | Commencement of                      |                                 |         |             |  |  |
|                    | patient safety                       |                                 |         |             |  |  |
|                    | resident role (April                 |                                 |         |             |  |  |
|                    | 2021)                                |                                 |         |             |  |  |

**RISK 3:** If the Trust is unable to accurately predict demand (for example, relating to the COVID-19 pandemic) and re-purpose its resources (physical, human and financial) with agility, the Trust will fail to manage clinical risk during periods of sustained or rapid change in the level or type of demand.

| Strategic<br>Risk  | relating to<br>(physical,<br>manage c | t is unable to acc<br>the COVID-19 pa<br>human and finan<br>linical risk during<br>or type of demand | andemic) a<br>cial) with a<br>periods of | nd re-pu<br>gility, the | rpose its reso<br>Trust will fail | urces<br>to | Strategic Objective Improving Patient Safety                |
|--------------------|---------------------------------------|--|--|-------------------------|-----------------------------------|-------------|---|
| Lead               | Quality                               | Risk Rating  | Current                                  | Target                  | Risk Type                         | Patient     |   |
| Committee          |                                       |  |  |                         |                                   | harm        | Tracker   |
| Executive Lead     | Medical<br>Director                   | Consequence  | 4  | 4                       | Risk<br>Appetite                  | Avoid       | 25  |
| Date of Assessment |                                       | Likelihood   | 3  | 2                       | Risk<br>Treatment<br>Strategy     | Treat       | 20  |
| Date of<br>Review  | 19/04/21                              | Risk Rating  | 12                                       | 8                       |                                   |             | 10 5 0 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr Score Target |

| Cause              | Controls            | Gaps in Controls | Action    | Sources of Assurance | Gaps in<br>Assurance | Action     | Assurance Rating |
|--------------------|---------------------|------------------|-----------|----------------------|----------------------|------------|------------------|
| Rapid or sustained | Board approved      | Inability to     | None      | MK place-            | Incomplete           | Enhanced   | _                |
| period of upheaval | major incident plan | accurately       | Currently | based and ICS-       | oversight of OP      | visibility |                  |
| and change         | and procedures      | predict or       | -         | based planning       | delays               | of OPD     |                  |

| caused by the       |                     | forecast levels of | and resilience  | PTL and  |  |
|---------------------|---------------------|--------------------|-----------------|----------|--|
| Covid-19            | Rigorous monitoring | activity and risk  | fora            | non RTT  |  |
| pandemic and        | of capacity,        | -                  |                 | pathways |  |
| need to respond     | performance and     |                    | Regional and    |          |  |
| and maintain        | quality indicators  |                    | national data   |          |  |
| clinical safety and |                     |                    | and forecasting |          |  |
| quality             | Established         |                    |                 |          |  |
|                     | command and control |                    | COVID MARC      |          |  |
|                     | governance          |                    | Meeting (Data,  |          |  |
|                     | mechanisms          |                    | Intelligence,   |          |  |
|                     |                     |                    | Collaboration   |          |  |
|                     | Gold (Daily)        |                    | with partners)  |          |  |
|                     | Level 3/4 Incident  |                    | •               |          |  |
|                     | management          |                    |                 |          |  |

**RISK 4:** If the Trust does not carefully manage its significant digital change programme, then the delivery of clinical services will be impaired.

| Strategic<br>Risk |          | et does not carefune, then the delive |         |        |           |         | Strategic Objective | Improving Patient Safety |  |  |  |
|-------------------|----------|---------------------------------------|---------|--------|-----------|---------|---------------------|--------------------------|--|--|--|
| Lead              | Quality  | Risk Rating                           | Current | Target | Risk Type | Patient | Tree                |                          |  |  |  |
| Committee         |          |                                       |         |        |           | harm    | Trac                | cker                     |  |  |  |
| Executive         | Deputy   | Consequence                           | 4       | 4      | Risk      | Avoid   | 25                  |                          |  |  |  |
| Lead              | CEO      |                                       |         |        | Appetite  |         |                     |                          |  |  |  |
| Date of           |          | Likelihood                            | 2       | 2      | Risk      | Treat   | 20                  |                          |  |  |  |
| Assessment        |          |                                       |         |        | Treatment |         |                     |                          |  |  |  |
|                   |          |                                       |         |        | Strategy  |         | 15                  |                          |  |  |  |
| Date of           | 19/04/21 | Risk Rating                           | 8       | 8      |           |         |                     |                          |  |  |  |
| Review            |          |                                       |         |        |           |         | 10                  |                          |  |  |  |
|                   |          |                                       |         |        |           |         | 10                  |                          |  |  |  |
|                   |          |                                       |         |        |           |         | _                   |                          |  |  |  |
|                   |          |                                       |         |        |           |         | 5                   |                          |  |  |  |
|                   |          |                                       |         |        |           |         |                     |                          |  |  |  |
|                   |          |                                       |         |        |           |         | 0 — Oct No.         | , Doe Jon Foly Mar Apr   |  |  |  |
|                   |          |                                       |         |        |           |         | Jul Aug Sep Oct Nov | / Dec Jan Feb Mar Apr    |  |  |  |
|                   |          |                                       |         |        |           |         | Score               | Score Target             |  |  |  |
|                   |          |                                       |         |        |           |         |                     |                          |  |  |  |

| Cause              | Controls            | Gaps in        | Action      | Sources of    | Gaps in        | Action     | Assurance |
|--------------------|---------------------|----------------|-------------|---------------|----------------|------------|-----------|
|                    |                     | Controls       |             | Assurance     | Assurance      |            | Rating    |
| Inadequate         | Robust governance   | None currently | Continue to | Established   | None currently | Continued  |           |
| assessment of      | structures in place |                | maintain    | governance    |                | iterative  |           |
| clinical risk/     | with programme      |                | programme   | and external/ |                | testing of |           |
| impact on clinical | management at all   |                | governance  | independent   |                | products   |           |
|                    | levels              |                | and keep    |               |                |            |           |

| services or |                        | resourcing | escalation and | post-roll |  |
|-------------|------------------------|------------|----------------|-----------|--|
| practices   | Clinical oversight     | under      | review process | out       |  |
|             | through CAG            | review     |                |           |  |
| Inadequate  |                        |            |                |           |  |
| resourcing  | Thorough planning      |            |                |           |  |
|             | and risk assessment    |            |                |           |  |
| Inadequate  | Regular review of      |            |                |           |  |
| training    | resourcing             |            |                |           |  |
|             |                        |            |                |           |  |
|             | Regular review of      |            |                |           |  |
|             | progress               |            |                |           |  |
|             | Risks and issues       |            |                |           |  |
|             |                        |            |                |           |  |
|             | reported               |            |                |           |  |
|             | Track record of        |            |                |           |  |
|             | successful delivery of |            |                |           |  |
|             | IT projects            |            |                |           |  |

**RISK 5:** Failure to provide capacity to match demand for elective care, including cancer and screening programmes

| Strategic  | Failure to pr | ovide capacity to  | match dem  | Strategic Objective | Improving Patient Safety |         |                       |                       |
|------------|---------------|--------------------|------------|---------------------|--------------------------|---------|-----------------------|-----------------------|
| Risk       | including ca  | ncer and screening | ng program | mes                 |                          |         |                       |                       |
| Lead       | Quality       | Risk Rating        | Current    | Target              | Risk Type                | Patient | _                     |                       |
| Committee  |               |                    |            |                     |                          | harm    | Trac                  | ker                   |
| Executive  | Director of   | Consequence        | 5          | 5                   | Risk                     | Avoid   | 25                    |                       |
| Lead       | Operations    |                    |            |                     | Appetite                 |         |                       |                       |
| Date of    |               | Likelihood         | 4          | 2                   | Risk                     | Treat   | 20                    |                       |
| Assessment |               |                    |            |                     | Treatment                |         | 20                    |                       |
|            |               |                    |            |                     | Strategy                 |         | 15                    |                       |
| Date of    | 30/03/21      | Risk Rating        | 20         | 10                  |                          |         | 13                    |                       |
| Review     |               |                    |            |                     |                          |         | 10                    |                       |
|            |               |                    |            |                     |                          |         |                       |                       |
|            |               |                    |            |                     |                          |         | 5                     |                       |
|            |               |                    |            |                     |                          |         | 3                     |                       |
|            |               |                    |            |                     |                          |         |                       |                       |
|            |               |                    |            |                     |                          |         | Jun Jul Aug Seo Oct   | Nov Dec Jan Feb Mar   |
|            |               |                    |            |                     |                          |         | Juli Juli Aug 3e0 Oct | NOV DEC Jail LED MIGI |
|            |               |                    |            |                     |                          |         | Score                 | Target                |
|            |               |                    |            |                     |                          |         |                       |                       |

| Cause            | Controls               | Gaps in<br>Controls | Action       | Sources of Assurance | Gaps in<br>Assurance | Action | Assurance Rating |
|------------------|------------------------|---------------------|--------------|----------------------|----------------------|--------|------------------|
| Cessation of all | Compliance with        |                     | Continue to  | Established          |                      |        |                  |
| routine elective | national guidance      |                     | maintain     | governance           |                      |        |                  |
| care, including  |                        |                     | programme    | and external/        |                      |        |                  |
| cancer screening | Granular               |                     | governance   | independent          |                      |        |                  |
| and other        | understanding of       |                     | and keep     | escalation and       |                      |        |                  |
| pathways, during | demand and             |                     | resourcing   | review process       |                      |        |                  |
| the peaks of the | capacity               |                     | under review |                      |                      |        |                  |
| Covid-19         | requirements with      |                     |              |                      |                      |        |                  |
| pandemic         | use of national tools. |                     |              |                      |                      |        |                  |

| Inability to match |                         |                    |                 | Regional and    |  |  |
|--------------------|-------------------------|--------------------|-----------------|-----------------|--|--|
| capacity with      | Robust oversight at     |                    |                 | national        |  |  |
| demand             | Board, and sub          |                    |                 | monitoring.     |  |  |
|                    | committees.             |                    |                 |                 |  |  |
|                    |                         | Historic issue     | Dedicated       |                 |  |  |
|                    | Divisional and CSU      | with ASI &         | project         | Project reports |  |  |
|                    | management of WL.       | capacity           | resource        | & training      |  |  |
|                    |                         |                    | commissioned    | programme       |  |  |
|                    | Agreement of local      |                    |                 | 1 2 3 2 2       |  |  |
|                    | standards and           |                    |                 |                 |  |  |
|                    | criteria for            |                    |                 |                 |  |  |
|                    | alternative pathway     |                    | Trust-wide and  |                 |  |  |
|                    | management -            |                    | local Recovery  |                 |  |  |
|                    | clinical prioritisation |                    | Plans in place  |                 |  |  |
|                    | and validation          |                    | '               | Mutual aid      |  |  |
|                    |                         |                    |                 | options.        |  |  |
|                    | Long-wait harm          |                    |                 |                 |  |  |
|                    | reviews                 |                    |                 | BLMK System     |  |  |
|                    |                         | Limitations to     |                 | working.        |  |  |
|                    | Use of Independent      | what ISP can       |                 |                 |  |  |
|                    | Sector.                 | take.              |                 |                 |  |  |
|                    |                         |                    |                 |                 |  |  |
|                    |                         | Resilience and     |                 |                 |  |  |
|                    | Extension of working    | well being of      |                 |                 |  |  |
|                    | hours and additional    | staff and need     |                 |                 |  |  |
|                    | WLI to compensate       | for A/L and rest.  |                 |                 |  |  |
|                    | capacity deficits       |                    |                 |                 |  |  |
|                    | through distancing      |                    |                 |                 |  |  |
|                    | and IPC                 |                    |                 |                 |  |  |
|                    | requirements.           |                    |                 |                 |  |  |
|                    |                         |                    |                 |                 |  |  |
|                    | Additional capacity     | Set up time for    | Reconfiguration |                 |  |  |
|                    | being sourced and       | services off site. | of MKUH         |                 |  |  |
|                    | services                |                    | capacity        |                 |  |  |
|                    | reconfigured.           |                    |                 |                 |  |  |

| Ī |  | services to best |  |  |
|---|--|------------------|--|--|
|   |  | use ISP          |  |  |

**RISK 6:** If the Trust does not establish and maintain effective capacity management processes it will be unable to cope with high demand for ITU and inpatient care during a public health crisis (or due to the Covid-19 pandemic)

| Strategic<br>Risk | managem<br>for ITU an | st does not establinent processes it with inpatient care of pandemic) | will be una | ble to cop | Strategic Objective Improving Patient Safety |         |   |
|-------------------|-----------------------|---|-------------|------------|--|---------|---|
| Lead              | Quality               | Risk Rating   | Current     | Target     | Risk Type                                    | Patient | t                                       |
| Committee         |                       |   |             |            |  | harm    | Tracker                                 |
| Executive         | Medical               | Consequence   | 5           | 5          | Risk   | Avoid   | 30                                      |
| Lead              | Director              |   |             |            | Appetite                                     |         |   |
| Date of           |                       | Likelihood  | 2           | 2          | Risk   | Treat   | 25                                      |
| Assessment        |                       |   |             |            | Treatment                                    |         |   |
| _                 |                       |   |             |            | Strategy                                     |         | 20                                      |
| Date of           | 19/04/21              | Risk Rating   | 10          | 10         |  |         | 15                                      |
| Review            |                       |   |             |            |  |         |   |
|                   |                       |   |             |            |  |         | 10                                      |
|                   |                       |   |             |            |  |         |   |
|                   |                       |   |             |            |  |         | 5                                       |
|                   |                       |   |             |            |  |         | 0 —                                     |
|                   |                       |   |             |            |  |         | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr |
|                   |                       |   |             |            |  |         | Score Target                            |
|                   |                       |   |             |            |  |         |   |
|                   |                       |   |             |            |  |         |   |

| Cause              | Controls            | Gaps in<br>Controls | Action    | Sources of Assurance | Gaps in Assurance | Action    | Assurance Rating |
|--------------------|---------------------|---------------------|-----------|----------------------|-------------------|-----------|------------------|
| Demand for ITU     | Increased capacity  | Inability to        | None      | Tested escalation    | None currently    | None      |                  |
| and inpatient beds | across the hospital | accurately          | currently | plans                |                   | currently |                  |
| exceeds capacity,  |                     | forecast demand     |           |                      |                   |           |                  |

| including                               | Increased capacity                       |  | Active part of    |  |  |
|---|--|--|-------------------|--|--|
| escalation capacity within the hospital | for ITU                                  |  | regional networks |  |  |
| and regionally                          | Clear escalation                         |  | Clear view of     |  |  |
|   | plans                                    |  | CPAP support for  |  |  |
|   |  |  | COVID-19          |  |  |
|   | Real time visibility of regional demand/ |  | patients          |  |  |
|   | capacity                                 |  | Medical Director  |  |  |
|   |  |  | and Chief Nurse   |  |  |
|   |  |  | liaising with     |  |  |
|   |  |  |                   |  |  |

**RISK 7:** If the radiotherapy pathway provided until 2019/20 in Milton Keynes by Genesis Care (under contract with OUH) is not replaced, the access and experience of patients on clinical oncology (radiotherapy) pathways will continue to be negatively impacted.

## **Strategic Objective 2: Improving Patient Experience**

| Strategic<br>Risk  | by Genesi<br>access an | otherapy pathway<br>is Care (under co<br>nd experience of p<br>apy) pathways wi | ntract with<br>patients on | OUH) is clinical o | not replaced,<br>ncology      | the          | Strategic Objective  | Improving Patient<br>Experience |
|--------------------|------------------------|---|----------------------------|--------------------|-------------------------------|--------------|----------------------|---------------------------------|
| Lead<br>Committee  | Quality                | Risk Rating   | Current                    |                    |                               | Patient harm | Tra                  | icker                           |
| Executive Lead     | Medical<br>Director    | Consequence   | 4                          | 4                  | Risk<br>Appetite              | Avoid        | 25                   |                                 |
| Date of Assessment |                        | Likelihood  | 4                          | 2                  | Risk<br>Treatment<br>Strategy | Treat        | 20 —                 |                                 |
| Date of<br>Review  | 19/04/21               | Risk Rating   | 16                         | 8                  |                               |              | 10                   |                                 |
|                    |                        |   |                            |                    |                               |              | 5 —                  |                                 |
|                    |                        |   |                            |                    |                               |              | 0 Jul Aug Sep Oct No | ov Dec Jan Feb Mar Apr          |
|                    |                        |   |                            |                    |                               |              | Score                | Target                          |

| Cause             | Controls                | Gaps in            | Action     | Sources of      | Gaps in        | Action    | Assurance |
|-------------------|-------------------------|--------------------|------------|-----------------|----------------|-----------|-----------|
|                   |                         | Controls           |            | Assurance       | Assurance      |           | Rating    |
| Break down in the | Contingency for the     | Contracting and    | Continued  | Minutes of      | Lines of       | Continued |           |
| established       | provision of treatment  | commissioning      | lobbying   | established     | assurance      | work with |           |
| relationship (sub | to patients in Oxford   | process outside    | for        | radiotherapy    | outside the    | partners  |           |
| contract) between | and the ongoing         | the Trust's direct | resolution | executive group | Trust's direct |           |           |
| Oxford University | provision of palliative | control or         |            |                 | control        |           |           |
| Hospitals and the | and prostate            | management         |            |                 |                |           |           |

|                     | -                       | , |  |                 |  |
|---------------------|-------------------------|---|--|-----------------|--|
| private Genesis     | radiotherapy at         |   |  | Impact of ICS   |  |
| Care facility       | Linford Wood or in      |   |  | capital control |  |
| (Linford Wood,      | Northampton             |   |  | limits          |  |
| Milton Keynes)      |                         |   |  |                 |  |
| which has           | Promotion of            |   |  |                 |  |
| provided local      | agreement between       |   |  |                 |  |
| radiotherapy to     | OUH and                 |   |  |                 |  |
| MK residents for    | Northampton General     |   |  |                 |  |
| the last six years. | Hospital to facilitate  |   |  |                 |  |
| This breakdown      | access to facilities at |   |  |                 |  |
| results in less     | Northampton for         |   |  |                 |  |
| choice and longer   | those who prefer        |   |  |                 |  |
| travel distances    | treatment in this       |   |  |                 |  |
| for patients        | location.               |   |  |                 |  |
| requiring           |                         |   |  |                 |  |
| radiotherapy.       | Promotion of rapid      |   |  |                 |  |
| Patients tend not   | options appraisal and   |   |  |                 |  |
| to differentiate    | decision making at      |   |  |                 |  |
| between the         | OUH and MKUH in         |   |  |                 |  |
| different NHS       | relation to a medium    |   |  |                 |  |
| provider            | to long term solution   |   |  |                 |  |
| organisations.      | for radiotherapy        |   |  |                 |  |
| This risk           | provision on site at    |   |  |                 |  |
| materialised        |                         |   |  |                 |  |
|                     | Milton Keynes           |   |  |                 |  |
| 16.12.2019 when     | University Hospital     |   |  |                 |  |
| the contract        | (build, operation,      |   |  |                 |  |
| expired and no      | governance etc.) and    |   |  |                 |  |
| extension was       | route to capital        |   |  |                 |  |
| agreed.             | funding.                |   |  |                 |  |
|                     | Proactive               |   |  |                 |  |
|                     | communications          |   |  |                 |  |
|                     | strategy in relation to |   |  |                 |  |
|                     | current service         |   |  |                 |  |
|                     |                         |   |  |                 |  |
|                     | delivery issues.        |   |  |                 |  |

**RISK 8:** If the Trust does not effectively work with patients and families in delivering care and positive patient experience the national patient surveys may not demonstrate improvement.

## **Strategic Objective 2: Improving Patient Experience**

| Strategic<br>Risk  | delivering     | t does not effective<br>care and positive<br>ay not demonstra | patient ex | perience |                   |              | Strategic Objective Improving Patient Experience |
|--------------------|----------------|---|------------|----------|-------------------|--------------|--|
| Lead<br>Committee  | Quality        | Risk Rating   | Current    |          | Risk Type         | Patient harm | Tracker  |
| Executive Lead     | Chief<br>Nurse | Consequence   | 4          | 4        | Risk<br>Appetite  | Minimal      | 25   |
| Date of Assessment |                | Likelihood  | 4          | 2        | Risk<br>Treatment | Treat        | 20   |
| Date of            | 21/04//21      | Risk Rating   | 16         | 8        | Strategy          |              | 15   |
| Review             |                |   |            |          |                   |              | 10   |
|                    |                |   |            |          |                   |              | 5 —  |
|                    |                |   |            |          |                   |              | 0 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr        |
|                    |                |   |            |          |                   |              | Score Target                                     |

| Cause           | Controls          | Gaps in<br>Controls | Action      | Sources of Assurance | Gaps in Assurance | Action        | Assurance Rating |
|-----------------|-------------------|---------------------|-------------|----------------------|-------------------|---------------|------------------|
| Lack of         | Corporate Patient | Engagement          | To develop  | Annual:              | Comprehensive     | Liaise with   |                  |
| appropriate     | and Family        | with patients for   | bank of     | PLACE surveys        | analysis of       | information   |                  |
| intervention to | Experience Team   | Co-production       | patients to | National Patient     | patient ethnic    | dept for info |                  |
| improve patient | function,         | of service          | engage with | Experience           | groups to         | on patient    |                  |
| experience      | resources and     | developments.       | for         | Improvement          | ensure meeting    | demographics. |                  |

|                 |                    |                              | Τ                | Г.,           | T |  |
|-----------------|--------------------|------------------------------|------------------|---------------|---|--|
| (measured       | governance         | involvement                  | Framework        | all           |   |  |
| through the     | arrangements in    | in wider                     | NHSI             | requirements. |   |  |
| national        | place at Trust,    | organisational               | Assessment       |               |   |  |
| surveys).       | division and       | changes.                     | and action plan  |               |   |  |
|                 | department levels, |                              | Quarterly:       |               |   |  |
| Children and    | including but not  | Lead:                        | Quarterly        |               |   |  |
| Young People    | limited to:        | Head of                      | reports with     |               |   |  |
| Survey          |                    | Patient and                  | themes and       |               |   |  |
|                 | Patent             | Family                       | areas of for     |               |   |  |
| Adult Inpatient | Experience         | Experience.                  | improvement.     |               |   |  |
| Survey          | Strategy           |                              | Patient          |               |   |  |
|                 | Learning           | Timescale:                   | experience       |               |   |  |
| Urgent and      | Disabilities       |                              | strategy action  |               |   |  |
| Emergency       | Strategy           | October 2021                 | plan progress.   |               |   |  |
| Care Survey     | Dementia           | <ul><li>subject to</li></ul> | Perfect Ward     |               |   |  |
|                 | Strategy           | national                     | Patient          |               |   |  |
| Maternity       | Nutrition steering | restrictions re              | Experience       |               |   |  |
| Survey          | group              | COVID-19.                    | Audit.           |               |   |  |
|                 | Catering steering  |                              | Monthly:         |               |   |  |
| Cancer Patient  | group              |                              | FFT results -    |               |   |  |
| Experience      | Domestic           |                              | thematic review. |               |   |  |
| Survey          | planning group     |                              | Monthly          |               |   |  |
|                 | Discharge          |                              | operational      |               |   |  |
|                 | steering group     |                              | meeting to       |               |   |  |
|                 | Induction training |                              | review and       |               |   |  |
|                 |                    |                              | triangulate data |               |   |  |
|                 |                    |                              | for top themes   |               |   |  |
|                 | '15 Step           |                              | and inform       |               |   |  |
|                 | 'Challenge         |                              | focused areas    |               |   |  |
|                 |                    |                              | of work for next |               |   |  |
|                 | Quarterly Patient  |                              | month's          |               |   |  |
|                 | Experience Board,  |                              | activities.      |               |   |  |
|                 | monthly Patient    |                              | Department       |               |   |  |
|                 | experience         |                              | surveys          |               |   |  |
|                 | operational        |                              |                  |               |   |  |

| meetings and     | External       |
|------------------|----------------|
| supporting       | Reviews :      |
| substructure of  | Healthwatch    |
| steering groups. | Maternity      |
|                  | Voices         |
|                  | partnership    |
|                  | (MVP)          |
|                  | Cancer Patient |
|                  | Partnership    |
|                  | Website:       |
|                  | 'You said we   |
|                  | did'           |

**RISK 9:** If the Trust does not effectively work to use feedback from complaints and PALS contacts to inform learning and embed related changes patient experience will not be improved.

## **Strategic Objective 2: Improving Patient Experience**

| Strategic<br>Risk  | complaint      | st does not effections and PALS controls attent experience | acts to info | rm learni | ng and embe                   | d related    | Strategic Objective Improving Patient Experience          |
|--------------------|----------------|--|--------------|-----------|-------------------------------|--------------|---|
| Lead<br>Committee  | Quality        |  |              |           | Risk Type                     | Patient harm | Tracker   |
| Executive Lead     | Chief<br>Nurse | Consequence  | 4            | 4         | Risk<br>Appetite              | Minimal      | 25  |
| Date of Assessment |                | Likelihood   | 3            | 2         | Risk<br>Treatment<br>Strategy | Treat        | 20  |
| Date of Review     | 21/04/21       | Risk Rating  | 12           | 8         | Ollulogy                      |              | 10  |
|                    |                |  |              |           |                               |              | 5   |
|                    |                |  |              |           |                               |              | 0 ————————————————————————————————————                    |
|                    |                |  |              |           |                               |              | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr  ——Score ——Target |

| Cause             | Controls            | Gaps in         | Action     | Sources of        | Gaps in        | Action       | Assurance |
|-------------------|---------------------|-----------------|------------|-------------------|----------------|--------------|-----------|
|                   |                     | Controls        |            | Assurance         | Assurance      |              | Rating    |
| Lack of           | Corporate Patient   | Quality         | Current    | Annual:           | Patients       | Develop      |           |
| appropriate       | Experience Team     | surveillance    | review     | Complaints and    | specific needs | mechanisms   |           |
| intervention to   | function, resources | system to       | underway   | PALS Report       | supporting     | for feedback |           |
| improve patient   | and governance      | triangulate     | for        | Quarterly:        | them to        | for all      |           |
| experience        | arrangements in     | feedback from   | systems to | Quarterly reports | feedback:      | groups.      |           |
| following receipt | place at Trust,     | complaints with | link and   | with themes and   | Cognitively    |              |           |
|                   | division and        | incidents and   |            |                   | impaired       |              |           |

| of complaints and | department levels,                       | other quality             | triangulate           | areas of for                   | Learning          | Use         |  |
|-------------------|--|---------------------------|-----------------------|--------------------------------|-------------------|-------------|--|
| PALS contacts.    | including but not                        | measures                  | data.                 | improvement.                   | Disabilities      | demographic |  |
| T ALO COMacio.    | limited to:                              | across the                | uaia.                 | Patient                        | Sensory Deficit   | to          |  |
|                   | iiiiiiiGu to.                            | organisation.             |                       | experience                     | : vision, hearing | demonstrate |  |
|                   | Patent Experience                        | organisation.             |                       | strategy action                | , speech          | complaints  |  |
|                   | Strategy                                 | Audit of                  | Divisions             | plan progress.                 | Language          | sources.    |  |
|                   | • Learning                               | identified                | to audit              | Perfect Ward                   | difficulties      | Sources.    |  |
|                   | Disabilities Strategy                    |                           |                       | Patient                        | Children and      |             |  |
|                   |  | learning in divisions to  | learning              |                                |                   |             |  |
|                   | Dementia Strategy     Nutrition steering |                           | from                  | Experience<br>Audit.           | young people.     |             |  |
|                   | Nutrition steering                       | ensure learning embedded. | feedback              | Monthly:                       |                   |             |  |
|                   | group                                    | embedded.                 | and report to Patient | Monthly                        |                   |             |  |
|                   | Catering steering                        |                           | Experience            | operational                    |                   |             |  |
|                   | group  • Domestic planning               |                           | Board.                | meeting to                     |                   |             |  |
|                   |  |                           | Doard.                | review and                     |                   |             |  |
|                   | group                                    |                           |                       |                                |                   |             |  |
|                   | Discharge steering                       |                           |                       | triangulate data               |                   |             |  |
|                   | group                                    |                           |                       | for top                        |                   |             |  |
|                   | Induction training                       |                           |                       | complaints themes and          |                   |             |  |
|                   | Customer service                         |                           |                       | inform focused                 |                   |             |  |
|                   | training – NHS Elect                     |                           |                       | areas of work for              |                   |             |  |
|                   | _  |                           |                       | next month's                   |                   |             |  |
|                   | program                                  |                           |                       | activities.                    |                   |             |  |
|                   | Leadership training                      |                           |                       | Divisional review              |                   |             |  |
|                   | includes how to                          |                           |                       |                                |                   |             |  |
|                   | receive feedback                         |                           |                       | of learning from complaints in |                   |             |  |
|                   | from patients.                           |                           |                       | CIG.                           |                   |             |  |
|                   | 110111                                   |                           |                       | Complaints                     |                   |             |  |
|                   | Appreciative inquire                     |                           |                       | questionnaire for              |                   |             |  |
|                   | approach to support                      |                           |                       | complaints re                  |                   |             |  |
|                   | complaints handling                      |                           |                       | process and                    |                   |             |  |
|                   |  |                           |                       | experience.                    |                   |             |  |
|                   | and response letters.                    |                           |                       | PALS KPIs                      |                   |             |  |
|                   | IEIIEIS.                                 |                           |                       |                                |                   |             |  |
|                   |  |                           |                       | responding to feedback in a    |                   |             |  |
|                   |  |                           |                       | reeuback in a                  |                   |             |  |

| Monthly divisional meetings with Head of Patient and | timely manner to initiate change and learning. |  |
|--|--|--|
| Family Experience to review themes,                  | Website:                                       |  |
| complaints, associated changes,                      | 'You said we did                               |  |
| and learning.  |  |  |

**RISK 10:** If clinical audit requirements are not completed the Trust will fail to meet the requirements of clinical compliance regimes including NICE

## **Strategic Objective 3: Improving Clinical Effectiveness**

| Strategic<br>Risk  |  | udit requirements<br>equirements of cli |         |        | Strategic Objective           | Improving Clinical<br>Effectiveness |                |  |  |  |
|--------------------|--|---|---------|--------|-------------------------------|-------------------------------------|----------------|--|--|--|
| Lead<br>Committee  | Quality                                | Risk Rating                             | Current | Target | Risk Type                     | Patient<br>harm                     |                | Tracker                                  |  |  |
| Executive<br>Lead  | Director<br>of<br>Corporate<br>Affairs | Consequence                             | 4       | 4      | Risk<br>Appetite              | Minimal                             | 25 — 20 — 20 — |  |  |  |
| Date of Assessment |  | Likelihood                              | 3       | 2      | Risk<br>Treatment<br>Strategy | Treat                               | 15             |  |  |  |
| Date of<br>Review  | 20/04/21                               | Risk Rating                             | 12      | 8      |                               |                                     |                | Oct Nov Dec Jan Feb Mar Apr Score Target |  |  |

| Cause           | Controls            | Gaps in         | Action    | Sources of     | Gaps in Assurance    | Action   | Assurance |
|-----------------|---------------------|-----------------|-----------|----------------|----------------------|----------|-----------|
|                 |                     | Controls        |           | Assurance      |                      |          | Rating    |
| 1. Lack of      | 1. Designated audit | 1. Resource to  | 1.        | Clinical Audit | 1.External           | Add to   |           |
| understanding/  | leads in CSUs/      | complete        | Resource  | and            | benchmarking         | internal |           |
| awareness of    | divisions           | audits          | review    | Effectiveness  | 2. Independent audit | audit    |           |
| audit           | 2. Clinical         |                 | currently | Board          |                      | plan for |           |
| requirements by | governance and      | 2. Audit policy | underway  |                |                      | 20121/22 |           |
| clinical audit  | administrative      | out of date     |           | External       |                      |          |           |
| leads           |                     |                 |           | benchmarking   |                      |          |           |

| 2. Resources not | support - allocated  | 2. A  | Audit     |  |  |
|------------------|----------------------|-------|-----------|--|--|
| adequate to      | by division          | poli  | icy       |  |  |
| support data     | 3. Recruited         | beir  | ng        |  |  |
| collection/      | additional clinical  | revi  | iewed     |  |  |
| interpretation/  | governance post to   | and   | d re-     |  |  |
| input            | medicine to support  | writ  | tten      |  |  |
| 3. Audit         | audit function       | (ad   | vanced    |  |  |
| programme        | (highest volume of   | first | t draft   |  |  |
| poorly           | audits)              | con   | nmented   |  |  |
| communicated     | 3. Audit programme   | on f  |           |  |  |
| 4. Lack of       | being simplified,    | furt  |           |  |  |
| engagement in    | with increased       |       | iew April |  |  |
| audit programme  | collaboration and    | 21)   |           |  |  |
| 5. Compliance    | work through the QI  |       |           |  |  |
| expectations not | programme            |       |           |  |  |
| understood/      | 4. Audit compliance  |       |           |  |  |
| overly complex   | criteria being       |       |           |  |  |
|                  | segmented to         |       |           |  |  |
|                  | enable focus on      |       |           |  |  |
|                  | compliance with      |       |           |  |  |
|                  | data returns;        |       |           |  |  |
|                  | opportunity for      |       |           |  |  |
|                  | learning/ changing   |       |           |  |  |
|                  | practice and         |       |           |  |  |
|                  | communication/       |       |           |  |  |
|                  | engagement           |       |           |  |  |
|                  | 5. Monthly review of |       |           |  |  |
|                  | all compliance       |       |           |  |  |
|                  | requirements,        |       |           |  |  |
|                  | including NICE and   |       |           |  |  |
|                  | policies             |       |           |  |  |

RISK 11: Failure to ensure adequate data quality leading to patient harm, reputational damage and regulatory failure

## **Strategic Objective 3: Improving Clinical Effectiveness**

| Strategic<br>Risk  |                        | nsure adequate da<br>damage and reg |         |        | Strategic Objective Improving Clinical Effectiveness |                 |  |
|--------------------|------------------------|-------------------------------------|---------|--------|--|-----------------|--|
| Lead<br>Committee  | Audit                  | Risk Rating                         | Current | Target | Risk Type  | Patient<br>harm | Tracker  |
| Executive Lead     | Director of Operations | Consequence                         | 4       | 4      | Risk<br>Appetite                                     | Minimal         | 25   |
| Date of Assessment |                        | Likelihood                          | 3       | 2      | Risk<br>Treatment<br>Strategy                        | Treat           | 15   |
| Date of<br>Review  | 30/03/21               | Risk Rating                         | 12      | 8      |  |                 | 10  5  O Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar  Score Target |

| Cause              | Controls            | Gaps in            | Action         | Sources of   | Gaps in   | Action | Assurance |
|--------------------|---------------------|--------------------|----------------|--------------|-----------|--------|-----------|
|                    |                     | Controls           |                | Assurance    | Assurance |        | Rating    |
| Failure to ensure  | Robust governance   | RPAS will          | RPAS           | Data Quality |           |        |           |
| adequate data      | around data quality | reduce the         | scheduled in   | Board        |           |        |           |
| quality leading to | processes including | numbers of         | for            |              |           |        |           |
| patient harm,      | executive ownership | manual input       | implementation | External     |           |        |           |
| reputational risk  |                     | errors             | in 2022        | benchmarking |           |        |           |
| and regulatory     | Audit work by data  |                    |                |              |           |        |           |
| failure because    | quality team        | Better training of | Director of    |              |           |        |           |
| data quality       |                     | the                | Transformation |              |           |        |           |

| processes are not | More robust data    | administration    | working with |  |  |
|-------------------|---------------------|-------------------|--------------|--|--|
| robust            | input rules leading | teams leading to  | OP areas to  |  |  |
|                   | to fewer errors     | more consistent   | improve      |  |  |
|                   |                     | recording of data | training     |  |  |

RISK 12: Failure to meet elective waiting time targets due to seasonal emergency pressure or further Covid-19 surges

## **Strategic Objective 4: Meeting Key Targets**

| Strategic  | Failure to me | eet elective waitir | ng time tar | gets due |           | Strategic Objective | Meeting Key Targets |                          |  |  |
|------------|---------------|---------------------|-------------|----------|-----------|---------------------|---------------------|--------------------------|--|--|
| Risk       | emergency     | oressure or furthe  | er Covid-19 | surges   |           |                     |                     |                          |  |  |
| Lead       | TEG           | Risk Rating         | Current     | Target   | Risk Type | Patient             | Tracker             |                          |  |  |
| Committee  |               |                     |             |          |           | harm                |                     |                          |  |  |
| Executive  | Director of   | Consequence         | 5           | 5        | Risk      | Minimal             | 25                  |                          |  |  |
| Lead       | Operations    |                     |             |          | Appetite  |                     |                     |                          |  |  |
| Date of    | _             | Likelihood          | 4           | 2        | Risk      | Treat               | 20                  |                          |  |  |
| Assessment |               |                     |             |          | Treatment |                     | 20                  |                          |  |  |
|            |               |                     |             |          | Strategy  |                     | 15                  |                          |  |  |
| Date of    | 30/03/21      | Risk Rating         | 20          | 10       |           |                     | 15                  |                          |  |  |
| Review     |               |                     |             |          |           |                     | 10                  |                          |  |  |
|            |               |                     |             |          |           |                     | 10                  |                          |  |  |
|            |               |                     |             |          |           |                     |                     |                          |  |  |
|            |               |                     |             |          |           |                     | 5 —                 |                          |  |  |
|            |               |                     |             |          |           |                     |                     |                          |  |  |
|            |               |                     |             |          |           |                     | O                   | Nav. Bas. Jan. Esk. Man. |  |  |
|            |               |                     |             |          |           |                     | Jun Jul Aug Sep Oct | Nov Dec Jan Feb Mar      |  |  |
|            |               |                     |             |          |           |                     | Score -             | Target                   |  |  |
|            |               |                     |             |          |           |                     |                     | -                        |  |  |

| Cause                | Controls             | Gaps in         | Action     | Sources of        | Gaps in   | Action | Assurance |
|----------------------|----------------------|-----------------|------------|-------------------|-----------|--------|-----------|
|                      |                      | Controls        |            | Assurance         | Assurance |        | Rating    |
| Elective activity is | Winter escalation    | Unpredictable   | Continued  | Emergency Care    |           |        |           |
| suspended (locally   | plans to flex demand | nature of both  | planning   | Board (external   |           |        |           |
| or by national       | and capacity         | emergency       | and daily  | partners)         |           |        |           |
| directive) to        |                      | demand and the  | reviews    | ,                 |           |        |           |
| enable the Trust to  | Plans to maintain    | surge nature of | (depending | Regional and      |           |        |           |
| cope with            | urgent elective work | Covid-19        | on Opel    | national tiers of |           |        |           |
| emergency            | and cancer services  |                 | and        | reporting and     |           |        |           |
| demand or further    | through periods of   | Workforce and   | incident   | planning          |           |        |           |
| Covid-19 surges,     | peak demand          | space (in       | levels)    |                   |           |        |           |

| resulting in increasing waits for patients needing elective treatment – including cancer care | Agreed plans with local system  National lead if level 4 incident, with established and tested plans | pandemic) rate limiting factors |  |  |  |
|---|--|---------------------------------|--|--|--|
|   | Significant national focus on planning to maintain elective care                                     |                                 |  |  |  |

**RISK 13:** If the Trust does not successfully appoint an external audit services provider in 2021 then the Trust will not be able to meet its statutory obligations

| Strategic<br>Risk  |                              | does not succe<br>2021 then the T |         |        | Strategic Objective  Being Well Governed and Financially Viable |           |                                      |  |  |  |  |
|--------------------|------------------------------|-----------------------------------|---------|--------|---|-----------|--------------------------------------|--|--|--|--|
| Lead<br>Committee  | Finance<br>and<br>Investment | Risk Rating                       | Current | Target | Risk Type   | Financial | Tracker                              |  |  |  |  |
| Executive Lead     | DoF                          | Consequence                       | 5       | 5      | Risk<br>Appetite  | Cautious  |                                      |  |  |  |  |
| Date of Assessment |                              | Likelihood                        | 2       | 2      | Risk<br>Treatment<br>Strategy                                   | Treat     | 15                                   |  |  |  |  |
| Date of<br>Review  | 22/04/21                     | Risk Rating                       | 10      | 10     |   |           | 5  O Jan Feb March Apr  Score Target |  |  |  |  |

| Cause              | Controls              | Gaps in            | Action        | Sources of      | Gaps in          | Action    | Assurance |
|--------------------|-----------------------|--------------------|---------------|-----------------|------------------|-----------|-----------|
|                    |                       | Controls           |               | Assurance       | Assurance        |           | Rating    |
| A number of audit  | The Trust is looking  | The Trust has      | The Trust     | External review | Intelligence of  | The Trust |           |
| firms are not      | to extend its current | limited control    | will consider | and reporting   | intent to tender | will      |           |
| bidding for audits | External Audit        | over which audit   | and           |                 | from framework   | undertake |           |
| currently due to   | Contract by a year    | firms will take-up | implement     |                 | listed suppliers | a timely  |           |
|                    | through a direct      | offers to tender   | as            |                 |                  | retender  |           |
| Pricing – there    | award for its current |                    | appropriate   |                 |                  | exercise  |           |
| have been recent   | external auditors     |                    | advice from   |                 |                  | for       |           |

| changes in         | Timely tender      | professional | services                                |
|--------------------|--------------------|--------------|---|
| regulatory         | exercise for       | associations | beyond                                  |
| requirements       | appointment beyond | to mitigate  | FY22 and                                |
| increasing costs,  | FY22               | risk to      | will                                    |
| in addition        |                    | successful   | identify                                |
| framework          |                    | external     | potential                               |
| contracts were     |                    | audit        | suppliers                               |
| tendered a         |                    | appointment  | early in                                |
| number of years    |                    | (e.g.        | this                                    |
| ago and the rates  |                    | HFMA).       | process                                 |
| are no longer at a |                    | ,            | i e e e e e e e e e e e e e e e e e e e |
| level that audit   |                    | The position |   |
| firms would        |                    | will be      |   |
| consider           |                    | reviewed     |   |
| acceptable         |                    | with         |   |
|                    |                    | updates      |   |
| Capacity- due to   |                    | provided to  |   |
| Covid many audit   |                    | the Audit    |   |
| clients in other   |                    | Committee    |   |
| sectors have       |                    |              |   |
| moved their audit  |                    |              |   |
| timetables which   |                    |              |   |
| has caused         |                    |              |   |
| capacity issues    |                    |              |   |
| ' '                |                    |              |   |
|                    |                    |              |   |

**RISK 14:** If the Trust does not maintain investment in its IT infrastructure and systems then all operational systems will be severely affected by IT failures such infiltration by cyber criminals.

| Strategic<br>Risk  | systems the                  | does not maintain<br>n all operational s<br>n infiltration by cyl | systems wi | Strategic Objective  Being Well Governed and Financially Viable |                               |           |  |  |  |  |  |
|--------------------|------------------------------|---|------------|---|-------------------------------|-----------|--|--|--|--|--|
| Lead<br>Committee  | Finance<br>and<br>Investment | Risk Rating   | Current    | Target  | Risk Type                     | Financial | Tracker  |  |  |  |  |
| Executive Lead     | Deputy<br>CEO                | Consequence   | 5          | 5   | Risk<br>Appetite              | Minimal   | 25 - 20 -  |  |  |  |  |
| Date of Assessment |                              | Likelihood  | 3          | 2   | Risk<br>Treatment<br>Strategy | Treat     | 15   |  |  |  |  |
| Date of<br>Review  | 19/04/21                     | Risk Rating   | 15         | 10  |                               |           | 5  |  |  |  |  |
|                    |                              |   |            |   |                               |           | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr  ——————————————————————————————————— |  |  |  |  |

| Cause                               | Controls  | Gaps in Controls | Action           | Sources of Assurance                           | Gaps in Assurance | Action            | Assurance Rating |
|-------------------------------------|---|------------------|------------------|--|-------------------|-------------------|------------------|
| Hardware failure due aged equipment | 2 dedicated cyber security posts                                      | None identified  | Continued review | External review and reporting                  | None currently    | None<br>currently |                  |
| Cyber attack                        | Good network protection from cyber security breaches such as Advanced |                  |                  | Purchases new equipment to install in 9 months |                   |                   |                  |

| - 1 |                       |  | T |  |
|-----|-----------------------|--|---|--|
|     | Threat Protection     |  |   |  |
|     | (ATP) – A part of the |  |   |  |
|     | national programmes   |  |   |  |
|     | to protect the cyber  |  |   |  |
|     | security of the       |  |   |  |
|     |                       |  |   |  |
|     | hospital              |  |   |  |
|     |                       |  |   |  |
|     | All Trust PCs less    |  |   |  |
|     | than 4 years old      |  |   |  |
|     |                       |  |   |  |
|     | Purchase new          |  |   |  |
|     | hardware – not        |  |   |  |
|     | implemented yet       |  |   |  |
|     | implomoritou yet      |  |   |  |
|     | EDD investment        |  |   |  |
|     | EPR investment        |  |   |  |

**RISK 15:** There is a risk that delays in the business case approvals process (including regulatory approvals), and/or delays in capital funds being made available (through PDC financing or other sources) prevent the Trust from being able to progress its entire capital programme in 2020/21 leading to a missed opportunity in the event funds cannot be carried forward to future years.

## Superseded by the risk associated with the HIP2 Programme – to be reviewed at the June 2021 Board Seminar Meeting

| Strategic<br>Risk  | (including re<br>made availa<br>Trust from b | sk that delays in togulatory approvation ble (through PDC) eing able to progmissed opportunature years. | ls), and/or<br>c financing<br>ress its ent | delays in<br>or other s<br>tire capita | Strategic Objective  Being Well Governed and Financially Viable |           |  |
|--------------------|--|---|--|--|---|-----------|--|
| Lead<br>Committee  | Finance<br>and<br>Investment                 | Risk Rating   | Current                                    | Target                                 | Risk Type   | Financial | Tracker  |
| Executive Lead     | DoF  | Consequence   | 4  | 4                                      | Risk<br>Appetite  | Cautious  | 20   |
| Date of Assessment |  | Likelihood  | 3  | 2                                      | Risk<br>Treatment<br>Strategy                                   | Treat     | 15   |
| Date of<br>Review  | 22/04//21                                    | Risk Rating   | 12   | 8                                      |   |           | 5  Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar  Score Target |

| Cause                                | Controls                                     | Gaps in<br>Controls           | Action    | Sources of                | Gaps in   | Action | Assurance |
|--------------------------------------|--|-------------------------------|-----------|---------------------------|-----------|--------|-----------|
| Despite incressed                    | 4. Canital                                   | The Trust has                 | Continued | Assurance External review | Assurance |        | Rating    |
| Despite increased                    | 1. Capital                                   |                               | review    |                           |           |        |           |
| investment being made available to   | prioritisation process                       | only limited influence on the | review    | and reporting             |           |        |           |
| respond to covid-                    | in place (through the Trust's Capital        |                               |           |                           |           |        |           |
| <u> </u>                             | Control Group (CCG)                          | national policy regarding the |           |                           |           |        |           |
| 19, the national                     | and Clinical Board                           | capital funding               |           |                           |           |        |           |
| NHS capital                          |  |                               |           |                           |           |        |           |
| financing regime remains under       | Investment Group                             | regime and the constraints on |           |                           |           |        |           |
|                                      | (CBIG) to ensure the                         | the national                  |           |                           |           |        |           |
| significant                          | Trust prioritises its                        | CDEL.                         |           |                           |           |        |           |
| pressure. Capital                    | capital schemes its resources effectively.   | CDEL.                         |           |                           |           |        |           |
| expenditure limits have been         | resources effectively.                       |                               |           |                           |           |        |           |
|                                      | 2 Alternative funding                        |                               |           |                           |           |        |           |
| implemented for                      | 2. Alternative funding sources identified to |                               |           |                           |           |        |           |
| NHS provider                         |  |                               |           |                           |           |        |           |
| organisations and whilst the Trust's | support continued investment in the          |                               |           |                           |           |        |           |
|                                      | Trust's estate and                           |                               |           |                           |           |        |           |
| capital plan is within this          |  |                               |           |                           |           |        |           |
| envelope there                       | physical infrastructure in line with         |                               |           |                           |           |        |           |
| •                                    |  |                               |           |                           |           |        |           |
| have, in the past,<br>been delays in | requirements in the event that funding is    |                               |           |                           |           |        |           |
| ,                                    | not made available.                          |                               |           |                           |           |        |           |
| funds being received to              | Tiot made available.                         |                               |           |                           |           |        |           |
| support capital                      | 3. Close working with                        |                               |           |                           |           |        |           |
| investment.                          | regulator partners to                        |                               |           |                           |           |        |           |
| investinent.                         | ensure the Trust is                          |                               |           |                           |           |        |           |
|                                      | supported through                            |                               |           |                           |           |        |           |
|                                      | the approvals                                |                               |           |                           |           |        |           |
|                                      | process and any                              |                               |           |                           |           |        |           |
|                                      | delays can be                                |                               |           |                           |           |        |           |
|                                      | escalated through the                        |                               |           |                           |           |        |           |
|                                      | NHS regional                                 |                               |           |                           |           |        |           |
|                                      | finance/capital teams.                       |                               |           |                           |           |        |           |

**RISK 16:** If the future NHS funding regime is not sufficient to cover the costs of the Trust, then the Trust will be unable to meet its financial performance obligations or achieve financial sustainability.

| Strategic<br>Risk  | Trust, then t                | NHS funding regi<br>he Trust will be u<br>or achieve financi | nable to m | eet its fin |                               | Strategic Objective  Being Well Governed and Financially Viable |   |
|--------------------|------------------------------|--|------------|-------------|-------------------------------|---|---|
| Lead<br>Committee  | Finance<br>and<br>Investment | Risk Rating  | Current    |             | Risk Type                     | Financial   | Tracker                                 |
| Executive Lead     | DoF                          | Consequence  | 5          | 5           | Risk<br>Appetite              | Cautious  | 20                                      |
| Date of Assessment |                              | Likelihood   | 4          | 2           | Risk<br>Treatment<br>Strategy | Treat   | 15                                      |
| Date of Review     | 22/04//21                    | Risk Rating  | 20         | 10          |                               |   | 10                                      |
|                    |                              |  |            |             |                               |   | 5                                       |
|                    |                              |  |            |             |                               |   | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr |
|                    |                              |  |            |             |                               |   | Score Target                            |

| Cause   | Controls   | Gaps in Controls   | Action   | Sources of Assurance                                 | Gaps in Assurance | Action            | Assurance Rating |
|---|--|--|--|--|-------------------|-------------------|------------------|
| Increase in operational expenditure in order to manage COVID-19 | 1. Cost and volume contracts replaced with block contracts (set nationally) for clinical income; | Financial regime<br>for FY22 only<br>valid for first half<br>of the year. Trust<br>has minimal | Continued review of national funding intentions to | Monthly financial performance monitoring information | None Currently    | None<br>Currently |                  |

| Reductions in non-           | 2. Top-up payments                 | ability to | maximise | Cost efficiency |  |  |
|------------------------------|------------------------------------|------------|----------|-----------------|--|--|
| NHS income                   | available where                    | influence. | time to  | reporting       |  |  |
| streams as a direct          | COVID-19 leads to                  |            | plan     |                 |  |  |
| result of COVID-             | additional costs over              |            | response | BLMK ICS        |  |  |
| 19.                          | and above block sum                |            |          | finance         |  |  |
|                              | amounts (until                     |            |          | performance     |  |  |
| Impaired operating           | September 2021);                   |            |          | reporting       |  |  |
| productivity                 |                                    |            |          |                 |  |  |
| leading to costs for         | 3. Budgets to be                   |            |          |                 |  |  |
| extended working             | reset for FY22 based               |            |          |                 |  |  |
| days and/or                  | on financial regime;               |            |          |                 |  |  |
| outsourcing.                 | financial controls and             |            |          |                 |  |  |
| D ( '' ) (                   | oversight to be                    |            |          |                 |  |  |
| Potential for                | reintroduced to                    |            |          |                 |  |  |
| material increase            | manage financial                   |            |          |                 |  |  |
| in efficiency                | performance                        |            |          |                 |  |  |
| requirement from NHS funding | 4 Cost officionay                  |            |          |                 |  |  |
| regime to support            | 4. Cost efficiency programme to be |            |          |                 |  |  |
| DHSC budget                  | reset to target focus              |            |          |                 |  |  |
| affordability.               | on areas of greatest               |            |          |                 |  |  |
| anordability.                | opportunity to deliver             |            |          |                 |  |  |
| Unknown funding              | opportunity to don'to.             |            |          |                 |  |  |
| regime beyond                |                                    |            |          |                 |  |  |
| September 2021               |                                    |            |          |                 |  |  |
| due to disruption            |                                    |            |          |                 |  |  |
| caused by COVID-             |                                    |            |          |                 |  |  |
| 19                           |                                    |            |          |                 |  |  |

**RISK 17:** There is a risk that the Trust has insufficient resources (financial or otherwise) or has insufficient physical capacity in order to clear the waiting list backlogs that occurred as a result of the COVID-19 pandemic, leading to delays in patients receiving treatment and a potential long-term financial pressure for the Trust through a requirement to deliver higher levels of activity each financial year.

## **Duplicate of Risk 16 – Recommended for removal**

| Strategic<br>Risk  | incurs additi                | sk that as a resul<br>onal costs, has a<br>ciently leading to | reduction | Strategic Objective  Being Well Governed and Financially Viable |                               |           |   |
|--------------------|------------------------------|---|-----------|---|-------------------------------|-----------|---|
| Lead<br>Committee  | Finance<br>and<br>Investment | Risk Rating   | Current   | Target  | Risk Type                     | Financial | Tracker                                   |
| Executive Lead     | DoF                          | Consequence   | 4         | 4   | Risk<br>Appetite              | Cautious  | 20  |
| Date of Assessment |                              | Likelihood  | 4         | 3   | Risk<br>Treatment<br>Strategy | Treat     | 15  |
| Date of<br>Review  | 30/03/21                     | Risk Rating   | 16        | 12  |                               |           | 10  |
|                    |                              |   |           |   |                               |           | 0 Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar |
|                    |                              |   |           |   |                               |           | Score —Target                             |

| Cause   | Controls  | Gaps in<br>Controls  | Action           | Sources of Assurance          | Gaps in Assurance | Action | Assurance<br>Rating |
|---|---|--|------------------|-------------------------------|-------------------|--------|---------------------|
| The COVID-19 pandemic led to the delay or cancellation of procedures and clinics which resulted in an increase in the size of the waiting list (at the Trust and across the NHS more broadly).  On-going measures in response to COVID-19 (such as social distancing measures) have the potential to reduce the available physical capacity at the Trust. | 1. Monitoring of the Trust's waiting list through divisional meetings, executive performance meetings, and Trust board subcommittees (including the Finance and Investment Committee);  2. Recovery plans developed in accordance with guidance issued by NHS England and NHS Improvement, including financial forecast to assess the impact of increasing activity alongside COVID-19 measures.  3. Financial incentive scheme in place to provide additional funding for performing activity in excess of baseline levels set by regulators | The Trust has only limited control over the allocation of additional financial resources to support its recover plans. | Continued review | External review and reporting |                   |        |                     |

| 4. Capital and         |  |  |  |
|------------------------|--|--|--|
| revenue bids           |  |  |  |
| submitted to           |  |  |  |
| regulators in order to |  |  |  |
| provide additional     |  |  |  |
| finance resource to    |  |  |  |
| create additional      |  |  |  |
| capacity to increase   |  |  |  |
| activity volumes at    |  |  |  |
| the Trust.             |  |  |  |

RISK 18: Insufficient capacity in the Neonatal Unit to accommodate babies requiring special care (finance and quality risk)

# A subject of review for re-allocation

| Strategic<br>Risk  | Insufficient of requiring sp                   | capacity in the Ne<br>ecial care | onatal Uni | Strategic Objective  Being Well Governed and Financially Viable/ Patient Safety |                               |           |   |  |  |  |  |
|--------------------|--|----------------------------------|------------|---|-------------------------------|-----------|---|--|--|--|--|
| Lead<br>Committee  | Finance<br>and<br>Investment<br>and<br>Quality | Risk Rating                      | Current    | Target  | Risk Type                     | Financial | Tracker   |  |  |  |  |
| Executive<br>Lead  | DoF  | Consequence                      | 4          | 4   | Risk<br>Appetite              | Cautious  |   |  |  |  |  |
| Date of Assessment |  | Likelihood                       | 3          | 2   | Risk<br>Treatment<br>Strategy | Treat     | 10  |  |  |  |  |
| Date of<br>Review  | 30/03/21                                       | Risk Rating                      | 12         | 8   |                               |           | 5  O  Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar  Score — Target |  |  |  |  |

| Cause                 | Controls             | Gaps in<br>Controls | Action    | Sources of Assurance | Gaps in<br>Assurance | Action | Assurance |
|-----------------------|----------------------|---------------------|-----------|----------------------|----------------------|--------|-----------|
| The current size of   | Reconfiguration of   | External            | Continued | External review      | Assurance            |        | Rating    |
| the Neonatal Unit     | cots to create more  | timeframe and       | review    | and reporting        |                      |        |           |
| does not meet the     | space                | approval process    | Teview    | and reporting        |                      |        |           |
| demands of the        | эрасс                | for HIP2 funding    |           |                      |                      |        |           |
| service. This risks   | Additional cots to   | Tor thir 2 fariding |           |                      |                      |        |           |
| high numbers of       | increase capacity    |                     |           |                      |                      |        |           |
| transfers of unwell   | moreage eapaons      |                     |           |                      |                      |        |           |
| babies and            | Parents asked to     |                     |           |                      |                      |        |           |
| potential delayed     | leave NNU during     |                     |           |                      |                      |        |           |
| repatriation of       | interventional       |                     |           |                      |                      |        |           |
| babies back to the    | procedures, ward     |                     |           |                      |                      |        |           |
| hospital. There is a  | rounds, etc to       |                     |           |                      |                      |        |           |
| risk that if the      | increase available   |                     |           |                      |                      |        |           |
| Trust continues to    | space                |                     |           |                      |                      |        |           |
| have insufficient     | •                    |                     |           |                      |                      |        |           |
| space in its NNU,     | HIP2 funding for new |                     |           |                      |                      |        |           |
| the unit's current    | Women and            |                     |           |                      |                      |        |           |
| Level 2 status        | Children's Hospital  |                     |           |                      |                      |        |           |
| could be removed      | announced            |                     |           |                      |                      |        |           |
| on the basis that     |                      |                     |           |                      |                      |        |           |
| the Trust is unable   |                      |                     |           |                      |                      |        |           |
| to fulfil its Network |                      |                     |           |                      |                      |        |           |
| responsibilities      |                      |                     |           |                      |                      |        |           |
| and deliver care in   |                      |                     |           |                      |                      |        |           |
| line with national    |                      |                     |           |                      |                      |        |           |
| requirements.         |                      |                     |           |                      |                      |        |           |

**RISK 19:** If the Trust does not retain staff then posts will be vacant resulting in workforce shortages across the hospital and/or increased temporary staffing expenditure.

| Strategic             |                             | does not retain st |             |             |                               |             | Strategic Objective Investing in Our People             |
|-----------------------|-----------------------------|--------------------|-------------|-------------|-------------------------------|-------------|---|
| Risk                  | expenditure                 | shortages across   | tne nospita | al or incre | ased tempora                  | ry staffing |   |
| Lead<br>Committee     | Workforce                   |                    | Current     | Target      | Risk Type                     | Staff       | Tracker   |
| Executive<br>Lead     | Director<br>of<br>Workforce | Consequence        | 4           | 4           | Risk<br>Appetite              | Cautious    | 25  |
| Date of<br>Assessment | VVOIRIOICC                  | Likelihood         | 2           | 2           | Risk<br>Treatment<br>Strategy | Treat       | 15  |
| Date of<br>Review     | 21/04/21                    | Risk Rating        | 8           | 8           |                               |             | 10  |
|                       |                             |                    |             |             |                               |             | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr  Score ——Target |

| Cause              | Controls               | Gaps in<br>Controls | Action    | Sources of Assurance | Gaps in Assurance | Action    | Assurance Rating |
|--------------------|------------------------|---------------------|-----------|----------------------|-------------------|-----------|------------------|
| Proximity to       | Variety of             | None Currently      | Continued | External review      | None Currently    | None      |                  |
| tertiary centres   | organisational         |                     | review    | and reporting        |                   | Currently |                  |
|                    | change/staff           |                     |           |                      |                   |           |                  |
| Lack of structured | engagement activities, |                     |           | Vacancy and          |                   |           |                  |
| career             | e.g. Event in the Tent |                     |           | Retention Rates      |                   |           |                  |
| development or     |                        |                     |           |                      |                   |           |                  |

| annautunitiaa far | Cobugata Douado and       |  |  |  |
|-------------------|---------------------------|--|--|--|
| opportunities for | Schwartz Rounds and       |  |  |  |
| progression       | coaching collaboratives   |  |  |  |
|                   | Recruitment and           |  |  |  |
| Benefits packages | retention premia          |  |  |  |
| elsewhere         | We Care programme         |  |  |  |
|                   | Onboarding and exit       |  |  |  |
| Culture within    | strategies/reporting      |  |  |  |
| isolated          | Staff survey              |  |  |  |
| departments       | Learning and              |  |  |  |
| ·                 | development               |  |  |  |
|                   | programmes                |  |  |  |
|                   | Health and wellbeing      |  |  |  |
|                   | initiatives, including    |  |  |  |
|                   | P2P and Care First        |  |  |  |
|                   | Staff friends and family  |  |  |  |
|                   | results/action plans      |  |  |  |
|                   | Links to the University   |  |  |  |
|                   | of Buckingham             |  |  |  |
|                   | Staff recognition - staff |  |  |  |
|                   | awards, long service      |  |  |  |
|                   | awards, GEM               |  |  |  |
|                   | Leadership                |  |  |  |
|                   | development and talent    |  |  |  |
|                   | management                |  |  |  |
|                   | Succession planning       |  |  |  |
|                   | Enhancement and           |  |  |  |
|                   | increased visibility of   |  |  |  |
|                   | benefits package          |  |  |  |
|                   | Recruitment and           |  |  |  |
|                   | retention focussed        |  |  |  |
|                   |                           |  |  |  |
|                   | workforce strategy and    |  |  |  |
|                   | plan to fill vacancies,   |  |  |  |
|                   | develop new roles and     |  |  |  |
|                   | deliver improvement to    |  |  |  |

| working experience/<br>environment. |  |  |  |
|-------------------------------------|--|--|--|
| Enhanced Benefits Package           |  |  |  |

**RISK 20:** If the Trust does not recruit to vacancies in the short term (0-18 months) then there will be workforce shortages across the hospital and/or increased temporary staffing expenditure.

| Strategic<br>Risk |             | does not recruit to<br>force shortages a | Strategic<br>Objective | Investing in Our<br>People |                |          |  |  |
|-------------------|-------------|--|------------------------|----------------------------|----------------|----------|--|--|
| Lead              | Workforce   | Risk Rating                              | At target level – no   | tracker                    |                |          |  |  |
| Committee         |             |  |                        |                            |                |          |  |  |
| Executive         | Director of | Consequence                              | 4                      | 4                          | Risk Appetite  | Cautious |  |  |
| Lead              | Workforce   |  |                        |                            |                |          |  |  |
| Date of           |             | Likelihood                               | 2                      | 2                          | Risk Treatment | Tolerate |  |  |
| Assessment        |             |  |                        |                            |                |          |  |  |
| Date of           | 21/04/21    | Risk Rating                              |                        |                            |                |          |  |  |
| Review            |             |  |                        |                            |                |          |  |  |

| Cause  | Controls   | Gaps in Controls | Action           | Sources of Assurance                         | Gaps in Assurance | Action            | Assurance Rating |
|--|--|------------------|------------------|--|-------------------|-------------------|------------------|
| National shortages of appropriately qualified staff in some clinical roles, particularly at consultant level for dermatology and acute medicine, and at middle grade level for urology and trauma and orthopaedics | Active monitoring of workforce key performance indicators Targeted overseas recruitment activity Apprenticeships and work experience opportunities Exploration and use of new roles to help bridge particular gaps | None Currently   | Continued review | External review and reporting  Vacancy Rates | None Currently    | None<br>Currently |                  |

| 0 111 1           | The second             |  | T | T | I |  |
|-------------------|------------------------|--|---|---|---|--|
| Competition from  | Use of recruitment     |  |   |   |   |  |
| surrounding       | and retention premia   |  |   |   |   |  |
| hospitals         | as necessary           |  |   |   |   |  |
|                   | Use of the Trac        |  |   |   |   |  |
| Buoyant locum     | recruitment tool to    |  |   |   |   |  |
| market            | reduce time to hire    |  |   |   |   |  |
|                   | and candidate          |  |   |   |   |  |
| National drive to | experience             |  |   |   |   |  |
| increase nursing  | Rolling programme to   |  |   |   |   |  |
| establishments    | recruit pre-           |  |   |   |   |  |
| leaving market    | qualification students |  |   |   |   |  |
| shortfall (demand | Use of enhanced        |  |   |   |   |  |
| outstrips supply) | adverts, social media  |  |   |   |   |  |
|                   | and recruitment days   |  |   |   |   |  |
|                   | Rollout of a dedicated |  |   |   |   |  |
|                   | workforce website      |  |   |   |   |  |
|                   | Review of benefits     |  |   |   |   |  |
|                   | offering and           |  |   |   |   |  |
|                   | assessment against     |  |   |   |   |  |
|                   | peers                  |  |   |   |   |  |
|                   | Creation of            |  |   |   |   |  |
|                   | recruitment            |  |   |   |   |  |
|                   | "advertising" films    |  |   |   |   |  |
|                   | Recruitment and        |  |   |   |   |  |
|                   | retention focussed     |  |   |   |   |  |
|                   | workforce strategy     |  |   |   |   |  |
|                   | and plan to fill       |  |   |   |   |  |
|                   | vacancies, develop     |  |   |   |   |  |
|                   | new roles and deliver  |  |   |   |   |  |
|                   | improvement to         |  |   |   |   |  |
|                   | working experience/    |  |   |   |   |  |
|                   | environment            |  |   |   |   |  |
|                   |                        |  |   |   |   |  |
| L                 | 1                      |  |   |   |   |  |

| Targeted recruitment   |  |  |  |
|------------------------|--|--|--|
| to reduce hard to fill |  |  |  |
| vacancies              |  |  |  |

**RISK 21:** If the Trust does not recruit to vacancies in the long term (19+ months) then there will be workforce shortages across the hospital and/or increased temporary staffing expenditure.

| Strategic<br>Risk  | then there v                | does not recruit t<br>will be workforce :<br>emporary staffing | shortages | across th | Strategic Objective           | Investing in Our People |                      |        |
|--------------------|-----------------------------|--|-----------|-----------|-------------------------------|-------------------------|----------------------|--------|
| Lead<br>Committee  | Workforce                   | Risk Rating  | Current   | Target    | Risk Type                     | Staff                   | Trac                 | ker    |
| Executive<br>Lead  | Director<br>of<br>Workforce | Consequence  | 4         | 4         | Risk<br>Appetite              | Cautious                | 25 — 20 —            |        |
| Date of Assessment |                             | Likelihood   | 3         | 2         | Risk<br>Treatment<br>Strategy | Tolerate                | 15                   |        |
| Date of<br>Review  | 21/04/21                    | Risk Rating  | 12        | 8         |                               |                         | 10 5 0 Mar Apr Score | Target |

| Cause  | Controls   | Gaps in        | Action           | Sources of                                   | Gaps in        | Action            | Assurance |
|--|--|----------------|------------------|--|----------------|-------------------|-----------|
|  |  | Controls       |                  | Assurance                                    | Assurance      |                   | Rating    |
| National<br>shortages of<br>appropriately<br>qualified staff in<br>some clinical | Monitoring of uptake of placements & training programmes | None Currently | Continued review | External review and reporting  Vacancy Rates | None Currently | None<br>Currently |           |

| -                   |                           |      |  |  |
|---------------------|---------------------------|------|--|--|
| roles, particularly | Targeted overseas         |      |  |  |
| at consultant level | recruitment activity      |      |  |  |
|                     | ,                         |      |  |  |
| Brexit may reduce   | Apprenticeships and       |      |  |  |
| overseas supply     | work experience           |      |  |  |
| Overseas supply     | opportunities             |      |  |  |
| Composition from    | opportunities             |      |  |  |
| Competition from    | Europeion and             |      |  |  |
| surrounding         | Expansion and             |      |  |  |
| hospitals           | embedding of new roles    |      |  |  |
|                     | across all areas          |      |  |  |
| Buoyant locum       |                           |      |  |  |
| market              | Rolling programme to      |      |  |  |
|                     | recruit pre-qualification |      |  |  |
| National drive to   | students                  |      |  |  |
| increase nursing    |                           |      |  |  |
| establishments      | Use of enhanced           |      |  |  |
| leaving market      | adverts, social media     |      |  |  |
| shortfall (demand   | and recruitment days      |      |  |  |
| outstrips supply)   |                           |      |  |  |
|                     | Review of benefits        |      |  |  |
| Large percentage    | offering and              |      |  |  |
| of workforce        | assessment against        |      |  |  |
| predicted to retire | peers                     |      |  |  |
| over the next       | peers                     |      |  |  |
| decade              | Development of MKUH       |      |  |  |
| uecaue              | •                         |      |  |  |
| Lorgo grounds       | training programmes       |      |  |  |
| Large growth        | Madfana Diamin            |      |  |  |
| prediction for MK - | Workforce Planning        |      |  |  |
| outstripping        |                           |      |  |  |
| supply              | Recruitment and           |      |  |  |
|                     | retention focussed        |      |  |  |
| Buoyant private     | workforce strategy and    |      |  |  |
| sector market       | plan to fill vacancies,   |      |  |  |
| creating            | develop new roles and     |      |  |  |
|                     | deliver improvement to    | <br> |  |  |

| competition for  | working  |  |  |  |
|--|--|--|--|--|
| entry level roles  | experience/environment   |  |  |  |
| New roles<br>upskilling existing<br>senior qualified     | International workplace plan                                   |  |  |  |
| staff creating a<br>likely gap in key<br>roles in future | Assisted EU staff to register for settled status and discussed |  |  |  |
| (e.g. band 6 nurses)                                     | plans to stay/leave with each to provide assurance that there  |  |  |  |
| Reducing potential international supply                  | will be no large scale<br>loss of EU staff post-<br>Brexit     |  |  |  |
| New longer training models                               |  |  |  |  |

**RISK 22:** If the Trust is unable to maintain a compliant training environment, 11 postgraduate training posts remain under threat of removal by HEE.

| Strategic<br>Risk  |                       | s unable to maint<br>e training posts re |         |        | Strategic Objective Investing in Our People/Patient Safety |       |   |
|--------------------|-----------------------|--|---------|--------|--|-------|---|
| Lead<br>Committee  | Workforce/<br>Quality | Risk Rating                              | Current | Target | Risk Type  | Staff | Tracker                                   |
| Executive<br>Lead  | Medical<br>Director   | Consequence                              | 4       | 4      | Risk<br>Appetite   | Avoid | 25  |
| Date of Assessment |                       | Likelihood                               | 3       | 2      | Risk<br>Treatment  | Treat | 20  |
| Date of            | 19/04/21              | Risk Rating                              | 12      | 8      | Strategy   |       | 15  |
| Review             |                       |  |         |        |  |       | 10  |
|                    |                       |  |         |        |  |       | 5   |
|                    |                       |  |         |        |  |       | 0 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr |
|                    |                       |  |         |        |  |       | Score Target                              |
|                    |                       |  |         |        |  |       |   |

| Cause   | Controls  | Gaps in Controls   | Action   | Sources of Assurance   | Gaps in Assurance | Action            | Assurance Rating |
|---|---|--|--|--|-------------------|-------------------|------------------|
| Poor training<br>environment: lack<br>of standardisation<br>of process;<br>variable levels of | Heavy involvement from clinical leaders outside the department (DD, DME, MD). | To date, we have not recruited to the additional posts approved in order to move | Positive<br>initial work<br>with<br>Professor<br>Belinda | HEETV<br>undertook a<br>virtual visit on<br>04/12/2020 and<br>the risk score | None Currently    | None<br>Currently |                  |

| support; and, persistent concerns around behaviours by consultants perceived as belittling / inappropriate / bullying. Risk raised in November 2019 following HEE TV quality meeting. | Change in clinical leadership model within the service.  Formative external review (Berendt consulting).  Close liaison with HEE TV Head of School.  Developmental work with consultant body and other senior clinicians in relation to vision and agreement of an ambitious forward-looking programme of work.  Agreement around further investments within the department to improve the working lives of trainees and the quality of the training environment. | away from a single tier middle grade rota 24/7. This currently sits in part with the Head of School as a rotation is envisaged.  The COVID-19 situation has resulted in additional complexity (development work etc.) | Dewar (Wee Culture) across the maternity department, using appreciative inquiry. | (HEE intensive support framework) was reduced from 'category 3 – major concerns' to 'category 2 – significant concerns.  For further review at the June 2021 Quality Committee. |  |  |  |
|---|---|---|--|---|--|--|--|
|---|---|---|--|---|--|--|--|

**RISK 23:** If the Trust does not maintain stocks of Personal Protective Equipment (PPE) and continue implementing the enhanced infection control measures it will be unable to maintain a safe working environment during the COVID-19 pandemic

| Strategic<br>Risk  | (PPE) and one measures it   | does not maintair<br>continue impleme<br>t will be unable to<br>COVID-19 pander | nting the e<br>maintain a | enhanced | Strategic Objective Investing in Our People |       |  |
|--------------------|-----------------------------|---|---------------------------|----------|---|-------|--|
| Lead<br>Committee  | Workforce                   | Risk Rating   | Current                   | Target   | Risk Type                                   | Staff | Tracker  |
| Executive<br>Lead  | Director<br>of<br>Workforce | Consequence   | 4                         | 4        | Risk<br>Appetite                            | Avoid | 25   |
| Date of Assessment |                             | Likelihood  | 2                         | 2        | Risk<br>Treatment<br>Strategy               | Treat | 15   |
| Date of<br>Review  | 21/04/21                    | Risk Rating   | 8                         | 8        |   |       | 10   |
|                    |                             |   |                           |          |   |       | 0  |
|                    |                             |   |                           |          |   |       | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr Score ——Target |

| Cause   | Controls           | Gaps in Controls   | Action            | Sources of Assurance          | Gaps in<br>Assurance | Action            | Assurance Rating |
|---|--------------------|--|-------------------|-------------------------------|----------------------|-------------------|------------------|
| Ability to maint<br>a safe working<br>environment<br>during the Cov | structure in place | None currently –<br>noted that this<br>risk may escalate<br>very quickly | None<br>Currently | Completed Risk<br>Assessments | None Currently       | None<br>Currently |                  |

|                     | 1                     | , |                  | 1 |  |
|---------------------|-----------------------|---|------------------|---|--|
| 19 pandemic due     | Oversight on all      |   | PPE Stock Level  |   |  |
| to a lack of        | critical stock,       |   | Reports          |   |  |
| equipment,          | including PPE         |   |                  |   |  |
| including PPE, or   | _                     |   | Staff Test Stock |   |  |
| inadequate staffing | Immediate escalation  |   | Levels           |   |  |
| numbers             | of issues with        |   |                  |   |  |
|                     | immediate response    |   | Staff Vaccine    |   |  |
|                     | through Gold/ Silver  |   | Uptake Report    |   |  |
|                     |                       |   |                  |   |  |
|                     | National and regional |   |                  |   |  |
|                     | response teams in     |   |                  |   |  |
|                     | place                 |   |                  |   |  |
|                     | piace                 |   |                  |   |  |
|                     | Workforce and         |   |                  |   |  |
|                     | Workplace Risk        |   |                  |   |  |
|                     | Assessments           |   |                  |   |  |
|                     | completed and any     |   |                  |   |  |
|                     |                       |   |                  |   |  |
|                     | necessary equipment   |   |                  |   |  |
|                     | or working            |   |                  |   |  |
|                     | adjustments           |   |                  |   |  |
|                     | implemented.          |   |                  |   |  |
|                     | 01-4,007/10 40 0 1,   |   |                  |   |  |
|                     | Staff COVID-19 Self-  |   |                  |   |  |
|                     | Test and vaccine      |   |                  |   |  |
|                     | offer to all MKUH     |   |                  |   |  |
|                     | workers               |   |                  |   |  |

**RISK 24:** If the Trust does not implement and progress staff health and wellbeing initiatives, there is the risk of staff burning out during or due to the COVID-19 pandemic

| Strategic  |                 | does not impleme                        |         |            |                |       | Strategic Objective Investing in Our People |
|------------|-----------------|---|---------|------------|----------------|-------|---|
| Risk       |                 | nitiatives, there is<br>COVID-19 pander |         | staff burr | ning out durin | g or  |   |
| Lead       | Workforce       |   | Current | Target     | Risk Type      | Staff |   |
| Committee  |                 | 3                                       |         | •          | 31             |       | Tracker                                     |
| Executive  | Director        | Consequence                             | 5       | 5          | Risk           | Avoid | 25 —  |
| Lead       | of<br>Workforce |   |         |            | Appetite       |       | 20  |
| Date of    |                 | Likelihood                              | 3       | 2          | Risk           | Treat | 20  |
| Assessment |                 |   |         |            | Treatment      |       | 15  |
| Date of    | 21/04/21        | Risk Rating                             | 15      | 10         | Strategy       |       | -   |
| Review     | 21/04/21        | Mak Rating                              | 10      | 10         |                |       | 10 —  |
|            |                 |   |         |            |                |       | 5   |
|            |                 |   |         |            |                |       |   |
|            |                 |   |         |            |                |       | 0 —   |
|            |                 |   |         |            |                |       | Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr     |
|            |                 |   |         |            |                |       | Score Target                                |

| Cause               | Controls              | Gaps in Controls | Action        | Sources of Assurance | Gaps in<br>Assurance | Action   | Assurance Rating |
|---------------------|-----------------------|------------------|---------------|----------------------|----------------------|----------|------------------|
| Staff burnout due   | Significant staff     | Significant      | Continued     | Regular virtual      | None Currently       | Package  |                  |
| to high-stress      | welfare programme     | uncertainty      | monitoring,   | all staff events     | -                    | of       |                  |
| working             | in place, with mental | about next wave  | continued     |                      |                      | measures |                  |
| environment,        | health, physical      | of the pandemic  | communication | Surveys              |                      | to       |                  |
| conditions of lock- | health and support    | and how it will  | and           | -                    |                      | support  |                  |
| down, recession     | and advice available  | affect staff     | engagement    |                      |                      |          |                  |

| and other social |                    | with staff about |  | remote  |  |
|------------------|--------------------|------------------|--|---------|--|
| factors          | Staff Hub in use   | support          |  | workers |  |
|                  |                    | systems          |  |         |  |
|                  | Remote working     |                  |  |         |  |
|                  | wellness centre in |                  |  |         |  |
|                  | place              |                  |  |         |  |
|                  |                    |                  |  |         |  |
|                  | 12 weeks of        |                  |  |         |  |
|                  | wellbeing focus    |                  |  |         |  |
|                  | January to March   |                  |  |         |  |
|                  |                    |                  |  |         |  |
|                  |                    |                  |  |         |  |
|                  |                    |                  |  |         |  |



Agenda item 7.3 Public Board 06/05/2021

### Meeting of the Audit Committee held on 23 March 2021

#### REPORT TO THE BOARD OF DIRECTORS

### **Matters approved by the Committee:**

The Committee approved write offs of £94k.

The Committee approved the Conflict of Interest, Hospitality, Gifts, Donations and Sponsorship Policy

### Summary of matters considered at the meeting:

#### **External Audit**

The Committee noted the external audit plan for 2021-22.

#### **Internal Audit**

The Committee noted the final reports on capital expenditure and key financial controls and recommencement of work paused due to the COVID-19 pandemic.

#### Health & Safety

The Committee noted the organisation's plans in the coming year to address above average levels of violence and aggression. These include joint working with local mental health care provider, Central and North West London Community Services.

Regarding positive tests for COVID-19, all cases contracted on site were reported to the Health & Safety Executive.

### Register of Interests of Decision-Making Staff 2020-21

The Committee recommended a review of processes regarding reporting of interests.



Agenda item
Public Board 06.05.21

### Meeting of the Finance and Investment Committee held on 29 March 2021

#### REPORT TO THE BOARD OF DIRECTORS

\_\_\_\_\_

### Matters reported at the meeting:

- Regarding the M11 Performance Dashboard, the Committee noted the continuing efforts to manage patient flow as A&E attendance levels returned to normal following the second surge of COVID.
- Regarding the M11 Finance Report, the Committee noted the actions taken nationally and locally to mitigate the financial impacts of COVID. The Committee noted the ongoing cost implications of treating patients safely as the Trust returns to prepandemic activity levels.
- Regarding the Capital Programme, Committee noted the volatility of the capital position in the NHS at the end of the financial year. The Committee noted the advanced level of deployment of available functionality within the Trust's electronic patient record system.



Agenda item 7.5 Public Board 06/05/2021

## Meeting of the Charitable Funds Committee held on 22 April 2021

#### REPORT TO THE BOARD OF DIRECTORS

### **Matters approved by the Committee:**

- The Budget Forecast for 2021/22. The target income for the year was £490k, and expenditure was forecasted to be £455k;
- The Charity Fundraising Plan for 2021/22;
- 12-month funding for a 'Meaning Activities Coordinator Role' from the Charitable Funds
- The provision of funding for 'MK Arts for Health' in 2021/22 by the Charitable Funds;
- The Charitable Funds Committee's Self-Evaluation Report.

### Matters referred to the Board for final approval:

There were no matters referred to the Board for final approval.

### Summary of matters considered at the meeting:

## Fundraising Update -

- a. Income for 2020/21 was £542k against a forecast target of £463k;
- b. The 3 Draeger BabyLeo incubators, which were procured with funding from the Charitable Funds, will be delivered on 03 May 2021.

**Arts for Health** –Supporting Health and Wellbeing with MKUH. The Charity's ambition is to embed Arts for Health within the Hospital by providing support on site for staff and patients dealing with the effects of COVID-19.



Agenda item 7.6 Public Board 23/03/2021

## Meeting of the Quality & Clinical Risk Committee held on 23 March 2021

#### REPORT TO THE BOARD OF DIRECTORS

#### **Matters Approved by the Committee:**

No matters were approved by the Committee.

#### Summary of matters considered at the meeting:

Clinical Quality Risks on the Board Assurance Framework (BAF) – The Committee focused on the steps being taken to enhance the assurance provided to the members by the BAF. The narrative in the 'Control' will be submitted to an audit by the internal auditors in Q4 of 2021/21.

**COVID-19/Site Update- Presentation –** The Committee noted that as of 23 March 2021, there were only 28 COVID-19 patients on admission and, the number of COVID-19 wards was down to just one.

**Quarterly Highlight Report –** The Committee reviewed and discussed four themes:

- a. The anticipated CQC Well-Led inspection of the Trust;
- b. Staffing issues in the Maternity Unit;
- c. Learning from the COVID-19 pandemic, focused on maintaining elements of the pandemic response such as an integrated ICU outreach function and an enhanced Oxygen stewardship process.

#### Patient Experience Update -

- a. The 'Patient Experience Team' had been integrated with the Chaplaincy and the Volunteers Teams, and had been renamed as the 'Patient Experience and Family Team';
- b. A patient experience matron had been appointed to support the Trust the team and their initiatives with clinical knowledge.

**Response to the Ockendon (Maternity Services) Report –** The Committee noted that an Action Plan based on the report's recommendation will be submitted to Trust Board for review in April 2021.

**Response to the Cumberlege Report –** The report was published in July 2020 after an enquiry into why women were harmed by drugs and implants. The Committee was informed that that the report's recommendations were already being implemented in the Trust. Women were already being provided with cultural support, and the Committee would updated on progress in future recommendations.



Agenda item 7.7 Public Board 21/04/2021

### Workforce & Development Assurance Committee Meeting held on 21 April 2021

#### REPORT TO THE BOARD OF DIRECTORS

### Matters approved by the Committee:

No matters were approved by the Committee.

### Matters referred to the Board for final approval:

There were no matters referred to the Board for final approval.

### Summary of matters considered at the meeting:

**Staff Story** – The Committee received a presentation from the new Workforce Matron who had been recruited to help drive the 'Workforce and Nursing agendas'. The new Matron has been a nurse for 20 years and had both clinical and operational experience.

**NHS People Plan, Workforce Strategy and Plan Update** – The Committee noted that the Workforce Strategy was due to be refreshed in 2021/22, and the NHS People Plan was being progressed.

**Equality, Diversity and Inclusion –** The Committee was informed that the Diversity and Inclusion Partners Programme was scheduled to commence at the end of June 2021, and the outline of a Cultural Intelligence Programme was under development.

**Objectives Update** – Majority of the objectives had been achieved, and would be refreshed as part of the steps being undertaken to refresh the Workforce Strategy.

**HR Systems and Compliance –** The Committee noted the positives of the Workforce Team effort to fill all healthcare assistant vacancies, and their keenness to demonstrate that the roles were meaningful.

#### Workforce Information Quarterly Report – The Committee noted the following:

- 1. Vacancy rate was at 10.5% against a target of 10%,;
- 2. The leaver turnover rate of 7.1% against a target of 10%;
- 3. A static group of known agency workers were generally relied upon in the hospital, which helped maintain the quality of care.

**Staff Health & Wellbeing (SHWB) Report –** A 'long-COVID' group had been established, so members can share experiences and support each other.

**Education Update –** 'Unconscious Bias' lessons has been incorporated into the Equality and Diversity Training module.

**Staff Survey –** The presentation on the Staff Survey results indicated that, developing improvement actions to resolve the issue of 'violence and aggression against staff', was of the highest priority for the Workforce Team.



|                     |                   |                   |                  | 1                      |                                      | NHS Foundation | Trust |  |
|---------------------|-------------------|-------------------|------------------|------------------------|--------------------------------------|----------------|-------|--|
| Meeting title       | Board of Directo  |                   |                  | Date: 6                |                                      |                |       |  |
| Report title:       | Use of Trust Seal |                   | Agenda item: 7.8 |                        |                                      |                |       |  |
| Lead director       | Name: Kate Jarm   | Name: Kate Jarman |                  |                        | Title: Director of Corporate Affairs |                |       |  |
| Report author       | Name: Julia Price |                   |                  | Title: Assistant Trust |                                      |                |       |  |
| Sponsor(s)          | Name. Sana i riss |                   | Secretary        |                        |                                      |                |       |  |
| Fol status:         | Public            |                   |                  |                        |                                      |                |       |  |
|                     |                   |                   |                  |                        |                                      |                |       |  |
| Report summary      | To inform the Bo  | ard of the use    | of the T         | rust Seal              |                                      |                |       |  |
| Purpose             | Information       | Approval          | То               | note                   | Х                                    | Decision       |       |  |
| (tick one box only) |                   | ] [               |                  |                        | ^                                    | -              |       |  |
| Recommendation      | That the Board o  | f Directors not   | e the use        | e of the T             | rust                                 | Seal since Ma  | rch   |  |
|                     | •                 |                   |                  |                        |                                      |                |       |  |
| Strategic           | Objective 7 becc  | me well led a     | nd financ        | cially sust            | aina                                 | ble.           |       |  |
| objectives links    |                   |                   |                  |                        |                                      |                |       |  |
| Board Assurance     | None              |                   |                  |                        |                                      |                |       |  |
| Framework links     |                   |                   |                  |                        |                                      |                |       |  |
| CQC outcome/        | None              |                   |                  |                        |                                      |                |       |  |
| regulation links    |                   |                   |                  |                        |                                      |                |       |  |
| Identified risks    | None              |                   |                  |                        |                                      |                |       |  |
| and risk            |                   |                   |                  |                        |                                      |                |       |  |
| management actions  |                   |                   |                  |                        |                                      |                |       |  |
| Resource            |                   |                   |                  |                        |                                      |                |       |  |
| implications        |                   |                   |                  |                        |                                      |                |       |  |
| Legal               | None              |                   |                  |                        |                                      |                |       |  |
| implications        | INOTIC            |                   |                  |                        |                                      |                |       |  |
| including           |                   |                   |                  |                        |                                      |                |       |  |
| equality and        |                   |                   |                  |                        |                                      |                |       |  |
| diversity           |                   |                   |                  |                        |                                      |                |       |  |
| assessment          |                   |                   |                  |                        |                                      |                |       |  |
|                     | l                 |                   |                  |                        |                                      |                |       |  |
|                     | 1                 |                   |                  |                        |                                      |                |       |  |
| Report history      | None              |                   |                  |                        |                                      |                |       |  |
| Next steps          | None              |                   |                  |                        |                                      |                |       |  |

**Appendices** 

## **Use of Trust Seal**

## 1. Purpose of the Report

In accordance with the Trust Constitution, this report informs the Board of one entry in the Trust seal register which has occurred since the last full meeting of the Board.

## 2. Context

Since the last Trust Board, the Trust Seal has been executed as follows:

30 March 2021 Advanced Payment Bond Galliford Try Construction Limited